<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1304740</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>12</Month>
				<Day>31</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>08</Month>
				<Day>27</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0263-7103</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>31</Volume>
						<Issue>11</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Nov</Month>
						</PubDate>
					</JournalIssue>
					<Title>British journal of rheumatology</Title>
					<ISOAbbreviation>Br J Rheumatol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Cytokine inter-relationships and their association with disease activity in arthritis.</ArticleTitle>
				<Pagination>
					<MedlinePgn>725-33</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>In order to investigate the relationships between cytokine production and arthritic disease we have determined the concentrations of immunoreactive interleukin-1 alpha (IL-1 alpha), IL-1 beta, IL-6, tumour necrosis factor-alpha (TNF-alpha), interferon-alpha (IFN-alpha), IFN-gamma, and soluble IL-2-receptor (sIL-2R), as well as bioactive IL-1 and IL-6, in synovial fluids (SF) and plasma of patients with a variety of arthritides. Careful assay revealed only minimal concentrations of IL-1, particularly its biologically active form, in SF. No IL-1 was detectable in the plasma of patients that had IL-1 in their SF. Concentrations of both immunoreactive IL-1 beta and TNF-alpha in SF of rheumatoid arthritis (RA) patients were significantly higher than those in SF from patients with other inflammatory arthritides or osteoarthritis (OA). IL-6 and sIL-2R concentrations in both SF and plasma were higher in RA patients than in OA patients, and were significantly correlated. Approximately half of the SF from patients with all arthropathies contained detectable IFN-alpha, whilst IFN-Y was present in less than 10%. There were significant associations between IL-6, sIL-2R, IL-1 beta, TNF-alpha and IFN-alpha. The concentration of these cytokines, where detectable, was also related to leukocyte counts in the SF, as well as to parameters assessing local and systemic disease activity. Although IL-6 was the cytokine most clearly related to other cytokines, and to parameters assessing disease activity, the relationship between general articular disease activity and IL-6 was only evident in patients with arthropathies other than rheumatoid arthritis.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Holt</LastName>
						<ForeName>I</ForeName>
						<Initials>I</Initials>
						<AffiliationInfo>
							<Affiliation>University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Cooper</LastName>
						<ForeName>R G</ForeName>
						<Initials>RG</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Denton</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Meager</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hopkins</LastName>
						<ForeName>S J</ForeName>
						<Initials>SJ</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Br J Rheumatol</MedlineTA>
				<NlmUniqueID>8302415</NlmUniqueID>
				<ISSNLinking>0263-7103</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015375">Receptors, Interleukin-2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<CommentsCorrectionsList>
				<CommentsCorrections RefType="CommentIn">
					<RefSource>Br J Rheumatol. 1993 Apr;32(4):350</RefSource>
					<PMID Version="1">8461937</PMID>
				</CommentsCorrections>
			</CommentsCorrectionsList>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001168" MajorTopicYN="N">Arthritis</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
					<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015375" MajorTopicYN="N">Receptors, Interleukin-2</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019947" MajorTopicYN="N">Receptors, Interleukin-6</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1304740</ArticleId>
				<ArticleId IdType="doi">10.1093/rheumatology/31.11.725</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1309841</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>02</Month>
				<Day>19</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2014</Year>
				<Month>11</Month>
				<Day>20</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1767</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>148</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Feb</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
					<ISOAbbreviation>J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Proinflammatory cytokines tumor necrosis factor-alpha and IL-6, but not IL-1, down-regulate the osteocalcin gene promoter.</ArticleTitle>
				<Pagination>
					<MedlinePgn>788-94</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>A proinflammatory cytokine cascade, including IL-1 alpha, IL-1 beta, TNF-alpha, IL-6, and IL-8, is activated in response to infection or immunologic insult. Besides their immunologic effects, several of these mediators stimulate bone resorption and inhibit bone formation. Osteocalcin, the most abundant noncollagenous protein present in bone, is an osteoblast-specific product whose production closely correlates with bone formation, and which has also been implicated in control of bone resorption. IL-1 and TNF have previously been shown to down-regulate osteocalcin production in vitro and in vivo, although the mechanism of this inhibition is unknown. In the present studies, IL-1 beta and TNF-alpha both inhibited 1,25-dihydroxyvitamin D3-stimulated production of osteocalcin protein and mRNA by ROS 17/2.8 osteosarcoma cells, whereas IL-6 had no effect on protein and only weakly inhibited mRNA. To determine if down-regulation was exerted at the transcriptional level, an osteocalcin promoter-chloramphenicol acetyltransferase (CAT) fusion gene was constructed (PHOC-CAT). After transient transfection of PHOC-CAT into ROS 17/2.8 osteosarcoma cells, reporter CAT activity was up-regulated by vitamin D at concentrations above 10(-12) M. In screening studies, TNF-alpha (-57%) and IL-6 (-37%) inhibited vitamin D-stimulated osteocalcin transcription, whereas IL-1 alpha, IL-1 beta, and IL-8 had no effect. Other immune cytokines and growth factors, including IL-2, IL-3, IL-7, and M-CSF, also failed to regulate osteocalcin transcription. Despite their lack of promoter regulation, IL-1 alpha and IL-1 beta also stimulated PGE2 production by ROS 17/2.8, further confirming the ability of the host cell to respond to these mediators. In dose-response experiments, down-regulation by TNF-alpha was significant at concentrations as low as 0.14 pM (0.1 U/ml), whereas approximately 10(4)-fold higher concentration of IL-6 was required to exert a similar effect. TNF-alpha-mediated down-regulation was unaffected by indomethacin. These data demonstrate that of these cytokines, TNF-alpha alone potently down-regulates osteocalcin promoter function, whereas IL-1 acts post-transcriptionally, possibly by reducing mRNA stability. Heterogeneity therefore exists among the proinflammatory cytokines with respect to the level at which control of osteocalcin expression is exerted.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Li</LastName>
						<ForeName>Y P</ForeName>
						<Initials>YP</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Immunology, Forsyth Research Institute, Boston, MA 02115.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Stashenko</LastName>
						<ForeName>P</ForeName>
						<Initials>P</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>DE-07378</GrantID>
						<Acronym>DE</Acronym>
						<Agency>NIDCR NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>DE-09018</GrantID>
						<Acronym>DE</Acronym>
						<Agency>NIDCR NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Immunol</MedlineTA>
				<NlmUniqueID>2985117R</NlmUniqueID>
				<ISSNLinking>0022-1767</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>104982-03-8</RegistryNumber>
					<NameOfSubstance UI="D015675">Osteocalcin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1C6V77QF41</RegistryNumber>
					<NameOfSubstance UI="D002762">Cholecalciferol</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>XXE1CET956</RegistryNumber>
					<NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002762" MajorTopicYN="N">Cholecalciferol</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005796" MajorTopicYN="N">Genes</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
					<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015675" MajorTopicYN="N">Osteocalcin</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1309841</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1311232</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>04</Month>
				<Day>02</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2013</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0013-7227</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>130</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Mar</Month>
						</PubDate>
					</JournalIssue>
					<Title>Endocrinology</Title>
					<ISOAbbreviation>Endocrinology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Adrenocorticotropin increases interleukin-6 release from rat adrenal zona glomerulosa cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1245-54</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Interleukin-6 (IL-6) is produced by adrenal zona glomerulosa cells; its release is stimulated by several secretagogues, including IL-1 alpha, IL-1 beta, and angiotensin II. The present study reports that ACTH (0.1-100 nM) increased the release of IL-6 from primary cultures of rat adrenal cells in a concentration-dependent manner. This increase was accompanied by an increase in cAMP content in cell extracts and in the incubation medium. The dynamics of IL-6 release from the adrenal cells also were investigated using a perifusion system; approximately 50 min were required for the effects of IL-1 alpha, IL-1 beta, and ACTH on IL-6 release to become apparent. Following withdrawal of the secretagogues, IL-6 release returned to basal levels within 90-120 min. In some experiments, the adrenal zona glomerulosa was separated from the zona fasciculata/reticularis to determine the origin of secretagogue-stimulated IL-6 release. PGE2 and forskolin increased IL-6 release from both cell types, but maximal release from zona glomerulosa cells was more than 10-fold greater than that from zona fasciculata/reticularis cells. ACTH (0.1-100 nM) increased intracellular cAMP levels in cells from both cell types in a concentration-dependent manner, but increased IL-6 release only from zona glomerulosa cells. Dexamethasone, an inhibitor of IL-6 production in several tissues, had no effect on either basal or stimulated IL-6 production in the adrenal. Because IL-1 beta is produced primarily by tissues of the immune system, whereas ACTH is a classical endocrine hormone, we investigated the effect of interaction of these proteins on IL-6 release from the adrenal. Together, IL-1 beta and ACTH stimulation of IL-6 release was greater than the sum of the effects of each substance separately; however, IL-1 beta did not potentiate the effect of ACTH on cAMP levels. Similarly, IL-1 beta potentiated IL-6 release stimulated by forskolin and (Bu)2cAMP. Thus, the adrenal may be an important convergence point between the immune and endocrine systems, and because IL-6 release is regulated by IL-1 alpha, IL-1 beta, ACTH, and angiotensin II, and this cytokine stimulates corticosterone release, IL-6 may play an important paracrine role in integrating the signals derived from these systems.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Judd</LastName>
						<ForeName>A M</ForeName>
						<Initials>AM</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, University of Virginia Health Sciences Center, Charlottesville 22908.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>MacLeod</LastName>
						<ForeName>R M</ForeName>
						<Initials>RM</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>CA-07535</GrantID>
						<Acronym>CA</Acronym>
						<Agency>NCI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>DK-42059</GrantID>
						<Acronym>DK</Acronym>
						<Agency>NIDDK NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Endocrinology</MedlineTA>
				<NlmUniqueID>0375040</NlmUniqueID>
				<ISSNLinking>0013-7227</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>11128-99-7</RegistryNumber>
					<NameOfSubstance UI="D000804">Angiotensin II</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1F7A44V6OU</RegistryNumber>
					<NameOfSubstance UI="D005576">Colforsin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9002-60-2</RegistryNumber>
					<NameOfSubstance UI="D000324">Adrenocorticotropic Hormone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>E0399OZS9N</RegistryNumber>
					<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000324" MajorTopicYN="N">Adrenocorticotropic Hormone</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000804" MajorTopicYN="N">Angiotensin II</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005576" MajorTopicYN="N">Colforsin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011919" MajorTopicYN="N">Rats, Inbred Strains</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015384" MajorTopicYN="N">Zona Glomerulosa</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1311232</ArticleId>
				<ArticleId IdType="doi">10.1210/endo.130.3.1311232</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1312844</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>04</Month>
				<Day>21</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>06</Month>
				<Day>12</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-291X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>183</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Mar</Month>
							<Day>16</Day>
						</PubDate>
					</JournalIssue>
					<Title>Biochemical and biophysical research communications</Title>
					<ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interaction of interferon-alpha with interleukin-1 beta or tumor necrosis factor-alpha on hepatitis B virus enhancer activity.</ArticleTitle>
				<Pagination>
					<MedlinePgn>904-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The interaction of IFN-alpha with IL-1 beta or TNF-alpha on hepatitis B surface antigen (HBsAg) expression was analysed in hepatitis B virus (HBV)-DNA integrated PLC/PRF/5 and non-integrated HuH-7 human hepatoma cells. Secretion of HBsAg in PLC/PRF/5 cells was reduced by IFN-alpha, IL-1 beta or TNF-alpha, and synergistically depressed when IFN-alpha was used in combination with IL-1 beta or TNF-alpha. By Northern blot analysis, the levels of HBsAg mRNA were suppressed by IFN-alpha in combination with IL-1 beta or TNF-alpha. In the chloramphenicol acetyltransferase plasmid transfection assay, IFN-alpha in combination with IL-1 beta or TNF-alpha caused a much greater suppression of HBV enhancer activity than IFN-alpha, IL-1 beta or TNF-alpha alone in both hepatoma cells. These findings suggest that the interaction of IFN-alpha with IL-1 beta or TNF-alpha synergistically represses HBV enhancer activity, resulting in depressed expression of HBsAg.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Hamasaki</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>First Department of Internal Medicine, Nagasaki University School of Medicine, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nakata</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nakao</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mitsuoka</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tsutsumi</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kato</LastName>
						<ForeName>Y</ForeName>
						<Initials>Y</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Shima</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ishii</LastName>
						<ForeName>N</ForeName>
						<Initials>N</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tamaoki</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nagataki</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
				<NlmUniqueID>0372516</NlmUniqueID>
				<ISSNLinking>0006-291X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006513">Hepatitis B e Antigens</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.3.1.28</RegistryNumber>
					<NameOfSubstance UI="D015500">Chloramphenicol O-Acetyltransferase</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015500" MajorTopicYN="N">Chloramphenicol O-Acetyltransferase</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006513" MajorTopicYN="N">Hepatitis B e Antigens</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012045" MajorTopicYN="N">Regulatory Sequences, Nucleic Acid</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>16</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>16</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>16</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1312844</ArticleId>
				<ArticleId IdType="pii">0006-291X(92)90569-7</ArticleId>
				<ArticleId IdType="doi">10.1016/0006-291x(92)90569-7</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1319454</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>07</Month>
				<Day>27</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>07</Month>
				<Day>09</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-0795</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>133</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jun</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of endocrinology</Title>
					<ISOAbbreviation>J Endocrinol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Release of interleukin-6 by human thyroid epithelial cells immortalized by simian virus 40 DNA transfection.</ArticleTitle>
				<Pagination>
					<MedlinePgn>477-82</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Interleukin-6 (IL-6) has actions on a variety of endocrine tissues. The cytokine is secreted by cells of the anterior pituitary and endocrine pancreas and has recently been shown to be produced by cultures of thyroid epithelial cells. In this study we have examined some of the factors which regulate IL-6 release from an immortalized human thyroid line (HTori3). IL-6 release over 24 h was stimulated by TSH (5000 microU/ml), by forskolin (0.01 mmol/l), by fetal calf serum (1-20%) and by epidermal growth factor (20 ng/ml). Stimulation was also apparent with gamma-interferon and with tumour necrosis factor at concentrations known to enhance class II major histocompatibility antigen expression by thyroid epithelium. The most potent factor tested was interleukin-1 (IL-1), which controls IL-6 release from other cell types. Threefold stimulation was found with 1 U/ml rising to 350-fold with 1000 U/ml. The effect of IL-1 took 2 h to develop and was blocked by cycloheximide (100 mumol/l). Stimulation was not markedly inhibited by pertussis toxin. Many of the actions of IL-1 are mediated by prostaglandin E2 (PGE2). At concentrations as low as 30 nmol/l, PGE2 stimulated IL-6 release but the maximum stimulation obtained with PGE2 was only threefold. The effect of IL-1 was not inhibited by indomethacin. These data provide further evidence that IL-6 is produced by human thyrocytes. The effect of IL-1 has not been demonstrated previously. Stimulation of IL-6 release by IL-1 did not appear to be mediated by prostaglandin.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Kennedy</LastName>
						<ForeName>R L</ForeName>
						<Initials>RL</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, University of Sheffield Clinical Sciences Centre, Northern General Hospital, U.K.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Jones</LastName>
						<ForeName>T H</ForeName>
						<Initials>TH</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Davies</LastName>
						<ForeName>R</ForeName>
						<Initials>R</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Justice</LastName>
						<ForeName>S K</ForeName>
						<Initials>SK</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lemoine</LastName>
						<ForeName>N R</ForeName>
						<Initials>NR</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>J Endocrinol</MedlineTA>
				<NlmUniqueID>0375363</NlmUniqueID>
				<ISSNLinking>0022-0795</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1F7A44V6OU</RegistryNumber>
					<NameOfSubstance UI="D005576">Colforsin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>62229-50-9</RegistryNumber>
					<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9002-71-5</RegistryNumber>
					<NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005576" MajorTopicYN="N">Colforsin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004815" MajorTopicYN="N">Epidermal Growth Factor</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004848" MajorTopicYN="N">Epithelium</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013539" MajorTopicYN="N">Simian virus 40</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1319454</ArticleId>
				<ArticleId IdType="doi">10.1677/joe.0.1330477</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1319763</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>08</Month>
				<Day>04</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>10</Month>
				<Day>28</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">1043-4666</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>4</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jan</Month>
						</PubDate>
					</JournalIssue>
					<Title>Cytokine</Title>
					<ISOAbbreviation>Cytokine</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Hormonal regulation of inflammatory cell cytokine transcript and bioactivity production in response to endotoxin.</ArticleTitle>
				<Pagination>
					<MedlinePgn>55-62</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Tumor necrosis factor (TNF), interleukin 1 (IL-1) and interleukin 6 (IL-6) are central mediators of the inflammatory response. We investigated the modulation of these cytokines by hormones in vitro. Murine adherent peritoneal exudate cells (PEC) were exposed to various concentrations of hormones followed by lipopolysaccharide (LPS, 10 micrograms/ml). TNF, IL-1 and IL-6 production were assessed by bioassays, enzyme-linked immunosorbent assays (ELISA) or Western blot, and specific RNA transcripts by Northern blot. Hydrocortisone in concentrations as low as 10 ng/ml had dramatic inhibitory effects on supernatant levels of TNF and IL-1 and on TNF, IL-1 and IL-6 transcript number. Supernatant levels of IL-6 were only slightly diminished by hydrocortisone. Adrenocorticotrophic hormone (ACTH) and insulin increased supernatant levels of TNF bioactivity in response to LPS, while each decreased available TNF-alpha gene transcripts. Thus TNF protein production was affected at a post-transcriptional level. ACTH and insulin increased supernatant levels of IL-6 produced in response to LPS without altering available transcripts. Corticotrophin-releasing factor (CRF), epinephrine and glucagon had no effect on supernatant levels of cytokine. Thus, physiological and pharmacological concentrations of hydrocortisone had dramatic inhibitory effects on the supernatant levels of TNF and IL-1, and on the number of available TNF, IL-1 and IL-6 transcripts in PEC exposed to LPS, but had minimal effects on supernatant levels of IL-6 bioactivity. This hydrocortisone action may be a specific negative feedback system for IL-1 and TNF, with relative sparing of IL-6.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Doherty</LastName>
						<ForeName>G M</ForeName>
						<Initials>GM</Initials>
						<AffiliationInfo>
							<Affiliation>Surgical Metabolism Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Jensen</LastName>
						<ForeName>J C</ForeName>
						<Initials>JC</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Buresh</LastName>
						<ForeName>C M</ForeName>
						<Initials>CM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Norton</LastName>
						<ForeName>J A</ForeName>
						<Initials>JA</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Cytokine</MedlineTA>
				<NlmUniqueID>9005353</NlmUniqueID>
				<ISSNLinking>1043-4666</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D004731">Endotoxins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006728">Hormones</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9002-60-2</RegistryNumber>
					<NameOfSubstance UI="D000324">Adrenocorticotropic Hormone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9007-92-5</RegistryNumber>
					<NameOfSubstance UI="D005934">Glucagon</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9015-71-8</RegistryNumber>
					<NameOfSubstance UI="D003346">Corticotropin-Releasing Hormone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>WI4X0X7BPJ</RegistryNumber>
					<NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>YKH834O4BH</RegistryNumber>
					<NameOfSubstance UI="D004837">Epinephrine</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000324" MajorTopicYN="N">Adrenocorticotropic Hormone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003346" MajorTopicYN="N">Corticotropin-Releasing Hormone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004731" MajorTopicYN="N">Endotoxins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004837" MajorTopicYN="N">Epinephrine</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005934" MajorTopicYN="N">Glucagon</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006728" MajorTopicYN="N">Hormones</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1319763</ArticleId>
				<ArticleId IdType="pii">1043-4666(92)90037-R</ArticleId>
				<ArticleId IdType="doi">10.1016/1043-4666(92)90037-r</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1321738</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>08</Month>
				<Day>27</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>06</Month>
				<Day>20</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0014-5793</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>306</Volume>
						<Issue>2-3</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jul</Month>
							<Day>20</Day>
						</PubDate>
					</JournalIssue>
					<Title>FEBS letters</Title>
					<ISOAbbreviation>FEBS Lett</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Soluble human interleukin-6-receptor modulates interleukin-6-dependent N-glycosylation of alpha 1-protease inhibitor secreted by HepG2 cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>257-61</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Interleukin-6 (IL-6) induces changes in gene expression and the N-glycosylation pattern of acute-phase proteins in hepatocytes. IL-6 exerts its action via a cell surface receptor complex consisting of an 80 kDa IL-6 binding protein (gp80) and a 130 kDa glycoprotein (gp130) involved in signal transduction. A genetically engineered gp80-derived soluble human IL-6-receptor (shIL-6-R) significantly enhanced the IL-6 effect on N-glycosylation changes (revealed by reactivity with the lectin-concanavalin A) of a1-protease inhibitor (PI) secreted by human hepatoma cells (HepG2). Stable transfection of IL-6-cDNA into HepG2 cells (HepG2-IL-6) resulting in constitutive secretion of 2 micrograms of IL-6 per 10(6) cells in 24 h led to a down-regulation of surface-bound gp80 and subsequent homologous desensitization of HepG2-IL-6 cells towards IL-6. Soluble human IL-6-R functionally substituted membrane-bound gp80 resulting in a reconstitution of responsiveness of HepG2-IL-6 cells.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Mackiewicz</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Institut für Biochemie, RWTH Aachen, Germany.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rose-John</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schooltink</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Laciak</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Górny</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Heinrich</LastName>
						<ForeName>P C</ForeName>
						<Initials>PC</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>FEBS Lett</MedlineTA>
				<NlmUniqueID>0155157</NlmUniqueID>
				<ISSNLinking>0014-5793</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000515">alpha 1-Antitrypsin</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D016475" MajorTopicYN="N">3T3 Cells</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006031" MajorTopicYN="N">Glycosylation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006505" MajorTopicYN="N">Hepatitis</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019947" MajorTopicYN="N">Receptors, Interleukin-6</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000515" MajorTopicYN="N">alpha 1-Antitrypsin</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>20</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>20</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>20</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1321738</ArticleId>
				<ArticleId IdType="pii">0014-5793(92)81012-B</ArticleId>
				<ArticleId IdType="doi">10.1016/0014-5793(92)81012-b</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1322806</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>09</Month>
				<Day>08</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>08</Month>
				<Day>19</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0090-1229</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>64</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Aug</Month>
						</PubDate>
					</JournalIssue>
					<Title>Clinical immunology and immunopathology</Title>
					<ISOAbbreviation>Clin Immunol Immunopathol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Induction of neutral proteinase and prostanoid production in bovine nasal chondrocytes by interleukin-1 and tumor necrosis factor alpha: modulation of these cellular responses by interleukin-6 and platelet-derived growth factor.</ArticleTitle>
				<Pagination>
					<MedlinePgn>135-44</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>We have previously reported that recombinant human interleukin-1 (IL-1) stimulates matrix erosion in bovine nasal cartilage explants (R. J. Smith et al., Inflammation 13, 367-382, 1989). This action of IL-1 is believed to be caused by matrix-degrading neutral proteinases produced by activated chrondrocytes. Accordingly, we investigated the effects of recombinant human interleukin-1 alpha (IL-1 alpha), recombinant human interleukin-1 beta (IL-1 beta), and recombinant human tumor necrosis factor alpha (TNF alpha) on bovine nasal chondrocyte (BNC) responsiveness. IL-1 alpha and IL-1 beta stimulated a time (0-72 hr) and concentration-dependent (0.01-10 ng/ml) production of collagenase, gelatinase, caseinase, and prostaglandin E2 (PGE2) in BNC monolayer cultures. Neutral proteinase and PGE2 production by BNC was also induced by TNF alpha (0.2-200 ng/ml) in a time-dependent (0-72 hr) manner. Recombinant human interleukin-6 (IL-6) caused a concentration-dependent (6-200 ng/ml) potentiation of IL-1-stimulated neutral proteinase and PGE2 production by BNC. However, recombinant human platelet-derived growth factor homodimer BB suppressed BNC responsiveness to IL-1. A recombinant human IL-1 receptor antagonist protein inhibited BNC activation by IL-1 but not TNF alpha.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Smith</LastName>
						<ForeName>R J</ForeName>
						<Initials>RJ</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Hypersensitivity Diseases Research, Upjohn Company, Kalamazoo, Michigan 49001.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Justen</LastName>
						<ForeName>J M</ForeName>
						<Initials>JM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ulrich</LastName>
						<ForeName>R G</ForeName>
						<Initials>RG</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lund</LastName>
						<ForeName>J E</ForeName>
						<Initials>JE</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sam</LastName>
						<ForeName>L M</ForeName>
						<Initials>LM</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Clin Immunol Immunopathol</MedlineTA>
				<NlmUniqueID>0356637</NlmUniqueID>
				<ISSNLinking>0090-1229</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C507763">IL1RN protein, human</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010982">Platelet-Derived Growth Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011500">Protein Synthesis Inhibitors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012795">Sialoglycoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1CC1JFE158</RegistryNumber>
					<NameOfSubstance UI="D003609">Dactinomycin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>98600C0908</RegistryNumber>
					<NameOfSubstance UI="D003513">Cycloheximide</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.-</RegistryNumber>
					<NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.-</RegistryNumber>
					<NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.23.1</RegistryNumber>
					<NameOfSubstance UI="D010434">Pepsin A</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.-</RegistryNumber>
					<NameOfSubstance UI="D018093">Gelatinases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.-</RegistryNumber>
					<NameOfSubstance UI="D008666">Metalloendopeptidases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.-</RegistryNumber>
					<NameOfSubstance UI="C030895">caseinase</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.3</RegistryNumber>
					<NameOfSubstance UI="D003012">Microbial Collagenase</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002356" MajorTopicYN="N">Cartilage</DescriptorName>
					<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003513" MajorTopicYN="N">Cycloheximide</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003609" MajorTopicYN="N">Dactinomycin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004790" MajorTopicYN="N">Enzyme Induction</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018093" MajorTopicYN="N">Gelatinases</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D053590" MajorTopicYN="N">Interleukin 1 Receptor Antagonist Protein</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008666" MajorTopicYN="Y">Metalloendopeptidases</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003012" MajorTopicYN="N">Microbial Collagenase</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010434" MajorTopicYN="N">Pepsin A</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010982" MajorTopicYN="N">Platelet-Derived Growth Factor</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011500" MajorTopicYN="N">Protein Synthesis Inhibitors</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012795" MajorTopicYN="Y">Sialoglycoproteins</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1322806</ArticleId>
				<ArticleId IdType="doi">10.1016/0090-1229(92)90191-p</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1322938</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>09</Month>
				<Day>09</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>11</Month>
				<Day>30</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0021-9738</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>90</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Aug</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of clinical investigation</Title>
					<ISOAbbreviation>J Clin Invest</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4.</ArticleTitle>
				<Pagination>
					<MedlinePgn>382-8</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>To study the interaction of lymphocytes and macrophages in the control of extracellular matrix turnover, we determined the effects of several soluble T cell products on mononuclear phagocyte production of metalloproteinases. Cytokines including IL-2, IL-4, IL-6, tumor necrosis factor alpha (TNF alpha), GM-CSF, and IFN-gamma were each tested for capacity to modulate macrophage metalloproteinase and tissue inhibitor of metalloproteinases (TIMP) expression. The addition of IL-4 to cells cultured under basal conditions caused a dose-dependent suppression in the release of 92-kD type IV collagenase without affecting TIMP production. 92-kD enzyme secretion was inhibited by 50% with 1-2 ng/ml of IL-4 and by 90% with 10 ng/ml of IL-4. When cells were first exposed to killed Staphylococcus aureus to induce metalloproteinase production, IL-4 potently blocked the stimulated release of both interstitial collagenase and 92-kD type IV collagenase, again without effect upon TIMP. Metabolic labeling experiments and Northern hybridizations demonstrated that IL-4 exerted its action at a pretranslational level. Furthermore, IL-4 possessed the capacity to inhibit metalloproteinase expression even in the relatively immature peripheral blood monocyte. As reported previously (Shapiro, S. D., E. J. Campbell, D. K. Kobayashi, and H. G. Welgus. 1990. J. Clin. Invest. 86:1204), IFN-gamma suppressed constitutive macrophage production of 92-kD type IV collagenase. Despite the frequent antagonism observed between IL-4 and IFN-gamma in other systems, the combination of these two agents lowered metalloproteinase biosynthesis dramatically, whereas IL-4 opposed the IFN-gamma-stimulated production of cytokines (IL-1 and TNF alpha). IL-6 had only minimal effect upon metalloproteinase production, but appeared to specifically augment TIMP release. In summary, cytokines released by activated T cells may profoundly reduce the capacity of the macrophage to mediate extracellular matrix degradation.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Lacraz</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
						<AffiliationInfo>
							<Affiliation>Immunology and Allergy Division, Hôpital Cantonal Universitaire, Geneva, Switzerland.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nicod</LastName>
						<ForeName>L</ForeName>
						<Initials>L</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Galve-de Rochemonteix</LastName>
						<ForeName>B</ForeName>
						<Initials>B</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Baumberger</LastName>
						<ForeName>C</ForeName>
						<Initials>C</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Dayer</LastName>
						<ForeName>J M</ForeName>
						<Initials>JM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Welgus</LastName>
						<ForeName>H G</ForeName>
						<Initials>HG</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AR32087</GrantID>
						<Acronym>AR</Acronym>
						<Agency>NIAMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>AR35805</GrantID>
						<Acronym>AR</Acronym>
						<Agency>NIAMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>HL29594</GrantID>
						<Acronym>HL</Acronym>
						<Agency>NHLBI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Clin Invest</MedlineTA>
				<NlmUniqueID>7802877</NlmUniqueID>
				<ISSNLinking>0021-9738</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019714">Tissue Inhibitor of Metalloproteinases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>207137-56-2</RegistryNumber>
					<NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.-</RegistryNumber>
					<NameOfSubstance UI="D008666">Metalloendopeptidases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.3</RegistryNumber>
					<NameOfSubstance UI="D003012">Microbial Collagenase</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008262" MajorTopicYN="N">Macrophage Activation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016676" MajorTopicYN="N">Macrophages, Alveolar</DescriptorName>
					<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008666" MajorTopicYN="N">Metalloendopeptidases</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003012" MajorTopicYN="N">Microbial Collagenase</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019714" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinases</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1322938</ArticleId>
				<ArticleId IdType="doi">10.1172/JCI115872</ArticleId>
				<ArticleId IdType="pmc">PMC443112</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Immunol. 1986 Jun 15;136(12):4538-41</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3486902</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Mol Biol. 1971 Dec 28;62(3):465-77</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">5136579</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1991 Jul;88(1):346-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1829097</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1991 Feb 5;266(4):2017-20</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1846608</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8154-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1896464</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1991 Feb 15;146(4):1286-93</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1991967</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1990 Oct 1;76(7):1392-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2119829</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Respir Cell Mol Biol. 1990 Oct;3(4):355-61</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2144978</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1990 Nov;86(5):1496-502</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2173721</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Chem Clin Biochem. 1989 Jun;27(6):351-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2547014</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol Methods. 1989 Oct 24;123(2):193-210</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2681422</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1987 Nov;80(5):1280-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2824558</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1987 Dec 1;166(6):1774-87</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2960773</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1985 Jul;76(1):219-24</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2991337</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1985 Dec 1;162(6):2163-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2999289</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1986 May;77(5):1675-81</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3009552</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Mar 1;140(5):1548-54</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3279117</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1987 Dec;80(6):1644-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3680518</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Coll Relat Res. 1983 May;3(3):205-15</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6191911</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Appl Environ Microbiol. 1981 Feb;41(2):449-54</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">7235693</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem J. 1991 Jul 1;277 ( Pt 1):277-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1649600</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1991 Apr 15;146(8):2724-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1707919</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1991 Apr 25;266(12):7870-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1850424</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Cell Biochem. 1991 Sep;47(1):1-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1939362</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Apr 15;144(8):3046-51</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2139076</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1990 Oct;86(4):1204-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2170447</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1982 Mar 1;155(3):914-23</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6977612</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1986 Jul 1;137(1):108-13</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2423600</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1989 May;86(10):3803-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2786204</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1986 Mar;83(6):1857-61</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2937061</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Apr 15;140(8):2625-32</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2965726</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1986 Feb;77(2):645-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3003163</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1986 Jul 15;137(2):519-24</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3088102</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1987 Oct;84(19):6889-93</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3498944</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Arthritis Rheum. 1991 Sep;34(9):1085-93</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1657008</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1323342</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>09</Month>
				<Day>14</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-4971</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>80</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Aug</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>Blood</Title>
					<ISOAbbreviation>Blood</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Leukotriene B4 enhances interleukin-6 (IL-6) production and IL-6 messenger RNA accumulation in human monocytes in vitro: transcriptional and posttranscriptional mechanisms.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1004-11</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Leukotriene B4 (LTB4) is a potent lipid mediator of inflammation, and some of its bioactivities may involve inflammatory cytokines. Moreover, it may participate in myelopoiesis, either directly or via the induction of cytokines and growth factors. When human monocytes were cultured in the presence of graded concentrations of LTB4, significant stimulation of production of bioactive and immunoreactive interleukin-6 (IL-6) was observed. Nanomolar concentrations of LTB4 were optimal and the LTB4 receptor antagonist LY 255283 could block its activity. The omega-oxidation products of LTB4, 20-OH-LTB4 and 20-COOH-LTB4, were only 22% and 2% effective, respectively. LTA4 was also effective in stimulating IL-6 production, but only at micromolar concentrations, whereas 5-HETE and 12-epi-LTB4 were ineffective. The signaling induced by LTB4 did not seem to involve protein kinase C or A, but rather a tyrosine kinase, as suggested by its inhibition with genistein. LTB4 induced an accumulation of IL-6 messenger RNA (mRNA) in treated monocytes with a dose-response similar to that of IL-6 protein production. Whereas IL-6 mRNA half-life in untreated cells was approximately 1 hour, it was extended to 3 hours in LTB4-treated monocytes. Moreover, nuclear transcription of IL-6 mRNA was augmented at 30 minutes by a factor of 5 in LTB4-treated cells. Pretreatment of cells with cyclohexamide before exposure to LTB4 superinduced IL-6 message expression, but partially inhibited the effect of LTB4 on IL-6 mRNA accumulation, suggesting that newly synthesized proteins may be involved in the transcriptional activation of the IL-6 gene by LTB4. These findings constitute a first demonstration that LTB4 stimulates IL-6 production and that the underlying mechanisms involve both increased IL-6 gene transcription and message stabilization. This may constitute an important mechanism through which rapidly produced mediators may modulate the subsequent production of regulatory or growth-promoting cytokines.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Rola-Pleszczynski</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Immunology Division, Faculty of Medicine, University of Sherbrooke, Québec, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Stanková</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Blood</MedlineTA>
				<NlmUniqueID>7603509</NlmUniqueID>
				<ISSNLinking>0006-4971</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007529">Isoflavones</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1CC1JFE158</RegistryNumber>
					<NameOfSubstance UI="D003609">Dactinomycin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1HGW4DR56D</RegistryNumber>
					<NameOfSubstance UI="D007975">Leukotriene B4</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>98600C0908</RegistryNumber>
					<NameOfSubstance UI="D003513">Cycloheximide</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>DH2M523P0H</RegistryNumber>
					<NameOfSubstance UI="D019833">Genistein</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.7.10.1</RegistryNumber>
					<NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>H037W1I5AL</RegistryNumber>
					<NameOfSubstance UI="C063823">LY 255283</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003513" MajorTopicYN="N">Cycloheximide</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003609" MajorTopicYN="N">Dactinomycin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019833" MajorTopicYN="N">Genistein</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007529" MajorTopicYN="N">Isoflavones</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007975" MajorTopicYN="N">Leukotriene B4</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013777" MajorTopicYN="N">Tetrazoles</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1323342</ArticleId>
				<ArticleId IdType="pii">S0006-4971(20)67659-5</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1330001</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>12</Month>
				<Day>16</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2006</Year>
				<Month>11</Month>
				<Day>15</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">1056-5477</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>11</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Aug</Month>
						</PubDate>
					</JournalIssue>
					<Title>Lymphokine and cytokine research</Title>
					<ISOAbbreviation>Lymphokine Cytokine Res</ISOAbbreviation>
				</Journal>
				<ArticleTitle>The induction of IL-6 and gelatinase B by IL-1 in mouse cell lines transformed with bovine papillomavirus: decreased production in tumorigenic cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>215-20</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Six cell lines, that were cloned from murine C127 cells infected by bovine papillomavirus type 1 (BPV1), were found to differ in the degree of transformation in vitro and of tumorigenicity in vivo. In these cell lines the degree of tumorigenicity was inversely correlated with IL-6 induction by IL-1 beta. Whereas the parental C127 cell line produced 15-30 U/ml of IL-6 spontaneously, none of the transformed cell lines produced significant levels of IL-6 constitutively. On induction by human IL-1 beta the parental C127 cell line produced up to 300 U/ml of IL-6, whereas the fully transformed ID14 cell line failed to produce any. The less transformed cell lines produced lower yields of IL-1 beta-induced IL-6, dependent on their degrees of transformation and tumorigenicity. Gelatinase B (96 kDa), a matrix metalloproteinase inducible by IL-1 beta, was dose-dependently regulated in the parental C127 cell line and in the weakly transformed cell line Tlc. These data suggest that transformation processes by BPV1 generally impair IL-1-regulated gene transcription. This impairment seems not to be located at the IL-1 beta receptor level, since in all the cell lines studied the numbers and affinities of the IL-1 beta binding sites were found to be comparable. This impairment seems not to be mediated by transformation-induced inactivation of the protein kinase C pathway since phorbol 12-myristate 13-acetate (PMA) induced IL-6 production equally well in all C127 cell-derived clones. It is suggested that BPV1 transformation can change the expression of host genes that might play a functional role in tumor immune surveillance and tumorigenicity in vivo.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Fuse</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Rega Institute for Medical Research, University of Leuven, Belgium.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Simizu</LastName>
						<ForeName>B</ForeName>
						<Initials>B</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Van Ranst</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Opdenakker</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Van Damme</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Lymphokine Cytokine Res</MedlineTA>
				<NlmUniqueID>9107882</NlmUniqueID>
				<ISSNLinking>1056-5477</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.-</RegistryNumber>
					<NameOfSubstance UI="D017364">Collagenases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.35</RegistryNumber>
					<NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D052688" MajorTopicYN="N">Bovine papillomavirus 1</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002472" MajorTopicYN="N">Cell Transformation, Viral</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017364" MajorTopicYN="N">Collagenases</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004790" MajorTopicYN="N">Enzyme Induction</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1330001</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1330702</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>12</Month>
				<Day>22</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>06</Month>
				<Day>20</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0014-5793</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>313</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Nov</Month>
							<Day>23</Day>
						</PubDate>
					</JournalIssue>
					<Title>FEBS letters</Title>
					<ISOAbbreviation>FEBS Lett</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2). Up-regulation by interleukin-6 and transforming growth factor beta 1.</ArticleTitle>
				<Pagination>
					<MedlinePgn>143-7</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Metalloproteinases and their specific inhibitors, believed to play a role in extracellular matrix metabolism, are regulated by inflammatory cytokines. Here we have addressed the question of whether liver, the major site of synthesis of plasma proteinase inhibitors, is also capable of synthesizing the tissue inhibitor of metalloproteinase-1 (TIMP-1). We show at mRNA and protein levels that TIMP-1 is expressed in differentiated human hepatoma cells (HepG2) and that its synthesis is up-regulated by interleukin-6 (IL-6), transforming growth factor beta 1 and phorbol 12-myristate 13-acetate. The physiological role of this phenomenon is underlined by the fact that lipopolysaccharide administration into rats in vivo, as well as IL-6-stimulation of rat hepatocytes in primary culture, also leads to an increase of TIMP-1 mRNA in liver cells.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Kordula</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
						<AffiliationInfo>
							<Affiliation>Institut für Biochemie der RWTH Aachen, Germany.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Güttgemann</LastName>
						<ForeName>I</ForeName>
						<Initials>I</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rose-John</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Roeb</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Osthues</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tschesche</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Koj</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Heinrich</LastName>
						<ForeName>P C</ForeName>
						<Initials>PC</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Graeve</LastName>
						<ForeName>L</ForeName>
						<Initials>L</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>FEBS Lett</MedlineTA>
				<NlmUniqueID>0155157</NlmUniqueID>
				<ISSNLinking>0014-5793</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019714">Tissue Inhibitor of Metalloproteinases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.-</RegistryNumber>
					<NameOfSubstance UI="D008666">Metalloendopeptidases</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008666" MajorTopicYN="N">Metalloendopeptidases</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019714" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinases</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>23</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>23</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>23</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1330702</ArticleId>
				<ArticleId IdType="pii">0014-5793(92)81431-K</ArticleId>
				<ArticleId IdType="doi">10.1016/0014-5793(92)81431-k</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1330799</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>12</Month>
				<Day>23</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>11</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0435-1339</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>27</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Oct</Month>
						</PubDate>
					</JournalIssue>
					<Title>Gastroenterologia Japonica</Title>
					<ISOAbbreviation>Gastroenterol Jpn</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Induction of interleukin 6 production by interleukin 1 and tumor necrosis factor in human hepatoma cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>685</MedlinePgn>
				</Pagination>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Kohda</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Internal Medicine (III), Asahikawa Medical College, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ono</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Torimoto</LastName>
						<ForeName>Y</ForeName>
						<Initials>Y</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ohhira</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mizuno</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tanaka</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sekiya</LastName>
						<ForeName>C</ForeName>
						<Initials>C</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Namiki</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Japan</Country>
				<MedlineTA>Gastroenterol Jpn</MedlineTA>
				<NlmUniqueID>0152744</NlmUniqueID>
				<ISSNLinking>0435-1339</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>10</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1330799</ArticleId>
				<ArticleId IdType="doi">10.1007/BF02774988</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1331218</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>12</Month>
				<Day>22</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>04</Month>
				<Day>09</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0091-6749</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>90</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Nov</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of allergy and clinical immunology</Title>
					<ISOAbbreviation>J Allergy Clin Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Platelet-activating factor enhances interleukin-6 production by alveolar macrophages.</ArticleTitle>
				<Pagination>
					<MedlinePgn>796-802</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The production of the cytokine interleukin-6 (IL-6) by rat alveolar macrophages (AMs) was analyzed after their stimulation with muramyl dipeptide (1 microgram/ml), in the presence of graded concentrations of platelet-activating factor (PAF). Significantly enhanced production of IL-6 was observed at 10(-10) to 10(-8) mol/L PAF, with peak effect at 10(-10) mol/L. This enhancement was blocked by three structurally unrelated specific PAF receptor antagonists BN 52021, WEB 2170, and CV 3988. The biologically inactive PAF precursor/metabolite, lyso-PAF, and the enantiomer enantio-PAF failed to induce significant enhancement in IL-6 production. In parallel, addition of PAF to AM triggered leukotriene B4 (LTB4) release. Inhibition of 5-lipoxygenase pathway by AA-861 or MK 886 inhibited the PAF-induced augmentation of both IL-6 and LTB4 production, suggesting an implication of endogenous leukotrienes in this mechanism. Furthermore, addition of exogenous LTB4 to AMs could augment their IL-6 production, with peak activity at 10(-12) mol/L LTB4, and reverse the inhibitory effects of 5-lipoxygenase inhibitors. Taken together, these observations suggest that PAF can modulate lung immune and inflammatory responses by enhancing IL-6 production and that this activity may be dependent on secondary 5-lipoxygenase metabolites. This may have clinical relevance in PAF-mediated events in the lung, such as the cellular components of late-phase asthma.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Thivierge</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Pediatrics, Faculty of Medicine, University of Sherbrooke, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rola-Pleszczynski</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Allergy Clin Immunol</MedlineTA>
				<NlmUniqueID>1275002</NlmUniqueID>
				<ISSNLinking>0091-6749</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D004224">Diterpenes</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D046934">Ginkgolides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007783">Lactones</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010972">Platelet Activating Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>080626SQ8C</RegistryNumber>
					<NameOfSubstance UI="C060893">MK-886</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1HGW4DR56D</RegistryNumber>
					<NameOfSubstance UI="D007975">Leukotriene B4</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>DF149B9460</RegistryNumber>
					<NameOfSubstance UI="C045856">ginkgolide B</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004224" MajorTopicYN="Y">Diterpenes</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D046934" MajorTopicYN="N">Ginkgolides</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007783" MajorTopicYN="N">Lactones</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007975" MajorTopicYN="N">Leukotriene B4</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016676" MajorTopicYN="N">Macrophages, Alveolar</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010972" MajorTopicYN="N">Platelet Activating Factor</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1331218</ArticleId>
				<ArticleId IdType="pii">0091-6749(92)90104-A</ArticleId>
				<ArticleId IdType="doi">10.1016/0091-6749(92)90104-a</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1336653</PMID>
			<DateCompleted>
				<Year>1993</Year>
				<Month>02</Month>
				<Day>12</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2013</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0004-069X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>40</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>1992</Year>
						</PubDate>
					</JournalIssue>
					<Title>Archivum immunologiae et therapiae experimentalis</Title>
					<ISOAbbreviation>Arch Immunol Ther Exp (Warsz)</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin 6 production by mononuclear phagocytes can be stimulated by leukotrienes.</ArticleTitle>
				<Pagination>
					<MedlinePgn>17-21</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Leukotriene B4 is a potent lipid mediator of inflammation, and some of its bioactivities may involve inflammatory cytokines. Human monocytes, cultured in the presence of graded concentrations of LTB4, were significantly stimulated in their production of IL6. Nanomolar concentrations of the mediator were optimal for stimulation of IL6 production, which was already significant at 6 hours. LTC4 showed a similar, albeit lower activity. In addition to stimulating IL6 protein production, LTB4 also augmented IL6 mRNA accumulation, which was maximal at 1 hour. Furthermore, LTB4-treated monocytes contained increased amounts of nuclear protein capable of binding to potential transcriptional promoter regions of the IL6 gene. These data suggest that leukotrienes may modulate the production of IL6 and indicate some underlying mechanisms which may be involved.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Stanková</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Pediatrics, Faculty of Medicine, University of Sherbrooke, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rola-Pleszczynski</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Switzerland</Country>
				<MedlineTA>Arch Immunol Ther Exp (Warsz)</MedlineTA>
				<NlmUniqueID>0114365</NlmUniqueID>
				<ISSNLinking>0004-069X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D013189">SRS-A</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1HGW4DR56D</RegistryNumber>
					<NameOfSubstance UI="D007975">Leukotriene B4</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007975" MajorTopicYN="N">Leukotriene B4</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012045" MajorTopicYN="N">Regulatory Sequences, Nucleic Acid</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013189" MajorTopicYN="N">SRS-A</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1336653</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1337557</PMID>
			<DateCompleted>
				<Year>1993</Year>
				<Month>03</Month>
				<Day>16</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>11</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0386-846X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>15</Volume>
						<Issue>9</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Sep</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of pharmacobio-dynamics</Title>
					<ISOAbbreviation>J Pharmacobiodyn</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Cyclic AMP mimics IL-1 action in augmenting the differentiation of a mouse myeloid leukemic cell line (M1).</ArticleTitle>
				<Pagination>
					<MedlinePgn>491-500</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>We have shown previously that recombinant human interleukin 1(IL-1) and interleukin 6 (IL-6) inhibited the proliferation of a mouse myeloid leukemic cell line (M1), and that IL-6 induced differentiation of the cells into macrophage-like cells and that IL-1 augmented this differentiation. Using this model we investigated the action mechanisms of IL-1 and IL-6. IL-6, but not IL-1, stimulated prostaglandin E2 (PGE2) production. The differentiative effect of IL-6 however, was not suppressed by indomethacin, although PGE2 induction by IL-6 was completely inhibited. Exogenously added PGE2 neither augmented the differentiative effect of IL-6 nor induced differentiation in combination with IL-1. Therefore, stimulation of PGE2 production did not appear to be essential for differentiative effects of these cytokines. Dibutyryl cAMP, 8-Br-cAMP and two adenylate cyclase-activating reagents, cholera toxin (CT) and forskolin (FK), all exhibited the similar augmenting effects as IL-1. These reagents augmented M1 cell differentiation by IL-6, and they did not induce differentiation in combination with IL-1. cAMP derivatives, CT, FK, IL-1 and IL-6 all inhibited the proliferation of M1 cells. CT and FK increased the intracellular cAMP levels. However, neither IL-1 nor IL-6 increased the cAMP levels. In contrast to the cAMP derivatives and reagents that activate adenylate cyclase activity, phorbol 12-myristate 13-acetate (PMA) and calcium ionophore neither induced nor augmented the differentiation in combination with either IL-1 or IL-6. Intracellular Ca2+ concentration was not altered by IL-1 or IL-6 suggesting that Ca2+/Calmodulin kinase and protein kinase C activation are not involved in this signal transduction pathway. Therefore, the present study suggests that IL-1 exhibits an effect similar to that of cAMP without affecting intracellular cAMP level.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Onozaki</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>From the Department of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Nagoya City University, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kato</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Inui</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Takuwa</LastName>
						<ForeName>Y</ForeName>
						<Initials>Y</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Akiyama</LastName>
						<ForeName>Y</ForeName>
						<Initials>Y</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Japan</Country>
				<MedlineTA>J Pharmacobiodyn</MedlineTA>
				<NlmUniqueID>7901854</NlmUniqueID>
				<ISSNLinking>0386-846X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007202">Indicators and Reagents</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>E0399OZS9N</RegistryNumber>
					<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 4.6.1.1</RegistryNumber>
					<NameOfSubstance UI="D000262">Adenylyl Cyclases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>SY7Q814VUP</RegistryNumber>
					<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000262" MajorTopicYN="N">Adenylyl Cyclases</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007202" MajorTopicYN="N">Indicators and Reagents</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007951" MajorTopicYN="N">Leukemia, Myeloid</DescriptorName>
					<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1337557</ArticleId>
				<ArticleId IdType="doi">10.1248/bpb1978.15.491</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1339917</PMID>
			<DateCompleted>
				<Year>1993</Year>
				<Month>11</Month>
				<Day>19</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2014</Year>
				<Month>11</Month>
				<Day>20</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0141-2760</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>37</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>1992</Year>
						</PubDate>
					</JournalIssue>
					<Title>Journal of clinical &amp; laboratory immunology</Title>
					<ISOAbbreviation>J Clin Lab Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>173-82</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Recently in Japan, one form of vitamin B12, methylcobalamin also known as methyl B12, has attracted the attention of physicians as a therapy for patients with rheumatoid arthritis. However, its immunological actions in vivo are still unknown. In this study, we induced the in vitro production of such cytokines as interleukin-6 (IL-6), interferon-gamma (IFN-gamma), and interleukin-1 beta (IL-1 beta) by adding various mitogens (phytohemagglutinin:PHA, concanavalin A: ConA, or pokeweed mitogen:PWM) as well as recombinant interleukin-2, and we investigated the effects of methyl B12 (final concentration, 8-8,000 ng/ml) on the production of these cytokines by peripheral mononuclear cells. As compared to the controls, IL-6 production induced by PHA and ConA on Day 4 of the culture was suppressed by an average 60-70% when methyl B12 (80-8,000 ng/ml) was added to the medium. IFN-gamma production decreased dose-dependently with methyl B12, i.e., it decreased to 46% of the control when this production was induced by rIL-2, and decreased to 56-66% when it was induced by mitogens. The effect of methyl B12 on IL-1 beta production on Day I of the culture was small. These findings indicate that methyl B12 suppresses mainly the cytokine production of T lymphocytes. Such suppressive effects as shown in the in vitro situation are expected to be expressed also in vivo in patients with rheumatoid arthritis, especially at articulation lesion sites.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Yamashiki</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Laboratory Medicine, Mie University School of Medicine, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nishimura</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kosaka</LastName>
						<ForeName>Y</ForeName>
						<Initials>Y</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Scotland</Country>
				<MedlineTA>J Clin Lab Immunol</MedlineTA>
				<NlmUniqueID>7808987</NlmUniqueID>
				<ISSNLinking>0141-2760</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010835">Phytohemagglutinins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011043">Pokeweed Mitogens</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>11028-71-0</RegistryNumber>
					<NameOfSubstance UI="D003208">Concanavalin A</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>BR1SN1JS2W</RegistryNumber>
					<NameOfSubstance UI="C019476">mecobalamin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>P6YC3EG204</RegistryNumber>
					<NameOfSubstance UI="D014805">Vitamin B 12</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
					<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003208" MajorTopicYN="N">Concanavalin A</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010835" MajorTopicYN="N">Phytohemagglutinins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011043" MajorTopicYN="N">Pokeweed Mitogens</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014805" MajorTopicYN="N">Vitamin B 12</DescriptorName>
					<QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1339917</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1341229</PMID>
			<DateCompleted>
				<Year>1994</Year>
				<Month>01</Month>
				<Day>13</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>10</Month>
				<Day>28</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0960-7404</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>1</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Feb</Month>
						</PubDate>
					</JournalIssue>
					<Title>Surgical oncology</Title>
					<ISOAbbreviation>Surg Oncol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Tumour necrosis factor mediates the survival benefit of interleukin 2 in a murine pulmonary metastases model.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Antibody to tumour necrosis factor (TNF Ab) markedly decreases the toxicity of systemic interleukin-2 (IL-2) in mice but does not completely abrogate the anti-tumour response in terms of number of pulmonary metastases. Experiments were performed with a murine model of pulmonary metastases treated with high-dose IL-2 and concomitant TNF Ab or control antibody (CON Ab) to determine the effects of TNF Ab on survival. Mice were given either equal doses of IL-2 and TNF Ab or CON Ab or equitoxic doses of IL-2. In four consecutive experiments mice given TNF Ab tolerated 5 to 6 additional IL-2 doses (a 40-60% increase in total doses) in the equitoxic IL-2 dose group compared to the maximally tolerated dose with CON Ab. In all four experiments TNF Ab-treated mice had decreased survival compared to the CON Ab group given equal doses of IL-2 and in two of four experiments this difference was statistically significant (P2 &lt; 0.01). Mice given 40-60% additional doses of IL-2 with TNF Ab had no improvement in survival compared with equitoxic doses of IL-2 with CON Ab in three of four experiments (P2 = 0.32, P2 = 0.67, P2 = 0.69). The TNF Ab preparation had no direct inhibition of IL-2 activity in an in vitro IL-2 proliferation bioassay. TNF Ab consistently blocks IL-2 toxicity and it also abrogates IL-2 therapeutic efficacy such that survival parallels treatment toxicity in this experimental model.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Fraker</LastName>
						<ForeName>D L</ForeName>
						<Initials>DL</Initials>
						<AffiliationInfo>
							<Affiliation>Surgical Metabolism Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Thom</LastName>
						<ForeName>A K</ForeName>
						<Initials>AK</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Doherty</LastName>
						<ForeName>G M</ForeName>
						<Initials>GM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Langstein</LastName>
						<ForeName>H N</ForeName>
						<Initials>HN</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Buresh</LastName>
						<ForeName>C M</ForeName>
						<Initials>CM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Norton</LastName>
						<ForeName>J A</ForeName>
						<Initials>JA</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D003160">Comparative Study</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Netherlands</Country>
				<MedlineTA>Surg Oncol</MedlineTA>
				<NlmUniqueID>9208188</NlmUniqueID>
				<ISSNLinking>0960-7404</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
					<QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
					<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName>
					<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
					<QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
					<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
					<QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>
					<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
					<QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1341229</ArticleId>
				<ArticleId IdType="pii">0960-7404(92)90050-U</ArticleId>
				<ArticleId IdType="doi">10.1016/0960-7404(92)90050-u</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1347198</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>03</Month>
				<Day>31</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2017</Year>
				<Month>12</Month>
				<Day>13</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0002-9513</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>262</Volume>
						<Issue>2 Pt 1</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Feb</Month>
						</PubDate>
					</JournalIssue>
					<Title>The American journal of physiology</Title>
					<ISOAbbreviation>Am J Physiol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Discriminatory effects of protein kinase inhibitors and calcium ionophore on endothelial ICAM-1 induction.</ArticleTitle>
				<Pagination>
					<MedlinePgn>C365-73</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Intercellular adhesion molecule 1 (ICAM-1) is a proinflammatory adhesion glycoprotein induced by cytokines such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) as well as lipopolysaccharide (LPS). Little is known, however, concerning the intracellular regulatory mechanisms that modulate ICAM-1 expression in endothelial cells. We probed the involvement of protein kinase function and intracellular calcium ion upon ICAM-1 expression of human umbilical vein endothelial cells activated alternatively by TNF-alpha, IL-1 beta, LPS, or phorbol 12-myristate 13-acetate (PMA). Methodologies for the detection of ICAM-1 included both enzyme-linked immunosorbent assay and immunoprecipitation from biosynthetically labeled cells. The protein kinase inhibitor H-7 blocked induction of ICAM-1 by all of the activators; nonlinear regression analysis revealed 50% inhibitory concentration (IC50) values of 6-10 microM. Another kinase inhibitor, HA1004, did not block expression of the adhesion molecule at concentrations up to 50 microM. In contrast, the kinase inhibitor staurosporine dose dependently inhibited ICAM-1 expression triggered by PMA (IC50 67 +/- 4 nM) but, at similar concentrations, did not inhibit ICAM-1 expression induced by the other inflammatory stimuli. The divalent cation ionophore ionomycin (0.5 microM) interacted synergistically with PMA but not with cytokines or LPS in upregulating ICAM-1. We conclude from these data that although PMA-induced ICAM-1 expression may be triggered through activation of protein kinase C, ICAM-1 induction by IL-1 beta, TNF-alpha, or LPS may involve distinct regulatory pathway(s).</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Myers</LastName>
						<ForeName>C L</ForeName>
						<Initials>CL</Initials>
						<AffiliationInfo>
							<Affiliation>Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut 06877.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Desai</LastName>
						<ForeName>S N</ForeName>
						<Initials>SN</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schembri-King</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Letts</LastName>
						<ForeName>G L</ForeName>
						<Initials>GL</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Wallace</LastName>
						<ForeName>R W</ForeName>
						<Initials>RW</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Am J Physiol</MedlineTA>
				<NlmUniqueID>0370511</NlmUniqueID>
				<ISSNLinking>0002-9513</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000470">Alkaloids</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>126547-89-5</RegistryNumber>
					<NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>37H9VM9WZL</RegistryNumber>
					<NameOfSubstance UI="D000001">Calcimycin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>56092-81-0</RegistryNumber>
					<NameOfSubstance UI="D015759">Ionomycin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>84477-87-2</RegistryNumber>
					<NameOfSubstance UI="D019307">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>H88EPA0A3N</RegistryNumber>
					<NameOfSubstance UI="D019311">Staurosporine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>NI40JAQ945</RegistryNumber>
					<NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D019307" MajorTopicYN="N">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000470" MajorTopicYN="N">Alkaloids</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000001" MajorTopicYN="N">Calcimycin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015815" MajorTopicYN="N">Cell Adhesion Molecules</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015759" MajorTopicYN="N">Ionomycin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D047428" MajorTopicYN="Y">Protein Kinase Inhibitors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019311" MajorTopicYN="N">Staurosporine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013755" MajorTopicYN="N">Tetradecanoylphorbol Acetate</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1347198</ArticleId>
				<ArticleId IdType="doi">10.1152/ajpcell.1992.262.2.C365</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1350224</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>06</Month>
				<Day>24</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2005</Year>
				<Month>11</Month>
				<Day>17</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">1148-5493</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>3</Volume>
						<Issue>2</Issue>
						<PubDate>
							<MedlineDate>1992 Mar-Apr</MedlineDate>
						</PubDate>
					</JournalIssue>
					<Title>European cytokine network</Title>
					<ISOAbbreviation>Eur Cytokine Netw</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Characterization of thymic cell subpopulations involved in IL-1- or GM-CSF-induced IL-6 production.</ArticleTitle>
				<Pagination>
					<MedlinePgn>89-95</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>IL-6 has been demonstrated by in vitro studies to be a cytokine involved in thymocyte activation We show herein that thymocytes cultured at high concentrations in the absence of comitogen respond to IL-1 and, to a lesser degree, to GM-CSF, by producing IL-6. This phenomenon disappears rapidly with decreasing cell densities, suggesting the involvement of a minor cellular component of the thymus which may be solely responsible for or cooperate in IL-6 production. We have analysed several thymic subpopulations for IL-6 production and show that accessory cells, and eventually their precursors, are the major if not exclusive, producers of this cytokine. Mature steroid-resistant thymocytes do not secrete IL-6. Production of IL-6 by total CD4-CD8- thymic cells is largely reduced by the depletion of mature accessory cells which express I-A and Mac-1 antigens. As shown previously, accessory cell precursors within the CD4-CD8- compartment are induced to differentiate into M phi and DC in response to IL-1 and GM-CSF. We provide evidence that this maturation is associated with IL-6 production. Thymic DC and phagocytic cells of the thymic reticulum (P-TR) in vitro produce high levels of IL-6 which are enhanced by GM-CSF or IL-1. These factors have a synergistic effect on IL-6 production by total thymocytes, and on CD4-CD8- cells that are not depleted for mature I-A+ Mac-1+ accessory cells.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Papiernik</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>U. 345 INSERM, CHU Necker-Enfants Malades, Paris, France.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Herbelin</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schneider</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Dy</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>France</Country>
				<MedlineTA>Eur Cytokine Netw</MedlineTA>
				<NlmUniqueID>9100879</NlmUniqueID>
				<ISSNLinking>1148-5493</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>83869-56-1</RegistryNumber>
					<NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008811" MajorTopicYN="N">Mice, Inbred DBA</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010586" MajorTopicYN="N">Phagocytes</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016176" MajorTopicYN="Y">T-Lymphocyte Subsets</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013950" MajorTopicYN="N">Thymus Gland</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1350224</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1350461</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>06</Month>
				<Day>26</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>05</Month>
				<Day>09</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0953-8178</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>4</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Apr</Month>
						</PubDate>
					</JournalIssue>
					<Title>International immunology</Title>
					<ISOAbbreviation>Int Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Co-engagement of CD3 with LFA-1 or ICAM-1 adhesion molecules enhances the frequency of activation of single murine CD4+ and CD8+ T cells and induces synthesis of IL-3 and IFN-gamma but not IL-4 or IL-6.</ArticleTitle>
				<Pagination>
					<MedlinePgn>475-85</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Interaction between the cell adhesion molecules lymphocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) augments T cell activation by increasing the avidity of T cell/antigen-presenting cell (APC) binding. To examine whether LFA-1 and ICAM-1 can also contribute to T cell activation in the absence of APCs, single murine CD4+ and CD8+ T cells were cultured with IL-2 and immobilized antibodies to CD3, CD4 or CD8, and LFA-1 or ICAM-1. The combination of anti-CD3, anti-CD4/CD8, and IL-2 stimulated approximately 20% of CD4+ cells and 30% of CD8+ cells to proliferate. Inclusion of anti-ICAM-1 antibody increased these frequencies to 30 and 40% respectively. Maximum activation frequencies were obtained with the combination of anti-CD3, anti-CD4/CD8, and anti-LFA-1 which stimulated cell division by approximately 40% of single CD4+ cells and at least 60% of single CD8+ cells. Under these conditions, 30-40% of the resultant CD4+ clones and greater than 90% of CD8+ clones secreted IL-3 and IFN-gamma. In addition to responding at higher frequencies that CD4+ cells, CD8+ cells formed larger clones which produced 4-fold higher levels of both cytokines. Although the expression of IL-2, IL-3, IFN-gamma, granulocyte-macrophage colony stimulating factor and tumor necrosis factor alpha could be detected in CD4+ and CD8+ clones at the mRNA level following reverse transcription and polymerase chain reaction amplification, neither the secreted nor mRNA expression of IL-4 or IL-6 was detected in any of the tested clones. It is concluded that co-stimulation of T cells via LFA-1 or ICAM-1 can enhance T cell receptor-dependent activation in the absence of accessory cells and that this mode of stimulation leads to the expression of a restricted range of cytokine genes.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Maraskovsky</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
						<AffiliationInfo>
							<Affiliation>Walter and Eliza Hall Institute of Medical Research, Post Office Royal Melbourne Hospital, Victoria, Australia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Troutt</LastName>
						<ForeName>A B</ForeName>
						<Initials>AB</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kelso</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Int Immunol</MedlineTA>
				<NlmUniqueID>8916182</NlmUniqueID>
				<ISSNLinking>0953-8178</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015815">Cell Adhesion Molecules</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016169">Lymphocyte Function-Associated Antigen-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>126547-89-5</RegistryNumber>
					<NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9007-49-2</RegistryNumber>
					<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015703" MajorTopicYN="Y">Antigens, CD</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015815" MajorTopicYN="N">Cell Adhesion Molecules</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002999" MajorTopicYN="N">Clone Cells</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016169" MajorTopicYN="N">Lymphocyte Function-Associated Antigen-1</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>4</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>4</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>4</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1350461</ArticleId>
				<ArticleId IdType="doi">10.1093/intimm/4.4.475</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1352498</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>08</Month>
				<Day>11</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2017</Year>
				<Month>11</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0014-2980</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>22</Volume>
						<Issue>7</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jul</Month>
						</PubDate>
					</JournalIssue>
					<Title>European journal of immunology</Title>
					<ISOAbbreviation>Eur J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Minimal growth requirements of mature T lymphocytes: interleukin (IL)-1 and IL-6 increase growth rate but not plating efficiency of CD4 cells stimulated with anti-CD3 and IL-2.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1707-11</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>We show that interleukin (IL)-2 is necessary and sufficient for the proliferation of both CD4 and CD8 subsets of peripheral murine T cells activated by plastic-bound anti-CD3 monoclonal antibodies (mAb). The frequency of proliferating cells (f) was 0.32 for CD4 cells and 0.63 for CD8 cells. These frequencies were not increased by the addition of IL-1 or IL-6, alone or in combination. These cytokines were unable to induce responsiveness to IL-2 in T cells confirming that they cannot substitute for the signal delivered via the TcR/CD3 complex. On the other hand, IL-1 and IL-6 increase the growth rate of CD4 cells. The addition of IL-6 significantly lowered the mean doubling time (dt) of CD4 cells (dt: 26 h vs. 38 h in the presence of IL-2 alone, p less than 0.01), while the addition of IL-1, ineffective by itself, combined with IL-6 further increased the growth rate of CD4 cells (dt: 23 h, p less than 0.001). The growth rate of CD8 cells stimulated with anti-CD3 and IL-2, was markedly faster than that of CD4 cells (dt: 18 h vs. 38 h, p less than 0.001) and was not significantly influenced by addition of IL-1 and/or IL-6.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Soldaini</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Biomedicine, University of Pisa.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>MacDonald</LastName>
						<ForeName>H R</ForeName>
						<Initials>HR</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nabholz</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Germany</Country>
				<MedlineTA>Eur J Immunol</MedlineTA>
				<NlmUniqueID>1273201</NlmUniqueID>
				<ISSNLinking>0014-2980</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000945">Antigens, Differentiation, T-Lymphocyte</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017252">CD3 Complex</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016827">CD8 Antigens</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000945" MajorTopicYN="N">Antigens, Differentiation, T-Lymphocyte</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017252" MajorTopicYN="N">CD3 Complex</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016827" MajorTopicYN="N">CD8 Antigens</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011948" MajorTopicYN="N">Receptors, Antigen, T-Cell</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1352498</ArticleId>
				<ArticleId IdType="doi">10.1002/eji.1830220707</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1369606</PMID>
			<DateCompleted>
				<Year>1995</Year>
				<Month>07</Month>
				<Day>20</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>02</Month>
				<Day>14</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0028-3835</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>56</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>Neuroendocrinology</Title>
					<ISOAbbreviation>Neuroendocrinology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Increased circulating interleukin-1 and interleukin-6 after intracerebroventricular injection of lipopolysaccharide.</ArticleTitle>
				<Pagination>
					<MedlinePgn>935-8</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Recently, it was demonstrated that intracerebroventricular (icv) injection of interleukin-1 (IL-1) stimulated circulating interleukin-6 (IL-6) to a greater degree than intravenous (i.v.) injection of IL-1. The goal of this study was to compare the efficacy of lipopolysaccharide (LPS), injected both icv and i.v., on circulating concentrations of IL-1 and IL-6. Both i.v. and icv injection of LPS stimulated plasma levels of IL-1 to a similar degree. However, i.v. injection of LPS was significantly more efficacious than icv injection of LPS in elevating circulating IL-6. These results demonstrate that like i.v. injection of LPS, icv injection of LPS stimulates plasma levels of IL-1 and IL-6. Increases in circulating cytokines during infectious diseases which are limited to the central nervous system may serve to activate peripheral functions of an acute phase response.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Gottschall</LastName>
						<ForeName>P E</ForeName>
						<Initials>PE</Initials>
						<AffiliationInfo>
							<Affiliation>US-Japan Biomedical Research Laboratories, Tulane University, Hebert Center, Belle Chasse, La 70037, USA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Komaki</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Arimura</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Switzerland</Country>
				<MedlineTA>Neuroendocrinology</MedlineTA>
				<NlmUniqueID>0035665</NlmUniqueID>
				<ISSNLinking>0028-3835</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
					<QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
					<QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>12</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1369606</ArticleId>
				<ArticleId IdType="doi">10.1159/000126328</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1371640</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>03</Month>
				<Day>27</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>07</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0002-9629</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>303</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Feb</Month>
						</PubDate>
					</JournalIssue>
					<Title>The American journal of the medical sciences</Title>
					<ISOAbbreviation>Am J Med Sci</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Case report: distinctive immune abnormalities in a patient with procainamide-induced lupus and serositis.</ArticleTitle>
				<Pagination>
					<MedlinePgn>99-104</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>To gain insight into the immunopathogenesis of drug-induced autoimmune disorders, lymphocyte and immunoglobulin distributions and cytokine levels were monitored in the peripheral blood and pleural fluid of a patient with procainamide-induced lupus and pleural effusion. Approximately 80% of the B cells in both compartments were CD5+ compared to 10% to 25% in normal adults. CD4/CD8 ratio and percentage CD4 were normal in peripheral blood. Serum levels of IgG (particularly IgG2), IL-6, and soluble IL-2R were slightly elevated, and those of IgA were significantly elevated compared to normal controls. Analysis of the pleural effusion revealed an increased CD4/CD8 ratio because of an increased percentage of CD4+CD29+ helper memory T cells, lack of expression of the resting B-cell marker CD21, immune complex deposition and complement consumption, increased relative levels of ANA, abnormally high levels of IL-6 and soluble IL-2R, and detectable levels of IL-1b, IFN-g and TNF-a. These observations provide evidence for the involvement of CD5+ B cells and differential helper T-cell activity in procainamide-induced lupus and for an association between local lymphocyte activation and organ pathology.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Klimas</LastName>
						<ForeName>N G</ForeName>
						<Initials>NG</Initials>
						<AffiliationInfo>
							<Affiliation>Miami Veterans Administration Medical Center, Florida.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Patarca</LastName>
						<ForeName>R</ForeName>
						<Initials>R</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Perez</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Garcia-Morales</LastName>
						<ForeName>R</ForeName>
						<Initials>R</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schultz</LastName>
						<ForeName>D</ForeName>
						<Initials>D</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schabel</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fletcher</LastName>
						<ForeName>M A</ForeName>
						<Initials>MA</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D002363">Case Reports</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Am J Med Sci</MedlineTA>
				<NlmUniqueID>0370506</NlmUniqueID>
				<ISSNLinking>0002-9629</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015704">CD4 Antigens</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018956">CD5 Antigens</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019012">Integrin beta1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015375">Receptors, Interleukin-2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>L39WTC366D</RegistryNumber>
					<NameOfSubstance UI="D011342">Procainamide</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName>
					<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015704" MajorTopicYN="N">CD4 Antigens</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018956" MajorTopicYN="N">CD5 Antigens</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019012" MajorTopicYN="N">Integrin beta1</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008177" MajorTopicYN="N">Lupus Vulgaris</DescriptorName>
					<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011342" MajorTopicYN="N">Procainamide</DescriptorName>
					<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015375" MajorTopicYN="N">Receptors, Interleukin-2</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012700" MajorTopicYN="N">Serositis</DescriptorName>
					<QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1371640</ArticleId>
				<ArticleId IdType="pii">S0002-9629(15)35758-X</ArticleId>
				<ArticleId IdType="doi">10.1097/00000441-199202000-00007</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1371701</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>04</Month>
				<Day>03</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>06</Month>
				<Day>09</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-3002</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>1138</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Feb</Month>
							<Day>14</Day>
						</PubDate>
					</JournalIssue>
					<Title>Biochimica et biophysica acta</Title>
					<ISOAbbreviation>Biochim Biophys Acta</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators.</ArticleTitle>
				<Pagination>
					<MedlinePgn>149-56</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The human hepatoma HuH-7 cell line was shown to constitutively express both a plasminogen activator (PA) and a plasminogen activator inhibitor (PAI). Four sublines of the HuH-7 cell line were analyzed and found to express differing amounts of both PA and PAI. The plasminogen activator produced by these cells was identified as urokinase based upon molecular weight, inhibition of activity with anti-UK but not anti-t-PA antibodies, adherence to an anti-UK affinity column and by Northern blotting demonstrating positive hybridization with the cDNA for UK, but not with the t-PA cDNA. The inhibitor produced by HuH-7 cells was identified as PAI-1 by molecular weight, immunoblotting techniques, adherence to an anti-PAI-1 affinity column, and by Northern blotting demonstrating positive hybridization with the cDNA for PAI-1, but not with the PAI-2 cDNA. The expression of both UK and PAI-1 by HuH-7 cells could be modulated by cytokines known to influence the acute phase response. The addition of interleukin-1 (IL-1) induced the expression of both UK and PAI-1. The increase of PAI-1 was due to an increase in amount of the PAI-1 mRNA. The presence of both interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) also increased UK and PAI-1 levels, although not as dramatically as IL-1. The addition of IL-1 together with IL-6 produced a slight synergistic response with respect to PAI-1 expression. This suggests that PAI-1 is able to respond to mediators which aid in the induction of the acute phase response. These studies demonstrate that cells of liver origin are able to produce components of the fibrinolytic system. The synthesis of these components can be altered by inflammatory mediators and thus may be involved in hepatic regulation of fibrinolysis in both normal and diseased states.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Arndt</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Joint Injury and Diseases Research Group, University of Calgary HSC, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Murphy</LastName>
						<ForeName>P</ForeName>
						<Initials>P</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hart</LastName>
						<ForeName>D A</ForeName>
						<Initials>DA</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Netherlands</Country>
				<MedlineTA>Biochim Biophys Acta</MedlineTA>
				<NlmUniqueID>0217513</NlmUniqueID>
				<ISSNLinking>0006-3002</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016895">Culture Media, Serum-Free</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015342">DNA Probes</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015849">Plasminogen Inactivators</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>63231-63-0</RegistryNumber>
					<NameOfSubstance UI="D012313">RNA</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9007-49-2</RegistryNumber>
					<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.21.73</RegistryNumber>
					<NameOfSubstance UI="D014568">Urokinase-Type Plasminogen Activator</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
					<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002846" MajorTopicYN="N">Chromatography, Affinity</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016895" MajorTopicYN="N">Culture Media, Serum-Free</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015342" MajorTopicYN="N">DNA Probes</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
					<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015849" MajorTopicYN="N">Plasminogen Inactivators</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014568" MajorTopicYN="N">Urokinase-Type Plasminogen Activator</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>14</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>14</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>14</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1371701</ArticleId>
				<ArticleId IdType="pii">0925-4439(92)90055-R</ArticleId>
				<ArticleId IdType="doi">10.1016/0925-4439(92)90055-r</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1377705</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>07</Month>
				<Day>31</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>11</Month>
				<Day>30</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0021-972X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>75</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jul</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of clinical endocrinology and metabolism</Title>
					<ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Cytokine modulation of progesterone and estradiol secretion in cultures of luteinized human granulosa cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>254-8</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>To clarify the possible roles of cytokines in the regulation of luteal cell function, we examined the effects of interferon (IFN), interleukin-1 (IL-1), and tumor necrosis factor (TNF) on progesterone and estradiol secretion in cultures of luteinized human granulosa cells. IFN gamma reduced hCG-stimulated progesterone secretion in a concentration-dependent manner; at its maximal inhibitory concentration (10 ng/mL), IFN gamma reduced progesterone secretion to 20% of that in the hCG-stimulated controls. Whereas other IFN (alpha and beta) reproduced the inhibitory effect of IFN gamma, IL-1 and TNF had no effect on hCG-stimulated progesterone secretion at concentrations of 1 and 10 ng/mL. IFN gamma also markedly reduced FSH-stimulated estradiol secretion. Unlike their effects on hCG-stimulated progesterone secretion, IL-1 and TNF reproduced the inhibitory effect of IFN gamma on FSH-stimulated estradiol secretion. IFN gamma significantly reduced both hCG- and FSH-stimulated cAMP generation in granulosa cells. IL-1 and TNF inhibited FSH-stimulated cAMP generation, but they did not inhibit hCG-stimulated cAMP generation. None of these cytokines reduced forskolin-stimulated cAMP generation, thus suggesting that these cytokines affect steps proximal to cAMP generation without affecting cAMP generation itself. IFN gamma also reduced progesterone secretion in response to (Bu)2cAMP, suggesting that it also affects steps distal to cAMP generation. This study has demonstrated that cytokines modulate the steroidogenesis of luteinized human granulosa cells in vitro; the results suggest that cytokines may play permissive roles in regulating luteal cell function.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Fukuoka</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Gynecology and Obstetrics, Faculty of Medicine, Kyoto University, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Yasuda</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Emi</LastName>
						<ForeName>N</ForeName>
						<Initials>N</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fujiwara</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Iwai</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Takakura</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kanzaki</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mori</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Clin Endocrinol Metab</MedlineTA>
				<NlmUniqueID>0375362</NlmUniqueID>
				<ISSNLinking>0021-972X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>4G7DS2Q64Y</RegistryNumber>
					<NameOfSubstance UI="D011374">Progesterone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>4TI98Z838E</RegistryNumber>
					<NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>63X7MBT2LQ</RegistryNumber>
					<NameOfSubstance UI="D003994">Bucladesine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9002-67-9</RegistryNumber>
					<NameOfSubstance UI="D007986">Luteinizing Hormone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9008-11-1</RegistryNumber>
					<NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>E0399OZS9N</RegistryNumber>
					<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003994" MajorTopicYN="N">Bucladesine</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006107" MajorTopicYN="N">Granulosa Cells</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007986" MajorTopicYN="N">Luteinizing Hormone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011374" MajorTopicYN="N">Progesterone</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1377705</ArticleId>
				<ArticleId IdType="doi">10.1210/jcem.75.1.1377705</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1380951</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>10</Month>
				<Day>01</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>07</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0192-0561</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>14</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jul</Month>
						</PubDate>
					</JournalIssue>
					<Title>International journal of immunopharmacology</Title>
					<ISOAbbreviation>Int J Immunopharmacol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>The effects of the antifungal azoles itraconazole, fluconazole, ketoconazole and miconazole on cytokine gene expression in human lymphoid cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>791-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The antifungal azole drugs itraconazole (itra; R51,211), fluconazole (flu; UK-49,858), ketoconazole (keto) and micronazole (mico) have been investigated for their suppressive influence on the gene expression of the immunoregulatory cytokines IL2, IL4, IL9, GM-CSF, TNF-alpha, IFN-gamma, as well as both chains of the IL2 receptor in human PBMC and of the cytokines in the human keratinocyte cell line HaCat 17.5. The results obtained in Northern blot analysis were compared with the effects of the established immunosuppressant drug CSA and the new immunosuppressive drug FK 506, as well as the cytokine TGF-beta, which is also immunosuppressive. While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta). Itra and mico did suppress accumulation of mRNA, but unlike CSA and FK 506, only at high doses (10 micrograms/ml) and after extended incubation (24 h). None of the drugs nor TGF-beta suppressed the expression of the IL2R-alpha and IL2R-beta genes or TNF-alpha-stimulated cytokine gene expression in keratinocytes. Itra and mico, 1 mg/ml (achievable serum level), caused only slight inhibition of the cytokines in PBMC after 6 and 24 h of incubation. These results demonstrate that the mode of action of the azoles is different from CSA and FK 506.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Friccius</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
						<AffiliationInfo>
							<Affiliation>Medizinisch-Naturwissenschaftliches-Forschungszentrum, Tübingen, Federal Republic of Germany.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Pohla</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Adibzadeh</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Siegels-Hübenthal</LastName>
						<ForeName>P</ForeName>
						<Initials>P</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schenk</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Pawelec</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Int J Immunopharmacol</MedlineTA>
				<NlmUniqueID>7904799</NlmUniqueID>
				<ISSNLinking>0192-0561</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>304NUG5GF4</RegistryNumber>
					<NameOfSubstance UI="D017964">Itraconazole</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>7NNO0D7S5M</RegistryNumber>
					<NameOfSubstance UI="D008825">Miconazole</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>83HN0GTJ6D</RegistryNumber>
					<NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>8VZV102JFY</RegistryNumber>
					<NameOfSubstance UI="D015725">Fluconazole</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>R9400W927I</RegistryNumber>
					<NameOfSubstance UI="D007654">Ketoconazole</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>WM0HAQ4WNM</RegistryNumber>
					<NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015725" MajorTopicYN="N">Fluconazole</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017964" MajorTopicYN="N">Itraconazole</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007654" MajorTopicYN="N">Ketoconazole</DescriptorName>
					<QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008825" MajorTopicYN="N">Miconazole</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1380951</ArticleId>
				<ArticleId IdType="pii">0192-0561(92)90077-X</ArticleId>
				<ArticleId IdType="doi">10.1016/0192-0561(92)90077-x</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1381189</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>10</Month>
				<Day>08</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>18</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0177-3593</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>373</Volume>
						<Issue>7</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jul</Month>
						</PubDate>
					</JournalIssue>
					<Title>Biological chemistry Hoppe-Seyler</Title>
					<ISOAbbreviation>Biol Chem Hoppe Seyler</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Tumor necrosis factor regulation of endothelial cell extracellular proteolysis: the role of urokinase plasminogen activator.</ArticleTitle>
				<Pagination>
					<MedlinePgn>555-66</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Morphological and functional changes in the endothelial cell phenotype which may be central to proinflammatory processes can be elicited by tumor necrosis factor alpha (TNF). Recent observations have indicated that TNF can promote the expression, synthesis and secretion of urokinase plasminogen activator (uPA) in low passage human umbilical vein endothelial cells which normally synthesize little uPA. To further address this issue, we evaluated the ability of TNF to regulate: 1) PA and plasminogen activator inhibitor (PAI-1) mRNA expression and 2) endothelial cell surface associated PA and PAI-1. TNF (100 U/ml) treatment of endothelial cultures induced steady state levels of uPA and PAI-1 mRNA following a 18 hr treatment both 6-fold and 2-fold, respectively utilizing northern analysis. In accord with Northern analyses, TNF stimulated a time and dose dependent increase in cell surface associated uPA antigen as determined by a cell based ELISA assay and immunofluorescence in conjunction with flow cytometry. Treatment of endothelial cell cultures with 100 U/ml of TNF resulted in a 3-fold increase in cell surface uPA antigen levels which peaked at 8 hr. In contrast, no changes in tissue-PA (tPA) and PAI-1 cell surface antigen expression were evident under analogous conditions over a 24 hr period. The TNF mediated increase in both uPA mRNA and cell surface uPA expression correlated with the increased ability of endothelial cells to invade matrix and organize into tube-like structures when cultured on Matrigel.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Niedbala</LastName>
						<ForeName>M J</ForeName>
						<Initials>MJ</Initials>
						<AffiliationInfo>
							<Affiliation>Institute of Inflammation and Autoimmunity, Miles Research Center, West Haven, CT.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Stein-Picarella</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Germany</Country>
				<MedlineTA>Biol Chem Hoppe Seyler</MedlineTA>
				<NlmUniqueID>8503054</NlmUniqueID>
				<ISSNLinking>0177-3593</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.21.-</RegistryNumber>
					<NameOfSubstance UI="D010960">Plasminogen Activators</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.21.73</RegistryNumber>
					<NameOfSubstance UI="D014568">Urokinase-Type Plasminogen Activator</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
					<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
					<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009693" MajorTopicYN="N">Nucleic Acid Hybridization</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010960" MajorTopicYN="N">Plasminogen Activators</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014568" MajorTopicYN="N">Urokinase-Type Plasminogen Activator</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1381189</ArticleId>
				<ArticleId IdType="doi">10.1515/bchm3.1992.373.2.555</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1382703</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>10</Month>
				<Day>29</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-4971</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>80</Volume>
						<Issue>7</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Oct</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Blood</Title>
					<ISOAbbreviation>Blood</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1750-7</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Transforming growth factor-beta 1 (TGF-beta 1) induces cell death in myeloid leukemia by apoptosis. In the M1 myeloid leukemia, this induction of apoptosis was inhibited by granulocyte colony-stimulating factor (G-CSF) or interleukin-6 (IL-6) and to a lesser extent by IL-1 alpha. IL-3 and stem cell factor/mast cell growth factor (SCF) showed only a marginal effect, and granulocyte-macrophage and macrophage CSFs (GM-CSF and M-CSF, respectively) were inactive. The induction of apoptosis by TGF-beta 1 in a different myeloid leukemia (7-M12) was inhibited by GM-CSF and IL-3 but not by the other cytokines. In the absence of TGF-beta 1, both M1 and 7-M12 leukemic cells were independent of hematopoietic cytokines for cell viability and growth. The cytotoxic compounds vincristine, vinblastine, adriamycin, cytosine arabinoside, cycloheximide, and sodium azide, some of which are used in cancer chemotherapy, induced cell death by apoptosis in both leukemias. As with TGF-beta 1, apoptosis induced by these cytotoxic compounds was inhibited by GM-CSF (7-M12 leukemia) and by G-CSF or IL-6 (M1 leukemia). Cyclosporine A decreased cell multiplication in M1 cells without inducing apoptosis, and G-CSF and IL-6 inhibited the cytostatic effect of cyclosporine A. It is suggested that the clinical use of cytokines to correct therapy-associated myelosuppression should be carefully timed to avoid protection of malignant cells from the cytotoxic action of the therapeutic compounds.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Lotem</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Molecular Genetics and Virology, Weizmann Institute of Science, Rehovot, Israel.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sachs</LastName>
						<ForeName>L</ForeName>
						<Initials>L</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Blood</MedlineTA>
				<NlmUniqueID>7603509</NlmUniqueID>
				<ISSNLinking>0006-4971</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D001386">Azides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016298">Hematopoietic Cell Growth Factors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007377">Interleukin-3</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019089">Stem Cell Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>04079A1RDZ</RegistryNumber>
					<NameOfSubstance UI="D003561">Cytarabine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>143011-72-7</RegistryNumber>
					<NameOfSubstance UI="D016179">Granulocyte Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>5J49Q6B70F</RegistryNumber>
					<NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>80168379AG</RegistryNumber>
					<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>83869-56-1</RegistryNumber>
					<NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>968JJ8C9DV</RegistryNumber>
					<NameOfSubstance UI="D019810">Sodium Azide</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>98600C0908</RegistryNumber>
					<NameOfSubstance UI="D003513">Cycloheximide</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001386" MajorTopicYN="N">Azides</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003513" MajorTopicYN="N">Cycloheximide</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003561" MajorTopicYN="N">Cytarabine</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004249" MajorTopicYN="Y">DNA Damage</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016179" MajorTopicYN="N">Granulocyte Colony-Stimulating Factor</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006410" MajorTopicYN="Y">Hematopoiesis</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016298" MajorTopicYN="N">Hematopoietic Cell Growth Factors</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007377" MajorTopicYN="N">Interleukin-3</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007942" MajorTopicYN="N">Leukemia, Experimental</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007951" MajorTopicYN="N">Leukemia, Myeloid</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019810" MajorTopicYN="N">Sodium Azide</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019089" MajorTopicYN="N">Stem Cell Factor</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014750" MajorTopicYN="N">Vincristine</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>10</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1382703</ArticleId>
				<ArticleId IdType="pii">S0006-4971(20)67540-1</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1383329</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>11</Month>
				<Day>25</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2017</Year>
				<Month>11</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1767</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>149</Volume>
						<Issue>9</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Nov</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
					<ISOAbbreviation>J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules.</ArticleTitle>
				<Pagination>
					<MedlinePgn>2841-50</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>CD19 is a member of the Ig superfamily expressed on the surface of B lymphocytes that may be involved in the regulation of B cell function. Immunoprecipitation studies with B cell lines solubilized by digitonin have shown CD19 to be part of a multimolecular complex that includes CD21 (CR2) and other unidentified proteins. In this study, two of the CD19-associated proteins were identified as TAPA-1, which is expressed on most cell types, and Leu-13, which is expressed on subsets of lymphoid cells. TAPA-1 and Leu-13 are physically associated in many cell lineages. CD19 and CD21 mAb each specifically coprecipitated proteins of the same size as those precipitated by TAPA-1 and Leu-13 mAb from B cell lines and cDNA-transfected K562 cell lines. Western blot analysis with a TAPA-1 mAb verified the identity of TAPA-1 in CD19 and CD21 immunoprecipitated materials. In addition, when TAPA-1 or Leu-13 were crosslinked and patched on the cell surface, all of the CD19 comigrated with TAPA-1 and some of the CD19 comigrated with Leu-13. Furthermore, mAb binding to CD19, CD21, TAPA-1, and Leu-13 on B cell lines induced similar biologic responses, including the induction of homotypic adhesion, inhibition of proliferation, and an augmentation of the increase in intracellular [Ca2+] induced by suboptimal cross-linking of surface Ig on B cell lines. Together, these data suggest that TAPA-1 and Leu-13 are broadly expressed members of a signal transduction complex in which lineage-specific proteins, such as CD19 and CD21, provide cell-specific functions.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Bradbury</LastName>
						<ForeName>L E</ForeName>
						<Initials>LE</Initials>
						<AffiliationInfo>
							<Affiliation>Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115-6084.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kansas</LastName>
						<ForeName>G S</ForeName>
						<Initials>GS</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Levy</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Evans</LastName>
						<ForeName>R L</ForeName>
						<Initials>RL</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tedder</LastName>
						<ForeName>T F</ForeName>
						<Initials>TF</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="N">
					<Grant>
						<GrantID>AI-26872</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>CA-34183</GrantID>
						<Acronym>CA</Acronym>
						<Agency>NCI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>CA-54464</GrantID>
						<Acronym>CA</Acronym>
						<Agency>NCI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Immunol</MedlineTA>
				<NlmUniqueID>2985117R</NlmUniqueID>
				<ISSNLinking>0022-1767</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018941">Antigens, CD19</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000943">Antigens, Differentiation</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000944">Antigens, Differentiation, B-Lymphocyte</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000954">Antigens, Surface</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C554798">CD81 protein, human</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017464">Receptors, Complement 3d</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D060225">Tetraspanin 28</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C062010">leu-13 antigen</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>SY7Q814VUP</RegistryNumber>
					<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018941" MajorTopicYN="N">Antigens, CD19</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000943" MajorTopicYN="N">Antigens, Differentiation</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000944" MajorTopicYN="N">Antigens, Differentiation, B-Lymphocyte</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000954" MajorTopicYN="N">Antigens, Surface</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008565" MajorTopicYN="Y">Membrane Proteins</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017464" MajorTopicYN="N">Receptors, Complement 3d</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D060225" MajorTopicYN="N">Tetraspanin 28</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1383329</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1385797</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>08</Month>
				<Day>19</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>04</Month>
				<Day>09</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0019-2805</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>76</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>May</Month>
						</PubDate>
					</JournalIssue>
					<Title>Immunology</Title>
					<ISOAbbreviation>Immunology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>30-4</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Pentoxifylline (PTX) is a methylxanthine compound known to inhibit the production of tumour necrosis factor-alpha (TNF-alpha) by monocytic cells. In this study, we found that PTX differentially regulates the production of TNF-alpha and interleukin-6 (IL-6). Indeed, PTX at high concentrations triggers the production of IL-6 but not of TNF-alpha by peripheral blood mononuclear cells (PBMC). Further experiments indicated that monocytes are responsible for this PTX-induced IL-6 production. When PBMC were stimulated with LPS, PTX was found to inhibit the secretion of TNF-alpha as well as the accumulation of TNF-alpha messenger RNA (mRNA). In contrast, no inhibitory effect was observed on the induction of IL-6. Similar results were obtained when PBMC were stimulated with OKT3 monoclonal antibody (mAb). In addition, the in vivo administration of PTX in transplant patients receiving the first dose of OKT3 allowed to decrease the systemic release of TNF-alpha but not of IL-6. Since monocytes represent a major source of TNF-alpha and IL-6 in these settings, additional experiments were performed in vitro on purified T cells stimulated with the CLB-T3/3, an anti-CD3 mAb which does not require the presence of accessory cells to activate T cells. In this system, PTX was found to inhibit the secretion of both TNF-alpha and IL-6 by T cells. We suggest that cAMP could be involved in these differential effects of PTX on production of TNF-alpha and of IL-6.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Schandené</LastName>
						<ForeName>L</ForeName>
						<Initials>L</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Immunology, Hôpital Erasme, Brussels, Belgium.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Vandenbussche</LastName>
						<ForeName>P</ForeName>
						<Initials>P</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Crusiaux</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Alègre</LastName>
						<ForeName>M L</ForeName>
						<Initials>ML</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Abramowicz</LastName>
						<ForeName>D</ForeName>
						<Initials>D</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Dupont</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Content</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Goldman</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Immunology</MedlineTA>
				<NlmUniqueID>0374672</NlmUniqueID>
				<ISSNLinking>0019-2805</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000945">Antigens, Differentiation, T-Lymphocyte</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017252">CD3 Complex</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>SD6QCT3TSU</RegistryNumber>
					<NameOfSubstance UI="D010431">Pentoxifylline</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000945" MajorTopicYN="N">Antigens, Differentiation, T-Lymphocyte</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017252" MajorTopicYN="N">CD3 Complex</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004306" MajorTopicYN="N">Dose-Response Relationship, Immunologic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010431" MajorTopicYN="N">Pentoxifylline</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011948" MajorTopicYN="N">Receptors, Antigen, T-Cell</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1385797</ArticleId>
				<ArticleId IdType="pmc">PMC1421741</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Leukoc Biol. 1986 Dec;40(6):747-54</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3023514</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lancet. 1989 Dec 23-30;2(8678-8679):1474-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2574766</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>N Engl J Med. 1987 Feb 12;316(7):379-85</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3543677</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1988 Sep;85(18):6802-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2842790</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Aug 15;141(4):1197-201</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3135322</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Biochem. 1986 Sep 15;159(3):625-32</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3758081</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1991 Apr 1;146(7):2088-94</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1826015</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Transplantation. 1991 Oct;52(4):674-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1833865</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunology. 1991 Jan;72(1):56-60</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1847694</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1991 Mar 15;146(6):1843-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1848573</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Surgery. 1991 Aug;110(2):192-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1858029</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lancet. 1990 Mar 3;335(8688):543</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1968555</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1990 Nov 1;172(5):1505-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2121890</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Dec 15;145(12):4185-91</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2124237</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunol Today. 1990 Dec;11(12):443-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2127356</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Sep 1;145(5):1337-42</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2143517</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1990 Nov;10(11):5736-46</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2233715</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1990 Nov;20(11):2439-43</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2253684</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1990 Jul 1;172(1):391-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2358784</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1988 May 5;263(13):6177-82</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2452159</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem Biophys Res Commun. 1988 Sep 30;155(3):1230-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2460096</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1989 Dec;9(12):5537-47</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2511437</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Transplantation. 1989 Apr;47(4):606-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2523100</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Feb 15;142(4):1274-80</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2536771</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell Immunol. 1989 May;120(2):291-300</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2541929</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lancet. 1989 Sep 30;2(8666):802-3</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2571039</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Clin Exp Immunol. 1986 Aug;65(2):387-95</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3098477</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1386409</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>09</Month>
				<Day>02</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2004</Year>
				<Month>11</Month>
				<Day>17</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0028-0836</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>358</Volume>
						<Issue>6386</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Aug</Month>
							<Day>06</Day>
						</PubDate>
					</JournalIssue>
					<Title>Nature</Title>
					<ISOAbbreviation>Nature</ISOAbbreviation>
				</Journal>
				<ArticleTitle>CD21 is a ligand for CD23 and regulates IgE production.</ArticleTitle>
				<Pagination>
					<MedlinePgn>505-7</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The molecule CD23, a low-affinity receptor for IgE (Fc epsilon R2), is a type II transmembrane molecule expressed on many haemopoietic cell types. CD23 has pleiotropic roles in the control of lymphocyte behaviour, suggesting that CD23 may interact with another ligand in addition to IgE. To identify such a CD23 ligand, we expressed and purified full-length recombinant CD23, incorporated it into fluorescent liposomes and used these as a probe. We report here that fluorescent liposomes carrying CD23 interact specifically with the cell-surface protein CD21, identified as the receptor for Epstein-Barr virus and the complement receptor-2 on B cells, some T cells and follicular dendritic cells. In addition, fluorescent CD23-liposomes were shown to bind to hamster kidney cells (BHK-21) transfected with CD21 complementary DNA. The interaction between fluorescent CD23-liposomes and B cells or CD21-transfected BHK-21 cells was specifically inhibited by anti-CD21 and anti-CD23 monoclonal antibodies. Western blotting analysis revealed that 14C-labelled liposomes carrying CD23, in contrast to anti-CD21 antibodies, reacted with a subtype of CD21 molecules. Triggering of CD21 either with an anti-CD21 antibody or with recombinant soluble CD23 was shown to increase specifically interleukin-4-induced IgE production from blood mononuclear cells. These results demonstrate that the cell-surface protein CD21 is a ligand for CD23 and that the pairing of these molecules may participate in the control of IgE production.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Aubry</LastName>
						<ForeName>J P</ForeName>
						<Initials>JP</Initials>
						<AffiliationInfo>
							<Affiliation>Glaxo Institute for Molecular Biology, Geneva, Switzerland.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Pochon</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Graber</LastName>
						<ForeName>P</ForeName>
						<Initials>P</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Jansen</LastName>
						<ForeName>K U</ForeName>
						<Initials>KU</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bonnefoy</LastName>
						<ForeName>J Y</ForeName>
						<Initials>JY</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Nature</MedlineTA>
				<NlmUniqueID>0410462</NlmUniqueID>
				<ISSNLinking>0028-0836</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000944">Antigens, Differentiation, B-Lymphocyte</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008024">Ligands</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011951">Receptors, Complement</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017464">Receptors, Complement 3d</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011961">Receptors, Fc</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017455">Receptors, IgE</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>37341-29-0</RegistryNumber>
					<NameOfSubstance UI="D007073">Immunoglobulin E</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000944" MajorTopicYN="N">Antigens, Differentiation, B-Lymphocyte</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007073" MajorTopicYN="N">Immunoglobulin E</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011951" MajorTopicYN="N">Receptors, Complement</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017464" MajorTopicYN="N">Receptors, Complement 3d</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011961" MajorTopicYN="N">Receptors, Fc</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017455" MajorTopicYN="N">Receptors, IgE</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>6</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>6</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>6</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1386409</ArticleId>
				<ArticleId IdType="doi">10.1038/358505a0</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1386759</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>09</Month>
				<Day>15</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>05</Month>
				<Day>18</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">1046-6673</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>2</Volume>
						<Issue>12</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jun</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of the American Society of Nephrology : JASN</Title>
					<ISOAbbreviation>J Am Soc Nephrol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin-1 regulates cytokine gene expression in human mesangial cells through the interleukin-1 receptor type 1.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1709-15</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>We have recently shown that interleukin-1 is a potent stimulus of gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells in culture. Here, we sought to determine whether interleukin-1 induces its own gene expression in human mesangial cells. Interleukin-1 mRNA levels were quantitated by Northern blot analysis with total cellular RNAs isolated from human mesangial cells exposed for 6 h to medium alone or in the presence of human recombinant interleukin-1 beta (1 to 100 ng/mL). Interleukin-1 induced interleukin-1 mRNA expression in a dose-dependent manner. An additional finding of this study was that human mesangial cells constitutively express the 80 kd interleukin-1 receptor type 1 gene. When human mesangial cells were exposed to interleukin-1, interleukin-1 receptor expression was not modified. Similarly, other stimuli like tumor necrosis factor, transforming growth factor beta, or interleukin-6 did not modulate interleukin-1 receptor expression. Recombinant interleukin-1 receptor antagonist blocked the interleukin-1 mRNA as well as interleukin-6 and interleukin-8 mRNA accumulation induced by interleukin-1 beta. Lipopolysaccharide, which is a known stimulus for interleukin-1 transcription in several cell types, also induced interleukin-1 mRNA accumulation, thus indicating that lipopolysaccharide mediates interleukin-1 gene activation in human mesangial cells through an interleukin-1-independent pathway. These data support the pivotal role of interleukin-1 in regulating mesangial cell cytokine genes and may be taken to indicate the existence of an interleukin-1-mediated positive feedback loop that might control the secretion of active cytokines within the glomeruli when an immunological or inflammatory injury takes place.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Zoja</LastName>
						<ForeName>C</ForeName>
						<Initials>C</Initials>
						<AffiliationInfo>
							<Affiliation>Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Italy.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bettoni</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Morigi</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Remuzzi</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rambaldi</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Am Soc Nephrol</MedlineTA>
				<NlmUniqueID>9013836</NlmUniqueID>
				<ISSNLinking>1046-6673</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017472">Receptors, Interleukin-1</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005920" MajorTopicYN="N">Glomerular Mesangium</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017472" MajorTopicYN="N">Receptors, Interleukin-1</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1386759</ArticleId>
				<ArticleId IdType="doi">10.1681/ASN.V2121709</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1386862</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>09</Month>
				<Day>14</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2014</Year>
				<Month>11</Month>
				<Day>20</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1767</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>149</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Aug</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
					<ISOAbbreviation>J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>IL-4 reciprocally regulates IL-1 and IL-1 receptor antagonist expression in human monocytes.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1283-8</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Activation of human monocytes with LPS induces coordinate expression of a number of cytokine genes, including IL-1 alpha, IL-1 beta, TNF-alpha, IL-6, and IL-8. The T cell-derived lymphokine, IL-4, inhibits expression of these genes in monocytes, suggesting that it may be an important physiologic regulator of cytokine production. We have previously shown that IL-4 reduces steady state messenger RNA (mRNA) levels for IL-1 beta in human monocytes by decreasing both IL-1 beta transcription and the t1/2 of newly formed IL-1 beta mRNA transcripts. In the present study, we extend these findings to show that IL-4 similarly accelerates the turnover of IL-6 mRNA in LPS-stimulated monocytes. However, this inhibition of cytokine expression and dramatic increase in the decay rate of cytokine mRNA does not extend to all LPS-inducible genes because IL-4 treatment did not inhibit the expression or accelerate the turnover of mRNA for the IL-1 receptor antagonist (IL-1ra) in the same cells. Although IL-1 beta and IL-1Ra are both LPS-inducible genes, they displayed distinct temporal patterns of expression. Peak steady state mRNA levels for IL-1ra lagged significantly behind that of IL-1 beta, suggesting a possible endogenous mechanism for limiting IL-1 biologic activity. Furthermore, although IL-4 suppressed expression of both IL-1 beta and IL-6, it up-regulated synthesis of IL-1ra mRNA and protein. Thus, IL-4 inhibits production of the proinflammatory cytokine, IL-1 beta, while concomitantly enhancing synthesis of the IL-1ra in activated human monocytes.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Fenton</LastName>
						<ForeName>M J</ForeName>
						<Initials>MJ</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, Boston University Medical Center, MA 02118.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Buras</LastName>
						<ForeName>J A</ForeName>
						<Initials>JA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Donnelly</LastName>
						<ForeName>R P</ForeName>
						<Initials>RP</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AI 29088</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Immunol</MedlineTA>
				<NlmUniqueID>2985117R</NlmUniqueID>
				<ISSNLinking>0022-1767</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C507763">IL1RN protein, human</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012795">Sialoglycoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>207137-56-2</RegistryNumber>
					<NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D053590" MajorTopicYN="N">Interleukin 1 Receptor Antagonist Protein</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
					<QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012795" MajorTopicYN="Y">Sialoglycoproteins</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1386862</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1387149</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>09</Month>
				<Day>22</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2008</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1767</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>149</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Sep</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
					<ISOAbbreviation>J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Tumor necrosis factor-alpha and IL-6 up-regulate IFN-gamma receptor gene expression in human monocytic THP-1 cells by transcriptional and post-transcriptional mechanisms.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1671-5</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>IFN-gamma is a potent activator of monocytic cell functions, including the stimulation of TNF-alpha and the control of IL-6 synthesis. These cytokines might act as autocrine or paracrine factors together with IFN-gamma in inducing biologic responses. In this study, we addressed the question of whether or not TNF-alpha and IL-6 play a role in modulating of IFN-gamma binding. Expression of IFN-gamma surface receptor was measured in the human monocytic THP-1 cells. The capacity of these cells to bind IFN-gamma increased with time after treatment with each cytokine. The number of IFN-gamma R per cell rose by three- and fourfold after 16 h of treatment with TNF-alpha and IL-6, respectively. Scatchard analysis of binding data showed that neither TNF-alpha nor IL-6 affected the affinity of IFN-gamma for its receptor. The increased surface expression of IFN-gamma R induced by TNF-alpha and IL-6 correlated with the rise in IFN-gamma mRNA receptor levels. TNF-alpha-mediated up-regulation of IFN-gamma R was due to an increase in transcriptional activity of the IFN-gamma R gene, as shown by run-on experiments. No significant modulation of IFN-gamma R gene transcription was observed in nuclei from cells treated with IL-6, whose effect appeared to be related to IFN-gamma mRNA receptor stabilization. Taken together, the present results provide, to our knowledge, the first evidence for cytokine-mediated up-regulation of IFN-gamma R in human monocytic cells. This up-regulation by TNF-alpha and IL-6, which are both produced by monocytes, occurs through different mechanisms, and may be of physiologic relevance in host defense.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Sanceau</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>Unité 196 INSERM Interférons et Cytokines, Institut Curie, Paris, France.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Merlin</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Wietzerbin</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Immunol</MedlineTA>
				<NlmUniqueID>2985117R</NlmUniqueID>
				<ISSNLinking>0022-1767</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017471">Receptors, Interferon</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017471" MajorTopicYN="N">Receptors, Interferon</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1387149</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1391232</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>10</Month>
				<Day>29</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2003</Year>
				<Month>11</Month>
				<Day>14</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">1056-5477</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>11</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jun</Month>
						</PubDate>
					</JournalIssue>
					<Title>Lymphokine and cytokine research</Title>
					<ISOAbbreviation>Lymphokine Cytokine Res</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.</ArticleTitle>
				<Pagination>
					<MedlinePgn>133-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Interleukin-6 (IL-6) is a pleiotropic cytokine and has been shown to support the growth of T and B lymphocytes in the presence of mitogens in vitro. IL-6 can induce human natural killer (NK) and interleukin-2 (IL-2)-induced lymphokine-activated killer cell (LAK) activity in vitro. It can also mediate antitumor effects in various murine models. In order to understand the mechanism of in vivo action, we have investigated the proliferation of lymphoid cells in vivo and the effects on NK, and LAK cell activities in response to IL-6 administration in mice. In vivo proliferation was measured by labeling the DNA of dividing cells with [125I]iodo-2'-deoxyuridine. C57BL/6 mice were injected ip with either IL-6 or HBSS control two times a day for 3 days and in vivo proliferation was measured. For comparative purpose IL-2 was administered and in vivo effects were analyzed. IL-6 caused significant proliferation of cells mainly in the spleen, while, IL-2 caused proliferation in the lungs, liver, spleen, and kidneys. Pretreatment irradiation (500 rad) of mice abrogated the IL-6-induced proliferation indicating radiosensitive cells are involved. Furthermore, in vivo proliferation was not observed in young nude mice treated with IL-6. To investigate whether the proliferating cells were cytotoxic, we tested for LAK (vs. fresh MCA-102 tumor targets) and NK (vs. Yac-1 tumor targets) activities in the organs of mice treated with IL-6 or IL-2 by 4 h 51Cr-release assay. IL-2 administration induced the generation of LAK activity and increased NK cytotoxicity in various organs, but IL-6 had no effect.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Puri</LastName>
						<ForeName>R K</ForeName>
						<Initials>RK</Initials>
						<AffiliationInfo>
							<Affiliation>Laboratory of Cellular Immunology, FDA, Bethesda, MD 20892.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Leland</LastName>
						<ForeName>P</ForeName>
						<Initials>P</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Lymphokine Cytokine Res</MedlineTA>
				<NlmUniqueID>9107882</NlmUniqueID>
				<ISSNLinking>1056-5477</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015979" MajorTopicYN="N">Killer Cells, Lymphokine-Activated</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008221" MajorTopicYN="N">Lymphoid Tissue</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008223" MajorTopicYN="N">Lymphoma</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014916" MajorTopicYN="N">Whole-Body Irradiation</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1391232</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1405313</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>11</Month>
				<Day>13</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>07</Month>
				<Day>25</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0085-2538</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>42</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Aug</Month>
						</PubDate>
					</JournalIssue>
					<Title>Kidney international</Title>
					<ISOAbbreviation>Kidney Int</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Cultured mesangial cells from autoimmune MRL-lpr mice have decreased secreted and surface M-CSF.</ArticleTitle>
				<Pagination>
					<MedlinePgn>279-84</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>M-CSF has been implicated in the pathogenesis of lupus nephritis in MRL-lpr mice. We recently reported persistently high levels of serum M-CSF in MRL-lpr mice as early as one week of age, not present in normal mice including C3H mice. In addition, M-CSF transcripts in MRL-lpr renal cortex increased with an increase in the severity of nephritis. Because glomerular mesangial cells (MC) secrete M-CSF, we investigated whether cultured MRL-lpr MC secrete more M-CSF than C3H MC. Paradoxically, unstimulated MRL-lpr MC secreted substantially less M-CSF than C3H MC [26 +/- 11 vs. 109 +/- 7 colony forming units (CFU)]. We then explored whether MC could express membrane bound M-CSF. We detected a 31 kDa form of membrane M-CSF on both MRL-lpr and C3H MC. Fewer MRL-lpr MC than C3H MC (24 +/- 5% vs. 78 +/- 5%) expressed membrane M-CSF. Furthermore, the increase in the mean channel log fluorescence intensity on MRL-lpr MC was considerably less than in C3H MC, indicating a lower density of M-CSF on MRL-lpr MC. Because our prior studies established that MRL-lpr kidneys have enhanced expression of TNF alpha, we stimulated cultured MC with TNF alpha. TNF alpha increased M-CSF secretion by stimulated MRL-lpr by twofold over unstimulated MRL-lpr MC, but did not increase M-CSF in C3H MC. In addition, M-CSF secretion was modestly greater in stimulated MRL-lpr MC compared to stimulated C3H MC. In conclusion, this is the first report of membrane M-CSF detectable on cultured MC. These studies note that despite higher circulating M-CSF and renal M-CSF transcripts in MRL-lpr mice, cultured MRL-lpr MC have lower basal secreted and membrane bound M-CSF than cultured C3H MC.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Brennan</LastName>
						<ForeName>D C</ForeName>
						<Initials>DC</Initials>
						<AffiliationInfo>
							<Affiliation>Laboratory of Immunogenetics and Transplantation, Brigham and Women's Hospital, Boston, Massachusetts.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Jevnikar</LastName>
						<ForeName>A M</ForeName>
						<Initials>AM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bloom</LastName>
						<ForeName>R D</ForeName>
						<Initials>RD</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Brissette</LastName>
						<ForeName>W H</ForeName>
						<Initials>WH</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Singer</LastName>
						<ForeName>G G</ForeName>
						<Initials>GG</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kelley</LastName>
						<ForeName>V R</ForeName>
						<Initials>VR</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>CA-48626</GrantID>
						<Acronym>CA</Acronym>
						<Agency>NCI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>DK-36149</GrantID>
						<Acronym>DK</Acronym>
						<Agency>NIDDK NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>DK-40839</GrantID>
						<Acronym>DK</Acronym>
						<Agency>NIDDK NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Kidney Int</MedlineTA>
				<NlmUniqueID>0323470</NlmUniqueID>
				<ISSNLinking>0085-2538</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>81627-83-0</RegistryNumber>
					<NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005920" MajorTopicYN="N">Glomerular Mesangium</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016173" MajorTopicYN="N">Macrophage Colony-Stimulating Factor</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008817" MajorTopicYN="N">Mice, Mutant Strains</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1405313</ArticleId>
				<ArticleId IdType="pii">S0085-2538(15)57716-8</ArticleId>
				<ArticleId IdType="doi">10.1038/ki.1992.287</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1421015</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>12</Month>
				<Day>21</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2014</Year>
				<Month>11</Month>
				<Day>20</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">1148-5493</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>3</Volume>
						<Issue>4</Issue>
						<PubDate>
							<MedlineDate>1992 Jul-Aug</MedlineDate>
						</PubDate>
					</JournalIssue>
					<Title>European cytokine network</Title>
					<ISOAbbreviation>Eur Cytokine Netw</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin-1 and tumour necrosis factor production by human monocytoid cells: study on a single cell level.</ArticleTitle>
				<Pagination>
					<MedlinePgn>421-8</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Human IL-1 beta and TNF alpha production by normal and transformed monocytoid cells was studied using biological assays, cytokine specific ELISA and by immunocytochemical methods on a single cell level. Quiescent human blood monocytes and cultured in vitro transformed human monocytoid cell lines U-937, THP-1 and HL-60 did not contain IL-1 beta and TNF alpha in their cytoplasm. IL-1 beta synthesis and secretion was induced by LPS stimulation in nearly 90% monocytes, 15-20% U-937, 3-5% THP-1 and in no HL-60 cells. Normal human blood monocytes had a more rapid kinetics of IL-1 beta synthesis. IL-1 beta positive cells stained with antibodies to human IL-1 beta appeared at 1-2 hours after LPS application, while in monocytic cell lines only after 4-6 hours. Using immunoperoxidase staining of U-937 cells pulse labelled with 3H-thymidine, it was shown that proliferating cells did not synthetize IL-1 beta. Instead of IL-1 beta, TNF alpha could be induced by LPS in U-937 cells only after preliminary differentiation with PMA. Recombinant IL-1 beta induced a very low level of TNF alpha production in PMA-treated cells. Similarly recombinant TNF alpha alone induced IL-1 beta synthesis only in a few U-937 cells.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Simbirtsev</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Research Institute of Highly Pure Biochemicals, St. Petersburg, Russia.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Prokopieva</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ivanova</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Konusova</LastName>
						<ForeName>V</ForeName>
						<Initials>V</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Perumov</LastName>
						<ForeName>N D</ForeName>
						<Initials>ND</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ketlinsky</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>France</Country>
				<MedlineTA>Eur Cytokine Netw</MedlineTA>
				<NlmUniqueID>9100879</NlmUniqueID>
				<ISSNLinking>1148-5493</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>NI40JAQ945</RegistryNumber>
					<NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013755" MajorTopicYN="N">Tetradecanoylphorbol Acetate</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1421015</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1427600</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>12</Month>
				<Day>17</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2008</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0367-6102</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>67</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jul</Month>
						</PubDate>
					</JournalIssue>
					<Title>[Hokkaido igaku zasshi] The Hokkaido journal of medical science</Title>
					<ISOAbbreviation>Hokkaido Igaku Zasshi</ISOAbbreviation>
				</Journal>
				<ArticleTitle>[Synergism between transcription factors NF-IL6 and NF-kappa B in IL-6 gene regulation].</ArticleTitle>
				<Pagination>
					<MedlinePgn>563-74</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>NF-IL6 and NF-kappa B are nuclear proteins supposed to play an important role in the regulation of acute-phase protein synthesis and inflammatory response against infection and tissue injury as a host defence mechanism. In addition the promoter region of the interleukin-6 (IL-6) gene has a NF-kappa B binding motif as well as a NF-IL6 binding site. Considering of these facts, we come to investigate that there may be a synergistic effect between NF-IL6 and NF-kappa B in the regulation of IL-6 gene expression. In order to study it, some combinations of expression vectors NF-IL6 cDNA, NF-kappa B (p50/p65) cDNA and reporter plasmid K18-CAT which contains human IL-6 promoter linked to the chloramphenicol acetyltransferase (CAT) gene, were transfected into Jurkat cells and the CAT activities were examined. Co-transfection of NF-IL6 and NF-kappa B (p50/p65) cDNA revealed a dramatic increase of acetylated [14C] chloramphenicol, and its CAT activity reached to 40%. Then, co-transfection of NF-IL6 and NF-kappa B subunit p65 alone showed a high level of CAT activity, too. When 5' deletion mutant reporter plasmid K9-CAT lacking the NF-IL6 binding site was used, co-transfection of NF-IL6 and NF-kappa B (p50/p65) showed low level of CAT activity. These results indicate that there is a synergistic effect between NF-IL6 and NF-kappa B (p50/p65) in IL-6 gene regulation. Among two subunits of NF-kappa B (p50/p65), p65 seems to play an important role rather than p50 does in synergism between NF-IL6 and NF-kappa B. Besides, this synergistic function comes to work only when NF-IL6 binds to its binding site of IL-6 promoter region.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Fujikawa</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>jpn</Language>
				<PublicationTypeList>
					<PublicationType UI="D004740">English Abstract</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Japan</Country>
				<MedlineTA>Hokkaido Igaku Zasshi</MedlineTA>
				<NlmUniqueID>17410290R</NlmUniqueID>
				<ISSNLinking>0367-6102</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D022762">CCAAT-Enhancer-Binding Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9007-49-2</RegistryNumber>
					<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.3.1.28</RegistryNumber>
					<NameOfSubstance UI="D015500">Chloramphenicol O-Acetyltransferase</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D022762" MajorTopicYN="N">CCAAT-Enhancer-Binding Proteins</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015500" MajorTopicYN="N">Chloramphenicol O-Acetyltransferase</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1427600</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1428023</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>12</Month>
				<Day>04</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>10</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0882-0139</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>21</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Oct</Month>
						</PubDate>
					</JournalIssue>
					<Title>Immunological investigations</Title>
					<ISOAbbreviation>Immunol Invest</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Surface matrix binding alters murine peritoneal mononuclear phagocyte TNF-alpha and IL-6 induction.</ArticleTitle>
				<Pagination>
					<MedlinePgn>539-52</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Interferon-gamma (IFN-gamma) and bacterial lipopolysaccharide (LPS) are important promotors of mononuclear phagocyte (MO) activation. Signals derived from binding to a surface matrix also participate in promoting the activation process of MO. In this study, we examined the relative contribution of adherence in augmenting murine MO activation for cytokine production. Kinetic studies compared the production and secretion of tumor necrosis factor-alpha (TNF) and interleukin-6 (IL-6) by MO cultured as adherent monolayers to those of MO cultured as suspended cells in teflon vessels. All cells were maximally stimulated in vitro with IFN-gamma and LPS prior to analysis. Immunoprecipitation analysis of protein and RNA slot blots showed that both secreted protein and mRNA representing TNF and IL-6 are delayed two to six hours in nonadherent MO cultures compared to adherent MO cultures. Moreover, data from bioassays confirmed that these cytokines were completely functional in both systems examined. Although IFN-gamma/LPS were able to stimulate production and secretion of TNF and IL-6 in the nonadherent cells, without cell-matrix interaction, the process was significantly delayed. These data support the hypothesis that the physical event of adherence significantly facilitates the production of specific cytokines by activated MO.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Darville</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tabor</LastName>
						<ForeName>D R</ForeName>
						<Initials>DR</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Theus</LastName>
						<ForeName>S A</ForeName>
						<Initials>SA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Jacobs</LastName>
						<ForeName>R F</ForeName>
						<Initials>RF</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Immunol Invest</MedlineTA>
				<NlmUniqueID>8504629</NlmUniqueID>
				<ISSNLinking>0882-0139</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005109" MajorTopicYN="N">Extracellular Matrix</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010586" MajorTopicYN="N">Phagocytes</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>10</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1428023</ArticleId>
				<ArticleId IdType="doi">10.3109/08820139209069389</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1429553</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>12</Month>
				<Day>01</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>10</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0021-9258</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>267</Volume>
						<Issue>31</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Nov</Month>
							<Day>05</Day>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of biological chemistry</Title>
					<ISOAbbreviation>J Biol Chem</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Down-regulation of interleukin 6 receptors of mouse myelomonocytic leukemic cells by leukemia inhibitory factor.</ArticleTitle>
				<Pagination>
					<MedlinePgn>22035-42</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>We examined the effect of leukemia inhibitory factor (LIF) on the expression of interleukin 6 receptors (IL-6R) on mouse myelomonocytic leukemic M1 cells. Binding studies using 125I-labeled human and murine IL-6 revealed that LIF caused a decrease in IL-6 binding to M1 cells. The decrease became evident within 1 h, and the maximum decrease was observed at 3-6 h. Scatchard plot analysis revealed that M1 cells had a single class of high affinity receptors for IL-6 and that LIF-induced decrease in IL-6 binding was due to a decrease in the number of IL-6R on the cell surface and not to changes in their affinity. The affinity of IL-6R on M1 cells to human IL-6 (Kd = 2.25 nM) was about 10-fold lower than that to murine IL-6 (Kd = 200 pM). The amount of IL-6 secreted into culture media by M1 cells that were treated with LIF for up to 12 h was not enough to cause receptor down-regulation. Northern blot analysis demonstrated that IL-6R mRNA was down-regulated by LIF treatment, and similar regulation was also observed when the cells were treated with IL-6. The time course of the IL-6R mRNA level was similar to that of IL-6R expression on the cell surface, suggesting that the main mechanism responsible for the loss of high affinity IL-6R was the regulation of IL-6R mRNA. Although the half-life of IL-6R on the cell surface was about 30 min, the addition of LIF reduced it to 16 min, suggesting the existence of an additional mechanism responsible for the loss of high affinity IL-6R on the cell surface.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Yamaguchi</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Cell Biology, Kyoto University, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Michishita</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hirayoshi</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Yasukawa</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Okuma</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nagata</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Biol Chem</MedlineTA>
				<NlmUniqueID>2985121R</NlmUniqueID>
				<ISSNLinking>0021-9258</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006131">Growth Inhibitors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C507837">LIF protein, human</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C507840">LIFR protein, human</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D053605">Leukemia Inhibitory Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D053680">Leukemia Inhibitory Factor Receptor alpha Subunit</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C507838">Lif protein, mouse</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C507841">Lifr protein, mouse</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008222">Lymphokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018121">Receptors, Cytokine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D053606">Receptors, OSM-LIF</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006131" MajorTopicYN="N">Growth Inhibitors</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D053605" MajorTopicYN="N">Leukemia Inhibitory Factor</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D053680" MajorTopicYN="N">Leukemia Inhibitory Factor Receptor alpha Subunit</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015479" MajorTopicYN="N">Leukemia, Myelomonocytic, Acute</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008222" MajorTopicYN="N">Lymphokines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018121" MajorTopicYN="Y">Receptors, Cytokine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019947" MajorTopicYN="N">Receptors, Interleukin-6</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D053606" MajorTopicYN="N">Receptors, OSM-LIF</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>5</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>5</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>5</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1429553</ArticleId>
				<ArticleId IdType="pii">S0021-9258(18)41631-6</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1446592</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>12</Month>
				<Day>30</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2013</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0013-7227</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>131</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>Endocrinology</Title>
					<ISOAbbreviation>Endocrinology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Tumor necrosis factor-alpha induces clustering in ovarian theca-interstitial cells in vitro.</ArticleTitle>
				<Pagination>
					<MedlinePgn>2503-13</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Tumor necrosis factor-alpha (TNF) has been implicated in the regulation of steroidogenesis in theca-interstitial cells (TIC). The purpose of this study was to evaluate any change in TIC morphology during the time course of TNF-induced inhibition of LH-stimulated androstenedione production. Ovaries from immature hypophysectomized rats were enzymatically digested and highly purified TIC were obtained by density gradient centrifugation. TIC treated with TNF (0.1-10 ng/ml) demonstrated distinct clustering in the presence and absence of LH (50 ng/ml). The number of clusters and the mean area per cluster were greatest after 4 days as a result of treatment with 1 or 10 ng TNF/ml. In addition, a dose-dependent inhibition of LH-supported androstenedione production was induced by TNF. TNF also inhibited LH-induced androstenedione in TIC after 2, 4, or 6 days of continuous LH treatment, and TIC clustering still occurred. TIC clustering was impeded by the protein kinase inhibitor H7 at 10 microM; however, the protein kinase inhibitor, HA 1004 (5 microM), did not inhibit TNF-induced clustering in TIC. Since H7 blocked TNF induced clustering, but did not block TNF inhibition of LH stimulated androstenedione synthesis, it is suggested that alternate signal transduction pathways for TNF induced inhibition of LH-stimulated androstenedione and stimulation of clustering of TIC may exist. The results also indicate that the TNF-induced TIC clustering may be independent of the TNF-induced inhibition of LH-stimulated androstenedione production and states of LH-induced differentiation of TIC.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Zachow</LastName>
						<ForeName>R J</ForeName>
						<Initials>RJ</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Physiology, University of Kansas Medical Center, Kansas City 66160-7401.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tash</LastName>
						<ForeName>J S</ForeName>
						<Initials>JS</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Terranova</LastName>
						<ForeName>P F</ForeName>
						<Initials>PF</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>CA-50616</GrantID>
						<Acronym>CA</Acronym>
						<Agency>NCI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>GM-29496</GrantID>
						<Acronym>GM</Acronym>
						<Agency>NIGMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>HD-02528</GrantID>
						<Acronym>HD</Acronym>
						<Agency>NICHD NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Endocrinology</MedlineTA>
				<NlmUniqueID>0375040</NlmUniqueID>
				<ISSNLinking>0013-7227</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>409J2J96VR</RegistryNumber>
					<NameOfSubstance UI="D000735">Androstenedione</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9002-67-9</RegistryNumber>
					<NameOfSubstance UI="D007986">Luteinizing Hormone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>NI40JAQ945</RegistryNumber>
					<NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000735" MajorTopicYN="N">Androstenedione</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007016" MajorTopicYN="N">Hypophysectomy</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007986" MajorTopicYN="N">Luteinizing Hormone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010053" MajorTopicYN="N">Ovary</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013755" MajorTopicYN="N">Tetradecanoylphorbol Acetate</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013799" MajorTopicYN="N">Theca Cells</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>12</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1446592</ArticleId>
				<ArticleId IdType="doi">10.1210/endo.131.6.1446592</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1458343</PMID>
			<DateCompleted>
				<Year>1993</Year>
				<Month>01</Month>
				<Day>08</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>08</Month>
				<Day>27</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0171-967X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>51</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Nov</Month>
						</PubDate>
					</JournalIssue>
					<Title>Calcified tissue international</Title>
					<ISOAbbreviation>Calcif Tissue Int</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interactions of tumor necrosis factor with local and systemic factors in fetal rat limb bones.</ArticleTitle>
				<Pagination>
					<MedlinePgn>387-92</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>In many tissues the actions of tumor necrosis factor-alpha (TNF) are indirectly mediated through the production of autacoids or other cytokines. To determine the role that these factors might have in the action of TNF on bone resorption, we examined the effects of several selective inhibitors on TNF-stimulated resorption. The cyclooxygenase inhibitor indomethacin did not prevent TNF-stimulated resorption in fetal rat limb bones. Stimulation of resorption by TNF was also unaffected by the platelet activating factor antagonist WEB 2086. A 17.5 kD interleukin receptor antagonist protein, at concentrations that completely blocked the bone-resorbing actions of maximally effective concentrations of interleukin (IL)-1 beta, failed to affect the stimulatory actions of TNF. TNF-stimulated resorption was inhibited by both interferon-gamma and dexamethasone. Dexamethasone inhibited TNF-stimulated resorption more effectively than it inhibited parathyroid hormone (PTH)-stimulated resorption. When bones were treated simultaneously with low concentrations of TNF and PTH, potentiation of the bone-resorbing effects was elicited. These results suggest that TNF stimulates resorption through a pathway different from that by which PTH produces its effects. Transforming growth factor-beta (TGF-beta) enhanced responses to TNF; TGF-beta failed to inhibit the effects of TNF, even in long-term culture or when bones were pretreated with TGF-beta. Synergistic interactions between TNF and several other bone-resorbing factors have now been demonstrated. In contrast to the actions of TNF on certain other functions, the bone-resorbing effects of TNF, as determined in the fetal rat limb bone system, do not seem to be mediated by PAF, IL-1, or prostaglandins.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Shankar</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Pharmacology, Northwestern University Medical School, Chicago, Illinois 60611.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Stern</LastName>
						<ForeName>P H</ForeName>
						<Initials>PH</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AR-11262</GrantID>
						<Acronym>AR</Acronym>
						<Agency>NIAMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Calcif Tissue Int</MedlineTA>
				<NlmUniqueID>7905481</NlmUniqueID>
				<ISSNLinking>0171-967X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D001381">Azepines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010281">Parathyroid Hormone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010972">Platelet Activating Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012795">Sialoglycoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>105219-56-5</RegistryNumber>
					<NameOfSubstance UI="C052518">WEB 2086</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>7S5I7G3JQL</RegistryNumber>
					<NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>XXE1CET956</RegistryNumber>
					<NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001862" MajorTopicYN="N">Bone Resorption</DescriptorName>
					<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001842" MajorTopicYN="N">Bone and Bones</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000196" MajorTopicYN="Y">embryology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D046508" MajorTopicYN="N">Culture Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006614" MajorTopicYN="N">Hindlimb</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D053590" MajorTopicYN="N">Interleukin 1 Receptor Antagonist Protein</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010281" MajorTopicYN="N">Parathyroid Hormone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010972" MajorTopicYN="N">Platelet Activating Factor</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012795" MajorTopicYN="N">Sialoglycoproteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1458343</ArticleId>
				<ArticleId IdType="doi">10.1007/BF00316885</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Biol Chem. 1991 Aug 15;266(23):15369-76</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1869559</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 Jun 1;138(11):3812-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3495574</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Endocrinology. 1990 Feb;126(2):1250-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2404745</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>FASEB J. 1990 Aug;4(11):2860-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2199284</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1985 Jul;82(13):4535-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3859875</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1991 Nov;21(11):2775-80</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1834470</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Methods Enzymol. 1988;163:23-31</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2976871</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Endocrinology. 1991 Sep;129(3):1596-604</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1874190</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1987 Nov 1;166(5):1390-404</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3119758</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Anal Biochem. 1980 Feb;102(1):22-30</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">7356156</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem Biophys Res Commun. 1989 Mar 15;159(2):385-94</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2784674</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Bone Miner Res. 1988 Dec;3(6):621-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3266953</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 Dec 15;139(12):4129-34</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2826581</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Dec 15;145(12):4181-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2147937</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1988 Aug;85(15):5683-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3165196</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Endocrinology. 1989 Mar;124(3):1424-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2917519</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem Biophys Res Commun. 1988 May 31;153(1):109-15</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3377783</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1990 Jul 1;172(1):391-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2358784</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1988 Aug;82(2):680-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3165385</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Physiol. 1983 Sep;245(3):E303-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6604461</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1986 Aug 7-13;322(6079):547-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3736671</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1986 Jun 1;163(6):1433-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3486936</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Bone Miner Res. 1986 Oct;1(5):469-74</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3140604</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>FEBS Lett. 1988 Oct 24;239(1):50-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2846348</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 Mar 1;138(5):1464-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3492553</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Cell Biol. 1987 Jul;105(1):457-63</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3475276</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 Feb 1;138(3):775-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3805716</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1986 May 5;261(13):5693-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3754555</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Calcif Tissue Int. 1992 Feb;50(2):123-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1571830</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Prostaglandins. 1986 Apr;31(4):601-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3726153</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Bone Miner Res. 1990 Jan;5(1):77-83</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2309582</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1985 Nov;76(5):2016-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3877079</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1986 Feb 6-12;319(6053):516-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3511389</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Endocrinology. 1987 May;120(5):2029-36</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3106013</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lymphokine Res. 1989 Fall;8(3):359-63</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2674561</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Calcif Tissue Int. 1983 May;35(3):294-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6409386</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Calcif Tissue Int. 1983;35(2):172-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6687826</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>FEBS Lett. 1990 Mar 12;262(1):93-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2138568</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1975 Aug;56(2):408-13</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1171115</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1990 Aug 25;265(24):14505-11</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2143761</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Bone Miner Res. 1991 Aug;6(8):827-33</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1785373</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem Biophys Res Commun. 1978 Dec 14;85(3):966-75</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">310676</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1460280</PMID>
			<DateCompleted>
				<Year>1993</Year>
				<Month>01</Month>
				<Day>14</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2013</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1767</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>149</Volume>
						<Issue>12</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Dec</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
					<ISOAbbreviation>J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Role of protein kinase C activity in tumor necrosis factor-alpha gene expression. Involvement at the transcriptional level.</ArticleTitle>
				<Pagination>
					<MedlinePgn>3894-902</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Primary rat astrocytes express TNF-alpha protein in response to various stimuli including a combined treatment with IFN-gamma and LPS, or IFN-gamma and IL-1 beta. This study was undertaken to further elucidate the mechanisms underlying TNF-alpha gene expression in the astrocyte, and to determine the intracellular signaling pathways involved in IFN-gamma/LPS and/or IFN-gamma/IL-1 beta induction of the TNF-alpha gene. We demonstrate that TNF-alpha mRNA is rapidly induced, and mRNA levels peak after 2 h of stimulation. De novo protein synthesis is not required for TNF-alpha expression because the inclusion of cycloheximide does not prevent expression of the gene and acts to superinduce TNF-alpha mRNA levels. IFN-gamma/LPS induces transcriptional activation of the TNF-alpha gene as assessed by nuclear run-on experiments. Cycloheximide acts to increase both transcription of the TNF-alpha gene and stability of TNF-alpha mRNA thereby resulting in increased TNF-alpha steady state mRNA levels. Two protein kinase C (PKC) inhibitors, H7 and staurosporine, abrogate IFN-gamma/LPS- and IFN-gamma/IL-1 beta-induced TNF-alpha expression in a dose-dependent manner. PKC activity is required for transcription of the TNF-alpha gene, and does not appear to be involved in TNF-alpha mRNA stabilization. Taken together, these data demonstrate that TNF-alpha gene expression in primary rat astrocytes is induced in a PKC-dependent manner.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Chung</LastName>
						<ForeName>I Y</ForeName>
						<Initials>IY</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Cell Biology, University of Alabama, Birmingham 35294.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kwon</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Benveniste</LastName>
						<ForeName>E N</ForeName>
						<Initials>EN</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AI 27290</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Immunol</MedlineTA>
				<NlmUniqueID>2985117R</NlmUniqueID>
				<ISSNLinking>0022-1767</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000470">Alkaloids</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>84477-87-2</RegistryNumber>
					<NameOfSubstance UI="D019307">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>98600C0908</RegistryNumber>
					<NameOfSubstance UI="D003513">Cycloheximide</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.7.11.13</RegistryNumber>
					<NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>H88EPA0A3N</RegistryNumber>
					<NameOfSubstance UI="D019311">Staurosporine</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D019307" MajorTopicYN="N">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000470" MajorTopicYN="N">Alkaloids</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003513" MajorTopicYN="N">Cycloheximide</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015290" MajorTopicYN="N">Second Messenger Systems</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019311" MajorTopicYN="N">Staurosporine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>12</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>12</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>12</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1460280</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1475713</PMID>
			<DateCompleted>
				<Year>1993</Year>
				<Month>02</Month>
				<Day>03</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>10</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0740-7750</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>18</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Sep</Month>
						</PubDate>
					</JournalIssue>
					<Title>Somatic cell and molecular genetics</Title>
					<ISOAbbreviation>Somat Cell Mol Genet</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Chromosomal localization of the IL-6 receptor signal transducing subunit, gp130 (IL6ST).</ArticleTitle>
				<Pagination>
					<MedlinePgn>477-83</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Signal transduction in eukaryotic cells is a complex process mediated, normally, by the interaction of soluble extrinsic protein factors and their cognate receptors. One example of this phenomena is the inflammatory cytokine interleukin-6 and the IL-6 receptor. However, the IL-6 receptor, once its ligand is bound, associates with another membrane glycoprotein, gp130, to potentiate the cytokine response. To further understand the basis of this interaction, and its possible implications in cellular transforming events, the corresponding gene(s) must be studied. Here we find that the human gp130 gene product is homologous to two distinct chromosomal loci on chromosomes 5 and 17. Furthermore, the presence of two distinct gp130 gene sequences is restricted to primates and is not found in other vertebrates.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Kidd</LastName>
						<ForeName>V J</ForeName>
						<Initials>VJ</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Tumor Cell Biology, St. Jude Childrens Research Hospital, Memphis, Tennessee.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nesbitt</LastName>
						<ForeName>J E</ForeName>
						<Initials>JE</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fuller</LastName>
						<ForeName>G M</ForeName>
						<Initials>GM</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>GM44088</GrantID>
						<Acronym>GM</Acronym>
						<Agency>NIGMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>HL43155</GrantID>
						<Acronym>HL</Acronym>
						<Agency>NHLBI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Somat Cell Mol Genet</MedlineTA>
				<NlmUniqueID>8403568</NlmUniqueID>
				<ISSNLinking>0740-7750</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C494199">IL6ST protein, human</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D009838">Oligodeoxyribonucleotides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>133483-10-0</RegistryNumber>
					<NameOfSubstance UI="D050822">Cytokine Receptor gp130</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015703" MajorTopicYN="Y">Antigens, CD</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002886" MajorTopicYN="Y">Chromosomes, Human, Pair 17</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002895" MajorTopicYN="Y">Chromosomes, Human, Pair 5</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D050822" MajorTopicYN="N">Cytokine Receptor gp130</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009838" MajorTopicYN="N">Oligodeoxyribonucleotides</DescriptorName>
					<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019947" MajorTopicYN="N">Receptors, Interleukin-6</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1475713</ArticleId>
				<ArticleId IdType="doi">10.1007/BF01233087</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1490358</PMID>
			<DateCompleted>
				<Year>1993</Year>
				<Month>03</Month>
				<Day>03</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>08</Month>
				<Day>27</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0070-217X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>182</Volume>
						<PubDate>
							<Year>1992</Year>
						</PubDate>
					</JournalIssue>
					<Title>Current topics in microbiology and immunology</Title>
					<ISOAbbreviation>Curr Top Microbiol Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Genes expressed selectively in plasmacytomas: markers of differentiation and transformation.</ArticleTitle>
				<Pagination>
					<MedlinePgn>223-8</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>We have analyzed a murine plasmacytoma minus highly differentiated B lymphoma subtractive cDNA library and identified eight genes that are expressed in most plasmacytomas but at a much lower level, or not at all, in most B lymphomas. Four of the genes are markers of the terminal differentiation of B lymphocytes into plasma cells: placental alkaline phosphatase, also expressed in pre-B lymphomas xlr-3, a new X-linked member of the xlr multi-gene family EGP314, a pan-epithelial glycoprotein with sequence features of an adhesion molecule PC315, a gene that is up-regulated by IL6, but without obvious sequence homologies. Two of the genes are not clearly related to normal B cell differentiation, appearing to be associated with malignant transformation of plasma cells: PC326 is a new member of the beta-transducin mosaic protein gene family. It is an X-linked gene, expressed at a very low level in testis, but in no other normal tissue, including LPS- or IL6-induced plasma cells. It has a high level of expression (apparently dysregulated) in most (&gt; 85%) mineral oil induced plasmacytomas. However the likelihood that PC326 is expressed decreases as the tumor latency decreases when different retroviral agents are used to accelerate mineral oil induced plasmacytomagenesis. This suggests that PC326 expression may be a late event in a multi-step process of tumorigenesis. PC251 a new member of the hematopoietic growth factor receptor family, most homologous to IL5R alpha.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Bergsagel</LastName>
						<ForeName>P L</ForeName>
						<Initials>PL</Initials>
						<AffiliationInfo>
							<Affiliation>Navy Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20889-5105.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Victor-Kobrin</LastName>
						<ForeName>C</ForeName>
						<Initials>C</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Brents</LastName>
						<ForeName>L A</ForeName>
						<Initials>LA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mushinski</LastName>
						<ForeName>J F</ForeName>
						<Initials>JF</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kuehl</LastName>
						<ForeName>W M</ForeName>
						<Initials>WM</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Germany</Country>
				<MedlineTA>Curr Top Microbiol Immunol</MedlineTA>
				<NlmUniqueID>0110513</NlmUniqueID>
				<ISSNLinking>0070-217X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016184">Receptors, Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.6.5.1</RegistryNumber>
					<NameOfSubstance UI="D015293">Transducin</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002471" MajorTopicYN="N">Cell Transformation, Neoplastic</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010954" MajorTopicYN="N">Plasmacytoma</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
					<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016184" MajorTopicYN="N">Receptors, Colony-Stimulating Factor</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012091" MajorTopicYN="N">Repetitive Sequences, Nucleic Acid</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015293" MajorTopicYN="N">Transducin</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1490358</ArticleId>
				<ArticleId IdType="doi">10.1007/978-3-642-77633-5_27</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1500725</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>09</Month>
				<Day>14</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>11</Month>
				<Day>30</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1767</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>149</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Aug</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
					<ISOAbbreviation>J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Role of cytokines in alveolar macrophage accessory cell function in HIV-infected individuals.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1462-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Mononuclear phagocytes, including alveolar macrophages (AM), can be chronically infected with HIV and thus serve as a reservoir for the virus. Acting as AC during the generation of an immune response, HIV-infected mononuclear phagocytes can facilitate viral T cell infection by several mechanisms, including direct contact of T cells with HIV-infected macrophages as well as cytokine-induced up-regulation of latent T cell infection. Our laboratory has shown that AM from HIV-infected individuals have enhanced AC function compared to normal AM. In this study we explored AM production and secretion of IL-1 beta and IL-6, two cytokines critical for optimal AC function, in normal volunteers and HIV-infected patients. Cultured AM supernatants and lysates were generated in the presence and absence of LPS and standard mitogens. In initial mixing experiments HIV AM supernatants enhanced mitogen-induced T cell proliferation using normal AM as AC significantly more than normal AM supernatants, suggesting that HIV AM secreted more T cell stimulatory factors than normal AM. Neither group could enhance T cell proliferation induced by HIV AM suggesting these cells already secreted optimal levels of these factors. AM from HIV+ individuals produced and secreted more IL-1 beta (measured by ELISA) and IL-6 (measured in a B9 bioassay and by immunoprecipitation) than normal AM both spontaneously and in the presence of low LPS concentrations and mitogens. In some cases depleting HIV AM supernatants of IL-1 beta and IL-6 on immunoaffinity columns abrogated their enhancement properties indicating that these cytokines were important in the observed enhancement. However, in other patients different factors must also be involved as depletion of IL-1 beta and IL-6 in their AM supernatants had no effect on enhancement function. These results show that HIV AM secretory products are important in the enhanced AC function demonstrated by these cells. However, although augmented IL-1 beta and IL-6 secretion likely contribute significantly to this enhancement, other AC secretory factors and/or functions must also be involved.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Twigg</LastName>
						<ForeName>H L</ForeName>
						<Initials>HL</Initials>
						<Suffix>3rd</Suffix>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, Indiana University Medical Center, Indianapolis 46202.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Iwamoto</LastName>
						<ForeName>G K</ForeName>
						<Initials>GK</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Soliman</LastName>
						<ForeName>D M</ForeName>
						<Initials>DM</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>MO1 RR750</GrantID>
						<Acronym>RR</Acronym>
						<Agency>NCRR NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Immunol</MedlineTA>
				<NlmUniqueID>2985117R</NlmUniqueID>
				<ISSNLinking>0022-1767</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000938" MajorTopicYN="N">Antigen-Presenting Cells</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016676" MajorTopicYN="N">Macrophages, Alveolar</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1500725</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1505448</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>09</Month>
				<Day>22</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>11</Month>
				<Day>30</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0013-7227</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>131</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Sep</Month>
						</PubDate>
					</JournalIssue>
					<Title>Endocrinology</Title>
					<ISOAbbreviation>Endocrinology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Secretion and hormonal regulation of interleukin-6 production by mouse uterine stromal and polarized epithelial cells cultured in vitro.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1037-46</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Uterine stromal (USC) and uterine epithelial (UEC) cells were isolated from immature and mature mice to determine their ability to secrete interleukin-6 (IL-6) in response to ovarian steroids, IL-1 alpha, and soluble products produced by the heterologous cell type. In addition, the effect of IL-6 on embryo attachment and outgrowth in vitro was determined. UEC cultured on nitrocellulose filter inserts in a polarized manner secreted IL-6 with a 2.5- to 5-fold apical vs. basal preference, as determined by a B9 hybridoma cell proliferation assay and enzyme-linked immunosorbent assay. The hormonal status of animals at the time uteri were removed did not influence subsequent secretion of IL-6, as UEC isolated from immature, diestrous, and estrous stage mice exhibited both a similar amount and had a similar apical preference for secretion of IL-6. The addition of 17 beta-estradiol (E) to UEC cultures markedly inhibited total IL-6 secretion, but did not affect vectorial secretion. The inhibitory effect of E on IL-6 secretion by UEC was consistent with an apparent decrease in IL-6 transcript observed by a reverse transcriptase polymerase chain reaction assay. Other transcripts detected by this assay in UEC included IL-1 alpha, but not IL-1 beta or tumor necrosis factor-alpha. Secretion of IL-6 by UEC was not stimulated by IL-1 alpha, conditioned medium from USC, or coculture with USC. USC secreted IL-6, and while this also was inhibited by E, progesterone was more effective in this regard at physiological concentrations. In addition, there was a synergistic effect of E plus progesterone on inhibition of IL-6 secretion by USC. Secretion of IL-6 by USC was stimulated by IL-1 alpha, and coculture studies demonstrated the ability of UEC to stimulate a several-fold increase in IL-6 secretion by USC. The cytokine transcripts detected in USC cultures included IL-6 and IL-1 alpha, but not IL-1 beta. Transcripts for tumor necrosis factor-alpha were present in USC only after culture with IL-1 alpha. IL-6 added to blastocysts on laminin-coated tissue culture wells resulted in a transient inhibition of the rate of blastocyst attachment and, to a greater extent, an inhibition of the rate of embryo outgrowth. In addition, IL-6 inhibited the size of embryo outgrowths at 24 and 48 h of culture.(ABSTRACT TRUNCATED AT 400 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Jacobs</LastName>
						<ForeName>A L</ForeName>
						<Initials>AL</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Biochemistry and Molecular Biology, University of Texas M. D. Anderson Cancer Center, Houston 77030.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sehgal</LastName>
						<ForeName>P B</ForeName>
						<Initials>PB</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Julian</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Carson</LastName>
						<ForeName>D D</ForeName>
						<Initials>DD</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AI-16262</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>HD-07207</GrantID>
						<Acronym>HD</Acronym>
						<Agency>NICHD NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>HD-28072</GrantID>
						<Acronym>HD</Acronym>
						<Agency>NICHD NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Endocrinology</MedlineTA>
				<NlmUniqueID>0375040</NlmUniqueID>
				<ISSNLinking>0013-7227</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>4G7DS2Q64Y</RegistryNumber>
					<NameOfSubstance UI="D011374">Progesterone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>4TI98Z838E</RegistryNumber>
					<NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004031" MajorTopicYN="N">Diestrus</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010064" MajorTopicYN="N">Embryo Implantation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004848" MajorTopicYN="N">Epithelium</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004971" MajorTopicYN="N">Estrus</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011374" MajorTopicYN="N">Progesterone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014599" MajorTopicYN="N">Uterus</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1505448</ArticleId>
				<ArticleId IdType="doi">10.1210/endo.131.3.1505448</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1533231</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>05</Month>
				<Day>26</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>11</Month>
				<Day>13</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0021-9738</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>89</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>May</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of clinical investigation</Title>
					<ISOAbbreviation>J Clin Invest</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1551-7</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The present study was undertaken to evaluate the extent to which an endogenous interleukin-1 (IL-1) response contributes to the hemodynamic and metabolic consequences of sublethal endotoxemia or lethal Gram-negative septic shock. Young, healthy baboons received either a sublethal dose of lipopolysaccharide (LPS) or an LD100 of live Escherichia coli bacteria, and one half of the animals in each group were continuously infused with IL-1 receptor antagonist (IL-1ra). Plasma IL-1 beta was not detected in this model of endotoxemia. Administration of IL-1ra had only minimal effects on the modest hemodynamic and metabolic responses to sublethal endotoxemia, and did not attenuate the plasma cytokine response. In contrast, high circulating levels of IL-1 beta (range 300-800 pg/ml) were seen during lethal E. coli septic shock. IL-1ra treatment significantly attenuated the decrease in mean arterial blood pressure (MAP) (from -72 +/- 8 to -43 +/- 6 mm Hg; P less than 0.05) and cardiac output (from -0.81 +/- 0.17 to -0.48 +/- 0.15 liter/min; P less than 0.05), and significantly improved survival from 43 to 100% at 24 h (P less than 0.05). The plasma IL-1 beta and IL-6 responses to lethal E. coli septic shock were also significantly diminished by IL-1ra treatment (P less than 0.05), whereas tumor necrosis factor-alpha (TNF alpha) concentrations were unaffected. We conclude that an exaggerated systemic IL-1 beta response is characteristic of lethal E. coli septic shock, and contributes significantly to the hemodynamic and metabolic consequences of E. coli septic shock. IL-1ra can significantly attenuate the cytokine cascade and improve survival.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="N">
					<Author ValidYN="Y">
						<LastName>Fischer</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Surgery, Cornell University Medical College, New York 10021.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Marano</LastName>
						<ForeName>M A</ForeName>
						<Initials>MA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Van Zee</LastName>
						<ForeName>K J</ForeName>
						<Initials>KJ</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rock</LastName>
						<ForeName>C S</ForeName>
						<Initials>CS</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hawes</LastName>
						<ForeName>A S</ForeName>
						<Initials>AS</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Thompson</LastName>
						<ForeName>W A</ForeName>
						<Initials>WA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>DeForge</LastName>
						<ForeName>L</ForeName>
						<Initials>L</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kenney</LastName>
						<ForeName>J S</ForeName>
						<Initials>JS</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Remick</LastName>
						<ForeName>D G</ForeName>
						<Initials>DG</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bloedow</LastName>
						<ForeName>D C</ForeName>
						<Initials>DC</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>CA-52108</GrantID>
						<Acronym>CA</Acronym>
						<Agency>NCI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>GM-34695</GrantID>
						<Acronym>GM</Acronym>
						<Agency>NIGMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>GM-40586</GrantID>
						<Acronym>GM</Acronym>
						<Agency>NIGMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Clin Invest</MedlineTA>
				<NlmUniqueID>7802877</NlmUniqueID>
				<ISSNLinking>0021-9738</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D004731">Endotoxins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017472">Receptors, Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012795">Sialoglycoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004731" MajorTopicYN="N">Endotoxins</DescriptorName>
					<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D053590" MajorTopicYN="N">Interleukin 1 Receptor Antagonist Protein</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010215" MajorTopicYN="N">Papio</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017472" MajorTopicYN="N">Receptors, Interleukin-1</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName>
					<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012795" MajorTopicYN="Y">Sialoglycoproteins</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1533231</ArticleId>
				<ArticleId IdType="doi">10.1172/JCI115748</ArticleId>
				<ArticleId IdType="pmc">PMC443028</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1990 Jul;87(13):4966-70</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1695006</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Jul 1;143(1):162-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2499626</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1989 Oct;86(20):8029-33</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2530579</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1989 Nov 1;170(5):1627-33</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2809510</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>N Engl J Med. 1988 Jun 9;318(23):1481-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2835680</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1988 Apr;81(4):1162-72</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3258319</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Jun 1;167(6):1987-92</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3290384</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1987 Dec 17-23;330(6149):662-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3317066</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1986 Jun 1;163(6):1433-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3486936</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 Sep 15;139(6):1902-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3497982</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1986 Oct 24;234(4775):470-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3764421</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Physiol. 1991 Aug;261(2 Pt 2):R442-52</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1831602</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cytokine. 1991 Jan;3(1):1-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1883951</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1991 May 15;146(10):3478-82</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2026876</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Surg Gynecol Obstet. 1990 Apr;170(4):363-78</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2108507</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Dec 15;145(12):4185-91</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2124237</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1990 Jan 25;343(6256):336-40</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2137200</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1990 Dec 6;348(6301):550-2</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2147233</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Physiol. 1990 Oct;259(4 Pt 2):R724-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2221137</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Infect Dis. 1990 Jan;161(1):79-84</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2295861</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1990 Jun;85(6):1896-904</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2347917</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 Jun 15;138(12):4236-42</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2438338</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>FASEB J. 1991 Mar 1;5(3):338-43</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1825816</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1533322</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>05</Month>
				<Day>29</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-4971</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>79</Volume>
						<Issue>9</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>May</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Blood</Title>
					<ISOAbbreviation>Blood</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes.</ArticleTitle>
				<Pagination>
					<MedlinePgn>2356-63</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Interleukin-1 (IL-1) induces IL-1, tumor necrosis factor alpha (TNF alpha), and IL-6 gene expression and synthesis in a variety of cells. In this study, we investigated the ability of human recombinant IL-1 receptor antagonist (IL-1ra) to inhibit IL-1-induced cytokine production in human peripheral blood mononuclear cells (PBMC) and isolated monocytes. IL-1ra alone at concentrations as high as 1 microgram/mL did not induce IL-1 alpha, IL-1 beta, TNF alpha, or IL-6 synthesis. Suppression of IL-1-induced IL-1, TNF alpha, or IL-6 synthesis was dose-dependent (P less than or equal to .0001). At a twofold molar excess, IL-1ra inhibited IL-1-induced IL-1 or TNF alpha synthesis by 50% (P less than .01); an equimolar concentration of IL-1ra inhibited synthesis of these two cytokines by over 20% (P less than .05). A 10-fold molar excess of IL-1ra over IL-1 beta reduced IL-1 beta-induced IL-1 alpha by 95% (P = .01) and IL-1 alpha-induced IL-1 beta by 73% (P less than .01). IL-1ra added to PBMC 8 hours after stimulation with IL-1 beta was still able to inhibit IL-1 alpha, TNF alpha, and IL-6 synthesis (P less than or equal to .01). A similar reduction in IL-1 beta-induced IL-1 alpha was observed when IL-1 beta was removed from the cultures after 8 hours of stimulation (P less than .05), suggesting a prolonged presence of IL-1 or restimulation of IL-1 receptors on monocytes is required for the induction of cytokines. In elutriated monocytes, a 10-fold molar excess of IL-1ra reduced IL-1 beta-induced IL-1 alpha by 82% (P less than .05), TNF alpha by 64% (P = .05), and IL-6 by 47% (P less than .05). 125I-IL-1 beta was bound to purified monocytes, cross-linked, and immunoprecipitated. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed a band at 85 Kd corresponding to the 68-Kd IL-1 receptor type II (IL-1RtII). Excess unlabeled IL-1 beta or IL-1ra blocked the binding of 125I-IL-1 beta to the IL-1RtII. We conclude that IL-1ra inhibits IL-1-induced cytokine synthesis and competes with IL-1 for the IL-1RtII on human monocytes.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Granowitz</LastName>
						<ForeName>E V</ForeName>
						<Initials>EV</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, New England Medical Center Hospitals, Boston, MA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Clark</LastName>
						<ForeName>B D</ForeName>
						<Initials>BD</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Vannier</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Callahan</LastName>
						<ForeName>M V</ForeName>
						<Initials>MV</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Dinarello</LastName>
						<ForeName>C A</ForeName>
						<Initials>CA</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AI 07389</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>AI 15614</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Blood</MedlineTA>
				<NlmUniqueID>7603509</NlmUniqueID>
				<ISSNLinking>0006-4971</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C507763">IL1RN protein, human</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D053590">Interleukin 1 Receptor Antagonist Protein</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017472">Receptors, Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012795">Sialoglycoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D053590" MajorTopicYN="N">Interleukin 1 Receptor Antagonist Protein</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017472" MajorTopicYN="N">Receptors, Interleukin-1</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012795" MajorTopicYN="Y">Sialoglycoproteins</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1533322</ArticleId>
				<ArticleId IdType="pii">S0006-4971(20)72988-5</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1536986</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>03</Month>
				<Day>31</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>10</Month>
				<Day>28</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0937-941X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>2</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Mar</Month>
						</PubDate>
					</JournalIssue>
					<Title>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</Title>
					<ISOAbbreviation>Osteoporos Int</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Oestradiol inhibits the release of tumour necrosis factor but not interleukin 6 from adult human osteoblasts in vitro.</ArticleTitle>
				<Pagination>
					<MedlinePgn>94-102</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Oestrogens may control bone remodelling by directly regulating the synthesis of cytokines in osteoblasts. We have investigated the effects of oestradiol on the release of two cytokines, IL-6 and TNF, known to be produced by normal human osteoblast-like cells. The effect of oestradiol on basal and stimulated IL-6 and TNF release was investigated. The concentration of IL-6 and TNF in 24 h bone cell-conditioned medium was determined using bio- and immunoradiometric assays. The results showed that 17 beta-oestradiol (10(-10) and 10(-8) M) inhibited IL-1-stimulated TNF release in a dose dependent manner in 7 out of 9 patients. Maximal inhibition was observed with 10(-8) M 17 beta-oestradiol, producing an average 30% reduction in TNF release. In contrast 17 beta-oestradiol (10(-12)-10(-8) M) failed to consistently regulate basal or stimulated IL-6 release. IL-6 mRNA levels were also shown not to be modulated by 17 beta-oestradiol (10(-9) M) under stimulatory conditions. rhIL-1 alpha (10 U/ml) was a consistent and potent stimulator of IL-6 and TNF release, and the glucocorticoid hydrocortisone was found to be a powerful suppressor of both IL-6 and TNF release under basal or stimulatory conditions. In conclusion direct regulation of bone remodelling by oestradiol does not appear to be effected via the control of IL-6 production in osteoblasts. However, a suppression of osteoblastic TNF release could represent one facet of the control of bone formation and resorption by oestrogens.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Rickard</LastName>
						<ForeName>D</ForeName>
						<Initials>D</Initials>
						<AffiliationInfo>
							<Affiliation>Bath Institute for Rheumatic Diseases, UK.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Russell</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gowen</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Osteoporos Int</MedlineTA>
				<NlmUniqueID>9100105</NlmUniqueID>
				<ISSNLinking>0937-941X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>4TI98Z838E</RegistryNumber>
					<NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010006" MajorTopicYN="N">Osteoblasts</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1536986</ArticleId>
				<ArticleId IdType="doi">10.1007/BF01623843</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Endocrinology. 1990 Feb;126(2):1250-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2404745</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Arthritis Rheum. 1988 Dec;31(12):1500-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3143369</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol Methods. 1986 Dec 4;95(1):99-105</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3782828</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem Biophys Res Commun. 1989 Aug 15;162(3):1546-52</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2548501</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Bone Miner Res. 1990 Sep;5(9):983-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2281828</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Endocrinology. 1989 Mar;124(3):1424-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2917519</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 May 1;142(9):3134-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2651521</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1989 Apr;86(7):2398-402</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2522659</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1988 Jun;18(6):957-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3260188</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Endocrinology. 1989 Aug;125(2):825-33</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2752978</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Bone Miner Res. 1991 Feb;6(2):141-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1709332</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Cell Biol. 1987 Jul;105(1):457-63</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3475276</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 Feb 1;138(3):775-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3805716</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1986 Feb 6-12;319(6053):516-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3511389</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>N Engl J Med. 1988 Mar 31;318(13):818-28</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3281002</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Bone Miner Res. 1989 Aug;4(4):633-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2816508</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Metab Bone Dis Relat Res. 1984;5(5):229-34</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6333574</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Bone Miner Res. 1991 Jan;6(1):3-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2048428</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1537322</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>04</Month>
				<Day>02</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2013</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0013-7227</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>130</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Mar</Month>
						</PubDate>
					</JournalIssue>
					<Title>Endocrinology</Title>
					<ISOAbbreviation>Endocrinology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin-6: effects on and production by rat granulosa cells in vitro.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1750-2</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Treatment of FSH-stimulated granulosa cells with increasing amounts of interleukin-6 (IL-6) caused a significant concentration-dependent suppression of progesterone biosynthesis. However, basal progesterone production in non-FSH-stimulated cells remained unresponsive to the cytokine. Quantitation of IL-6 in the conditioned media from untreated granulosa cells by the 7TD1 hybridoma cell bioassay revealed detectable levels of IL-6. Further, FSH treatment caused a significant concentration-dependent increase in IL-6 release. In contrast, both basal and FSH-stimulated IL-6 release could be significantly suppressed by interferon gamma (INF-gamma). The results of the present study suggest: 1) a role for IL-6 in the regulation of progesterone production, 2) that the granulosa cell is a source of IL-6 and 3) that the release of IL-6 by the granulosa cell is a regulated event.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Gorospe</LastName>
						<ForeName>W C</ForeName>
						<Initials>WC</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Anatomy and Cell Biology, Medical University of South Carolina, Charleston 29425.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hughes</LastName>
						<ForeName>F M</ForeName>
						<Initials>FM</Initials>
						<Suffix>Jr</Suffix>
					</Author>
					<Author ValidYN="Y">
						<LastName>Spangelo</LastName>
						<ForeName>B L</ForeName>
						<Initials>BL</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>DK-42059</GrantID>
						<Acronym>DK</Acronym>
						<Agency>NIDDK NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>HD-25262</GrantID>
						<Acronym>HD</Acronym>
						<Agency>NICHD NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Endocrinology</MedlineTA>
				<NlmUniqueID>0375040</NlmUniqueID>
				<ISSNLinking>0013-7227</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>4G7DS2Q64Y</RegistryNumber>
					<NameOfSubstance UI="D011374">Progesterone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9002-68-0</RegistryNumber>
					<NameOfSubstance UI="D005640">Follicle Stimulating Hormone</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005640" MajorTopicYN="N">Follicle Stimulating Hormone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006107" MajorTopicYN="N">Granulosa Cells</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011374" MajorTopicYN="N">Progesterone</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011863" MajorTopicYN="N">Radioimmunoassay</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>11</Day>
					<Hour>19</Hour>
					<Minute>15</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2001</Year>
					<Month>3</Month>
					<Day>28</Day>
					<Hour>10</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>11</Day>
					<Hour>19</Hour>
					<Minute>15</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1537322</ArticleId>
				<ArticleId IdType="doi">10.1210/endo.130.3.1537322</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1537389</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>04</Month>
				<Day>01</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2014</Year>
				<Month>11</Month>
				<Day>20</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0014-2980</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>22</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Feb</Month>
						</PubDate>
					</JournalIssue>
					<Title>European journal of immunology</Title>
					<ISOAbbreviation>Eur J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin 6-induced differentiation of a human B cell line into IgM-secreting plasma cells is mediated by c-fos.</ArticleTitle>
				<Pagination>
					<MedlinePgn>607-10</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The role of the protooncogene c-fos in interleukin (IL) 6-induced B cell differentiation was assessed. Treatment of SKW 6.4 cells with IL 6 induced a transient and early stimulation of c-fos sense mRNA expression. The effect appeared within 30 min and returned to basal levels after 2 h. The addition of antisense oligonucleotides to c-fos significantly inhibited IL 6-induced IgM production by SKW 6.4 cells (p less than 0.001), whereas control oligonucleotides had no inhibitory effect. These results indicate that activation of c-fos is involved in IL 6-induced differentiation of SKW 6.4 cells into IgM-secreting cells.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Körholz</LastName>
						<ForeName>D</ForeName>
						<Initials>D</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Pediatric Hematology and Oncology, Heinrich-Heine-University Medical Center, Düsseldorf.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gerdau</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Enczmann</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Zessack</LastName>
						<ForeName>N</ForeName>
						<Initials>N</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Burdach</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Germany</Country>
				<MedlineTA>Eur J Immunol</MedlineTA>
				<NlmUniqueID>1273201</NlmUniqueID>
				<ISSNLinking>0014-2980</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016760">Proto-Oncogene Proteins c-fos</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016372">RNA, Antisense</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016762" MajorTopicYN="Y">Genes, fos</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010950" MajorTopicYN="N">Plasma Cells</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016760" MajorTopicYN="N">Proto-Oncogene Proteins c-fos</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016372" MajorTopicYN="N">RNA, Antisense</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1537389</ArticleId>
				<ArticleId IdType="doi">10.1002/eji.1830220248</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1564429</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>05</Month>
				<Day>19</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>07</Month>
				<Day>09</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-0795</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>132</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Mar</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of endocrinology</Title>
					<ISOAbbreviation>J Endocrinol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Osteoclast formation together with interleukin-6 production in mouse long bones is increased by insulin-like growth factor-I.</ArticleTitle>
				<Pagination>
					<MedlinePgn>433-8</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Insulin-like growth factor-I (IGF-I) is a potent stimulator of bone formation. Whether this growth factor also induces bone resorption has not been studied in detail. We used two organ culture systems to examine the direct effect of IGF-I on bone resorption. Fetal mouse radii/ulnae, containing mature osteoclasts, showed no response to IGF-I, indicating that osteoclastic activity is not influenced by IGF-I. Fetal mouse metacarpals/metatarsals, containing just osteoclast precursors and progenitors, showed an increase in resorption in response to IGF-I, indicating that IGF-I stimulates the formulation of osteoclast precursors/progenitors and thereby increases the number of osteoclasts. Interleukin-6 (IL-6) has been hypothesized to be a mediator of bone resorptive agents such as parathyroid hormone (PTH). Both radii/ulnae and metacarpals/metatarsals reacted to IGF-I with an increase in IL-6 production. IL-6 production by UMR-106 osteogenic osteosarcoma cells was positively modulated by IGF-I, indicating that osteoblasts are likely to be the cells responsible for increased IL-6 production by the bones, and that IL-6 might be a mediatory of IGF-I-stimulated bone resorption.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Slootweg</LastName>
						<ForeName>M C</ForeName>
						<Initials>MC</Initials>
						<AffiliationInfo>
							<Affiliation>Scientific Development Group, Organon International bv, Oss, The Netherlands.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Most</LastName>
						<ForeName>W W</ForeName>
						<Initials>WW</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>van Beek</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schot</LastName>
						<ForeName>L P</ForeName>
						<Initials>LP</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Papapoulos</LastName>
						<ForeName>S E</ForeName>
						<Initials>SE</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Löwik</LastName>
						<ForeName>C W</ForeName>
						<Initials>CW</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>J Endocrinol</MedlineTA>
				<NlmUniqueID>0375363</NlmUniqueID>
				<ISSNLinking>0022-0795</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010281">Parathyroid Hormone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>67763-96-6</RegistryNumber>
					<NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001862" MajorTopicYN="N">Bone Resorption</DescriptorName>
					<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001842" MajorTopicYN="N">Bone and Bones</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007334" MajorTopicYN="N">Insulin-Like Growth Factor I</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008815" MajorTopicYN="N">Mice, Inbred Strains</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010010" MajorTopicYN="N">Osteoclasts</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010281" MajorTopicYN="N">Parathyroid Hormone</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1564429</ArticleId>
				<ArticleId IdType="doi">10.1677/joe.0.1320433</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1566813</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>05</Month>
				<Day>21</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2017</Year>
				<Month>12</Month>
				<Day>13</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0002-9513</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>262</Volume>
						<Issue>4 Pt 1</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Apr</Month>
						</PubDate>
					</JournalIssue>
					<Title>The American journal of physiology</Title>
					<ISOAbbreviation>Am J Physiol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Transcriptional regulation of the endothelin-1 gene by TNF-alpha.</ArticleTitle>
				<Pagination>
					<MedlinePgn>C854-61</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Cytokines, such as tumor necrosis factor-alpha (TNF-alpha), induce profound alterations in endothelial cell phenotype and are implicated in the organ dysfunction that characterizes septic shock. We explored whether TNF-alpha modulates cellular expression of endothelin-1 (ET-1). ET-1 is a potent vasoconstrictor peptide released by endothelial, vascular smooth muscle, and mesangial cells that could function as a paracrine/autocrine regulator of vascular tone and proliferation. We found that TNF-alpha induced release of ET-1 from bovine aortic endothelial cells (BAEC) in a time- and concentration-dependent manner. Rates of ET-1 release were maximal over 1-8 h and declined to, or below, baseline values after 16 h. When measured at 8 h, TNF-alpha augmented ET-1 release over the range 0.1-250 ng/ml (threshold, 0.1 ng/ml; 50% effective dose, 1.6 +/- 1.2 ng/ml; maximal effect, 100 ng/ml). The increase in secretion was accompanied by a corresponding increase in the transcriptional rate of the ET-1 gene resulting in augmented preproendothelin-1 mRNA transcript levels. TNF-alpha-stimulated increases in ET-1 gene transcription were not dependent on new protein synthesis. Actinomycin D chase experiments suggested that enhanced stability of preproendothelin-1 mRNA could not account for the increase in ET-1 transcript levels. TNF-alpha increased ET-1 release and preproendothelin-1 mRNA content in bovine renal artery and bovine glomerular capillary endothelial cells, demonstrating that the TNF-alpha effect was evident in endothelial cells derived from a variety of sources. Furthermore, augmented ET-1 expression in response to TNF-alpha was evident in bovine glomerular mesangial cells.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Marsden</LastName>
						<ForeName>P A</ForeName>
						<Initials>PA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, St. Michael's Hospital, University of Toronto, Ontario, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Brenner</LastName>
						<ForeName>B M</ForeName>
						<Initials>BM</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>DK-35930</GrantID>
						<Acronym>DK</Acronym>
						<Agency>NIDDK NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Am J Physiol</MedlineTA>
				<NlmUniqueID>0370511</NlmUniqueID>
				<ISSNLinking>0002-9513</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019332">Endothelin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016232">Endothelins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019332" MajorTopicYN="N">Endothelin-1</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016232" MajorTopicYN="N">Endothelins</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005796" MajorTopicYN="Y">Genes</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007678" MajorTopicYN="N">Kidney Glomerulus</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014158" MajorTopicYN="Y">Transcription, Genetic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>4</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>4</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>4</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1566813</ArticleId>
				<ArticleId IdType="doi">10.1152/ajpcell.1992.262.4.C854</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1576016</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>06</Month>
				<Day>10</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>02</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">8756-3282</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>13</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
						</PubDate>
					</JournalIssue>
					<Title>Bone</Title>
					<ISOAbbreviation>Bone</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Effect of calcitriol on the secretion of prostaglandin E2, interleukin 1, and tumor necrosis factor alpha by human monocytes.</ArticleTitle>
				<Pagination>
					<MedlinePgn>185-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Cells of the monocyte/macrophage lineage express specific receptors for calcitriol (1,25-dihydroxyvitamin D3) and secrete prostaglandins and several cytokines with potent effects on bone metabolism. The aim of this study was to determine the effect of calcitriol on the secretion of prostaglandin E2 (PGE2), interleukin-1 (IL-1), and tumor necrosis factor (TNF alpha). Monocyte-enriched peripheral blood mononuclear cells (PBMC) from healthy subjects were cultured in the presence or absence of calcitriol (10(-11)-10(-7) M) and several stimulating agents. After 24 h, PGE2, IL-1, and TNF alpha were measured in the culture supernatants or lysates with specific immunoassays. Calcitriol induced a biphasic effect on PGE2 production by unstimulated cells and increased PGE2 synthesis by cells stimulated with either endotoxin or tau-interferon (IFN-tau). On the other hand, calcitriol inhibited the production of TNF alpha by monocytes stimulated with either IFN-tau or phorbol esters. This effect was not prevented by the addition of indomethacin, IL-1, or IL-2. Under the conditions used, we observed no effect of calcitriol on IL-1 alpha or IL-1 beta production. These results indicate that calcitriol induces in vitro marked changes in the secretion of monocyte products with known activity on bone cells. Further studies are needed to elucidate whether some effects of calcitriol on bone metabolism are mediated by the interaction of the sterol with cells of the immune system.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Zarrabeitia</LastName>
						<ForeName>M T</ForeName>
						<Initials>MT</Initials>
						<AffiliationInfo>
							<Affiliation>Departamento de Medicina Interna, Hospital Marques de Valdecilla, Facultad de Medicina, Santander, Spain.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Riancho</LastName>
						<ForeName>J A</ForeName>
						<Initials>JA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Amado</LastName>
						<ForeName>J A</ForeName>
						<Initials>JA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Olmos</LastName>
						<ForeName>J M</ForeName>
						<Initials>JM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gonzalez-Macias</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Bone</MedlineTA>
				<NlmUniqueID>8504048</NlmUniqueID>
				<ISSNLinking>1873-2763</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>FXC9231JVH</RegistryNumber>
					<NameOfSubstance UI="D002117">Calcitriol</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002117" MajorTopicYN="N">Calcitriol</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1576016</ArticleId>
				<ArticleId IdType="pii">8756-3282(92)90010-T</ArticleId>
				<ArticleId IdType="doi">10.1016/8756-3282(92)90010-t</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1590794</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>06</Month>
				<Day>23</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>06</Month>
				<Day>12</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-291X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>184</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>May</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>Biochemical and biophysical research communications</Title>
					<ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Role of protein kinase C (PKC) in bone resorption: effect of the specific PKC inhibitor 1-alkyl-2-methylglycerol.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1317-23</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The specific inhibitor of protein kinase C, 1-O-alkyl-2-O-methylglycerol (AMG), was studied for its effect on bone resorption, measured as 45Ca-release, in fetal mouse calvariae. AMG (1 to 50 microM) had no effect on basal bone resorption. AMG inhibited parathyroid hormone (40 nM) induced bone resorption in a dose-dependent manner. Resorption induced by 1,25 (OH)2-vitamin D3 (10 nM) or prostaglandin E2 (5 microM) was also inhibited by AMG. The release of beta-glucuronidase activity paralleled the course of the 45Ca-release. The production of interleukin 6, induced by parathyroid hormone, in fetal rat calvarial osteoblasts was not affected by AMG. AMG (1 to 50 microM) had no cytotoxic effects on cells or calvariae. From these results it is concluded that protein kinase C may have an important role in the regulation of bone resorption.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Bos</LastName>
						<ForeName>M P</ForeName>
						<Initials>MP</Initials>
						<AffiliationInfo>
							<Affiliation>Laboratory of Cell Biology and Histology, University of Leiden, Rijnsburgerweg, The Netherlands.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Most</LastName>
						<ForeName>W</ForeName>
						<Initials>W</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>van Leeuwen</LastName>
						<ForeName>J P</ForeName>
						<Initials>JP</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Herrmann-Erlee</LastName>
						<ForeName>M P</ForeName>
						<Initials>MP</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
				<NlmUniqueID>0372516</NlmUniqueID>
				<ISSNLinking>0006-291X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D005995">Glyceryl Ethers</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010281">Parathyroid Hormone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>10T9CSU89I</RegistryNumber>
					<NameOfSubstance UI="D019379">Teriparatide</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.7.11.13</RegistryNumber>
					<NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.2.1.31</RegistryNumber>
					<NameOfSubstance UI="D005966">Glucuronidase</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>FXC9231JVH</RegistryNumber>
					<NameOfSubstance UI="D002117">Calcitriol</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>SY7Q814VUP</RegistryNumber>
					<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001862" MajorTopicYN="Y">Bone Resorption</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001842" MajorTopicYN="N">Bone and Bones</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002117" MajorTopicYN="N">Calcitriol</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005966" MajorTopicYN="N">Glucuronidase</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005995" MajorTopicYN="N">Glyceryl Ethers</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010006" MajorTopicYN="N">Osteoblasts</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010281" MajorTopicYN="N">Parathyroid Hormone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019379" MajorTopicYN="N">Teriparatide</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1590794</ArticleId>
				<ArticleId IdType="pii">S0006-291X(05)80026-9</ArticleId>
				<ArticleId IdType="doi">10.1016/s0006-291x(05)80026-9</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1598073</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>07</Month>
				<Day>08</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>07</Month>
				<Day>01</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0024-3205</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>50</Volume>
						<Issue>24</Issue>
						<PubDate>
							<Year>1992</Year>
						</PubDate>
					</JournalIssue>
					<Title>Life sciences</Title>
					<ISOAbbreviation>Life Sci</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Contrasting effects of misoprostol on systemic and intrapulmonary lipopolysaccharide-induced tumor necrosis factor-alpha.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1869-76</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Tumor necrosis factor-alpha (TNF), a cytokine produced by mononuclear phagocytes in response to lipopolysaccharide stimulation, is a potent mediator of the inflammatory cascade. However, the immunomodulatory signals regulating TNF expression in the host are poorly defined. Recently, metabolites of the prostaglandin E series have been shown to inhibit TNF production in vitro. In order to determine if PGE1 alters TNF activity in vivo, rats were given misoprostol, a synthetic PGE1 analogue, or saline by gavage and subsequently challenged with either intravenous or intratracheal Escherichia coli lipopolysaccharide. These in vivo data show that PGE1 is a potent inhibitor of TNF production by systemic mononuclear phagocytes. In contrast, alveolar macrophages appear to be refractory to misoprostol's suppressive effects on LPS-induced TNF. This study supports in vitro observations that mononuclear phagocytes within different compartments exhibit differential responsiveness to immunomodulators.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Nakamura</LastName>
						<ForeName>C</ForeName>
						<Initials>C</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, Louisiana State University Medical Center, New Orleans.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nelson</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lippton</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bagby</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Summer</LastName>
						<ForeName>W</ForeName>
						<Initials>W</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AA07710</GrantID>
						<Acronym>AA</Acronym>
						<Agency>NIAAA NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Netherlands</Country>
				<MedlineTA>Life Sci</MedlineTA>
				<NlmUniqueID>0375521</NlmUniqueID>
				<ISSNLinking>0024-3205</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0E43V0BB57</RegistryNumber>
					<NameOfSubstance UI="D016595">Misoprostol</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001992" MajorTopicYN="N">Bronchoalveolar Lavage Fluid</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
					<QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
					<QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016676" MajorTopicYN="N">Macrophages, Alveolar</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016595" MajorTopicYN="N">Misoprostol</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010586" MajorTopicYN="N">Phagocytes</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011919" MajorTopicYN="N">Rats, Inbred Strains</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013268" MajorTopicYN="N">Stimulation, Chemical</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1598073</ArticleId>
				<ArticleId IdType="pii">0024-3205(92)90547-3</ArticleId>
				<ArticleId IdType="doi">10.1016/0024-3205(92)90547-3</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1605492</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>07</Month>
				<Day>10</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>06</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0077-8923</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>650</Volume>
						<PubDate>
							<Year>1992</Year>
							<Month>Apr</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>Annals of the New York Academy of Sciences</Title>
					<ISOAbbreviation>Ann N Y Acad Sci</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Tumor necrosis factor-alpha and interferon-gamma synthesis by cerebrospinal fluid-derived T cell clones in multiple sclerosis.</ArticleTitle>
				<Pagination>
					<MedlinePgn>341-6</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>T cell clones derived from cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS) were analysed for their capacity to produce interleukin 2 (IL-2), interleukin 4 (IL-4), interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha). They were also compared with liver-infiltrating T cell clones from patients with chronic active hepatitis. All the CSF T clones (both CD4+ and CD8+) produced large amounts of IFN-gamma and particularly of TNF-alpha, that was synthesized in a significantly larger amount than compared clones. Moreover, they were capable of secreting IL-2, but not IL-4. From our results, we conclude that first, the CSF CD4+ T clones could constitute a subset with functional properties similar to the T helper 1 (Th1)/inflammatory cell subset of the mouse; and second, the large amounts of TNF produced by CSF T cell clones strongly suggests a significant role for this cytokine as well as of IFN-gamma in MS immunopathogenesis.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Benvenuto</LastName>
						<ForeName>R</ForeName>
						<Initials>R</Initials>
						<AffiliationInfo>
							<Affiliation>Fondazione Andrea Cesalpino, I Clinica Medica, Università La Sapienza, Rome, Italy.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Paroli</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Buttinelli</LastName>
						<ForeName>C</ForeName>
						<Initials>C</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Franco</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Barnaba</LastName>
						<ForeName>V</ForeName>
						<Initials>V</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fieschi</LastName>
						<ForeName>C</ForeName>
						<Initials>C</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Balsano</LastName>
						<ForeName>F</ForeName>
						<Initials>F</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Ann N Y Acad Sci</MedlineTA>
				<NlmUniqueID>7506858</NlmUniqueID>
				<ISSNLinking>0077-8923</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>207137-56-2</RegistryNumber>
					<NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002999" MajorTopicYN="N">Clone Cells</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName>
					<QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>4</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>4</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>4</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1605492</ArticleId>
				<ArticleId IdType="doi">10.1111/j.1749-6632.1992.tb49149.x</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1607128</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>07</Month>
				<Day>23</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2006</Year>
				<Month>11</Month>
				<Day>15</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0393-5264</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>7</Volume>
						<Issue>2</Issue>
						<PubDate>
							<MedlineDate>1992 Mar-Apr</MedlineDate>
						</PubDate>
					</JournalIssue>
					<Title>Functional neurology</Title>
					<ISOAbbreviation>Funct Neurol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin-1 beta and interleukin-6 mRNA are expressed in human glioblastoma and neuroblastoma cells respectively.</ArticleTitle>
				<Pagination>
					<MedlinePgn>129-33</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>We report the expression of different interleukins (IL) in four human glioblastoma and neuroblastoma cell lines. The glioblastoma cell line LI, expresses IL-1 beta and IL-6 mRNA, though not IL-2 and IL-4. The expression of the former gene is modulated by retinoic acid. Two cell clones [BE(2)-C and BE(2)-M17] as well as the neuroblastoma cell line SK-N-BE(2), from which both clones were derived, express IL-6 mRNA, but not IL-1 beta, IL-2 or IL-4. Both IL-1 beta and IL-6 cytokines are known to increase hypothalamic CRH mRNA, a gene reported to be expressed in all these cell lines. The production of both cytokines and neuropeptides indicates a complex dialogue between tumour cells and anti-tumour immunity.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Stephanou</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Neuroendocrinology, Charing Cross Hospital, London, UK.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Knight</LastName>
						<ForeName>R A</ForeName>
						<Initials>RA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Annicchiarico-Petruzzelli</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Finazzi-Agrò</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lightmann</LastName>
						<ForeName>S L</ForeName>
						<Initials>SL</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Melino</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Italy</Country>
				<MedlineTA>Funct Neurol</MedlineTA>
				<NlmUniqueID>8707746</NlmUniqueID>
				<ISSNLinking>0393-5264</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005910" MajorTopicYN="N">Glioma</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1607128</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1611720</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>07</Month>
				<Day>27</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>08</Month>
				<Day>19</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0090-1229</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>63</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>May</Month>
						</PubDate>
					</JournalIssue>
					<Title>Clinical immunology and immunopathology</Title>
					<ISOAbbreviation>Clin Immunol Immunopathol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Human recombinant interleukin-4 induces proliferation and interleukin-6 production by cultured human skin fibroblasts.</ArticleTitle>
				<Pagination>
					<MedlinePgn>182-7</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The effect of human recombinant interleukin-4 (hrIL-4) on normal human adult dermal fibroblasts in terms of proliferation and IL-6 production was studied. Fibroblasts were exposed to different concentrations of IL-4 for various periods of time. Proliferation was measured using a [3H]thymidine incorporation assay. IL-6 production was measured at the transcriptional, protein, and functional levels by Northern blot analysis, radioimmunoassay, and B9 bioassay, respectively. Our results show that hrIL-4 significantly stimulated (two- to fivefold) fibroblasts to increase the incorporation of [3H]thymidine in a dose- and time-dependent manner. However, hrIL-1, hrIL-2, hrIL-5, or hrTNF alpha, at the same concentration (100 U/ml) and for the same time period (4 days), did not. In addition, IL-4 significantly induced (four- to eightfold) the production of immunoreactive and biologically functional IL-6. However, IL-4 was not as potent an inducer of IL-6 as IL-1. The IL-4-induced IL-6 production was dose and time dependent and was due, at least in part, to a dramatic increase in the steady-state levels of IL-6 mRNA. This is the first report describing the ability of IL-4 to activate human dermal fibroblasts in terms of proliferation and IL-6 production.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Feghali</LastName>
						<ForeName>C A</ForeName>
						<Initials>CA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana 70112.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bost</LastName>
						<ForeName>K L</ForeName>
						<Initials>KL</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Boulware</LastName>
						<ForeName>D W</ForeName>
						<Initials>DW</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Levy</LastName>
						<ForeName>L S</ForeName>
						<Initials>LS</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Clin Immunol Immunopathol</MedlineTA>
				<NlmUniqueID>0356637</NlmUniqueID>
				<ISSNLinking>0090-1229</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>207137-56-2</RegistryNumber>
					<NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1611720</ArticleId>
				<ArticleId IdType="doi">10.1016/0090-1229(92)90011-c</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1616052</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>07</Month>
				<Day>29</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2017</Year>
				<Month>12</Month>
				<Day>13</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0002-9513</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>262</Volume>
						<Issue>6 Pt 1</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jun</Month>
						</PubDate>
					</JournalIssue>
					<Title>The American journal of physiology</Title>
					<ISOAbbreviation>Am J Physiol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Effects of TNF-alpha and phorbol ester on human surfactant protein and MnSOD gene transcription in vitro.</ArticleTitle>
				<Pagination>
					<MedlinePgn>L688-93</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Tumor necrosis factor-alpha (TNF-alpha) and the phorbol ester, 12-O-tetradecanoyl-phorbol-13-acetate (TPA) decrease the synthesis of surfactant proteins association with decreased SP-A and SP-B mRNA. Nuclear run-on assays were utilized to test whether the inhibitory effects of TNF-alpha and TPA were associated with changes in surfactant protein gene transcription. SP-A gene transcription was inhibited by both TNF-alpha and TPA as assessed by nuclear run-on assays. Inhibitory effects of both agents on SP-A gene transcription were readily detected within 6 h after exposure and persisted for 24 h. While TNF-alpha and TPA decreased cellular SP-B mRNA content, transcription of the SP-B gene was not influenced by these agents. In contrast to the inhibitory effects of TPA and TNF-alpha on SP-A and SP-B mRNAs, steady-state mRNA and rate of transcription of human manganese superoxide dismutase (MnSOD) were increased by both agents. The time course and extent of increased MnSOD gene transcription by TNF-alpha and TPA were distinct. Transcription of the human beta-actin gene was not altered by either agent. The inhibitory effects of TPA and TNF-alpha on SP-A expression in pulmonary adenocarcinoma cells are associated with the inhibition of SP-A gene transcription. Loss of SP-B mRNA was not accompanied by decreased SP-B gene transcription. Actinomycin D blocked the inhibitory effects of TNF-alpha and TPA on SP-A and SP-B mRNA, supporting a role for posttranscriptional events in the modulation of the expression of the surfactant proteins SP-A and SP-B.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Whitsett</LastName>
						<ForeName>J A</ForeName>
						<Initials>JA</Initials>
						<AffiliationInfo>
							<Affiliation>Division of Pulmonary Biology, Children's Hospital Medical Center, Cincinnati, Ohio 45229.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Clark</LastName>
						<ForeName>J C</ForeName>
						<Initials>JC</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Wispé</LastName>
						<ForeName>J R</ForeName>
						<Initials>JR</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Pryhuber</LastName>
						<ForeName>G S</ForeName>
						<Initials>GS</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>HL-28623</GrantID>
						<Acronym>HL</Acronym>
						<Agency>NHLBI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>HL-38859</GrantID>
						<Acronym>HL</Acronym>
						<Agency>NHLBI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>HL-41496</GrantID>
						<Acronym>HL</Acronym>
						<Agency>NHLBI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Am J Physiol</MedlineTA>
				<NlmUniqueID>0370511</NlmUniqueID>
				<ISSNLinking>0002-9513</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D004273">DNA, Neoplasm</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1CC1JFE158</RegistryNumber>
					<NameOfSubstance UI="D003609">Dactinomycin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 1.15.1.1</RegistryNumber>
					<NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>NI40JAQ945</RegistryNumber>
					<NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004273" MajorTopicYN="N">DNA, Neoplasm</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003609" MajorTopicYN="N">Dactinomycin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005796" MajorTopicYN="N">Genes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007527" MajorTopicYN="N">Isoenzymes</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013755" MajorTopicYN="N">Tetradecanoylphorbol Acetate</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1616052</ArticleId>
				<ArticleId IdType="doi">10.1152/ajplung.1992.262.6.L688</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1623556</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>08</Month>
				<Day>07</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>07</Month>
				<Day>20</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0008-8749</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>142</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jul</Month>
						</PubDate>
					</JournalIssue>
					<Title>Cellular immunology</Title>
					<ISOAbbreviation>Cell Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Production of macrophage colony-stimulating factor (M-CSF) by human monocytes is differentially regulated by GM-CSF, TNF alpha, and IFN-gamma.</ArticleTitle>
				<Pagination>
					<MedlinePgn>361-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Macrophage colony-stimulating factor (M-CSF) stimulates the survival, proliferation, and differentiation of mononuclear phagocytes. In this study, the qualitative and relative quantitative ability of various cytokines to induce and to synergize in M-CSF production by monocytes was studied. GM-CSF and the phorbolester PMA were strong inducers of M-CSF m-RNA expression. This was correlated closely with the secretion of M-CSF protein as measured in the murine M-NFS-60 cell line bioassay. Both TNF alpha and IFN-gamma enhanced M-CSF message levels induced by GM-CSF, but only TNF alpha synergized with GM-CSF in the induction of M-CSF protein secretion. M-CSF transcripts induced by TNF alpha and IFN-gamma were much lower compared to those induced by GM-CSF and PMA and were not accompanied by the secretion of M-CSF protein. In addition, costimulation of cells with TNF alpha and IFN-gamma did not result in M-CSF production. Although M-CSF did not induce its own message, it further enhanced M-CSF transcripts induced by GM-CSF. LPS also failed to induce M-CSF message or secretion. These results show that cytokines differ in their ability to induce or to synergize in the induction of biologically active M-CSF protein. They further demonstrate that M-CSF message expression, induced by cytokines, does not always correlate with M-CSF protein secretion.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Gruber</LastName>
						<ForeName>M F</ForeName>
						<Initials>MF</Initials>
						<AffiliationInfo>
							<Affiliation>Division of Cytokine Biology, Food and Drug Administration, Bethesda, Maryland 20892.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gerrard</LastName>
						<ForeName>T L</ForeName>
						<Initials>TL</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D003160">Comparative Study</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Netherlands</Country>
				<MedlineTA>Cell Immunol</MedlineTA>
				<NlmUniqueID>1246405</NlmUniqueID>
				<ISSNLinking>0008-8749</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010703">Phorbol Esters</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>81627-83-0</RegistryNumber>
					<NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>83869-56-1</RegistryNumber>
					<NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016173" MajorTopicYN="N">Macrophage Colony-Stimulating Factor</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010703" MajorTopicYN="N">Phorbol Esters</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1623556</ArticleId>
				<ArticleId IdType="pii">0008-8749(92)90297-3</ArticleId>
				<ArticleId IdType="doi">10.1016/0008-8749(92)90297-3</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1632458</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>08</Month>
				<Day>18</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2020</Year>
				<Month>12</Month>
				<Day>26</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0002-9440</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>141</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jul</Month>
						</PubDate>
					</JournalIssue>
					<Title>The American journal of pathology</Title>
					<ISOAbbreviation>Am J Pathol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.</ArticleTitle>
				<Pagination>
					<MedlinePgn>129-38</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Hodgkin's disease (HD) is a neoplastic disease that is characterized by unbalanced and/or unregulated cytokine production. Information accumulated in our own and other laboratories indicates that the cytokines interleukin-1 (IL-1), IL-5, IL-9, tumor necrosis factor-alpha (TNF-alpha), granulocyte colony-stimulating factor (G-CSF), macrophage CSF (M-CSF), and transforming growth factor-beta (TGF-beta) are secreted by Hodgkin's and Reed-Sternberg (H-RS) cells. These and perhaps additional cytokines are likely to be responsible for the unique histopathologic and clinical alterations seen in patients with HD. In this study, we confirmed that IL-6 is produced by cultured H-RS cells as well as by H-RS cells in tissues. By using an enzyme-linked immunosorbent assay, we found that approximately 2 to 10 ng/ml of IL-6 was secreted by cultured H-RS cells (10(6) cells/ml). In tissues, we were able to immunolocalize IL-6 in the cytoplasm in 10 to 30% of H-RS cells by using rabbit polyclonal and mouse monoclonal anti-IL-6 antibodies. There was no correlation among the IL-6 staining intensity, number of H-RS cells stained, and the degree of plasma cell infiltration. However, in 3 of 17 cases studied, a large number (60%) of H-RS cells were positive for IL-6, and in these patients, abundant plasma cells were present. In one patient, the involved lymph node also showed histologic features similar to those of Castleman's disease. In this patient, we noted abundant IL-6 expression not only in H-RS cells, but also in most reactive histiocytes. The cultured H-RS cells did not express functional receptors for IL-6, and exogenously added IL-6 did not induce proliferation of these cells. We also conducted studies with specific anti-IL-4 antibodies, which did not show IL-4 production by H-RS cells in both cultures and tissues. In tissues, only rare IL-4 positive lymphoid cells or dendritic cells were identified. Thus, the study demonstrated that adequate amounts of IL-6 are required for an abundant plasma cell reaction, and that an additional source of IL-6 from histiocytes is essential for the formation of Castleman's disease-like changes in lymph nodes involved by HD. Furthermore, IL-4 is not likely to be responsible for the T-lymphocyte reaction in tissues, by a mechanism distinct from that in T-cell-rich B-cell lymphomas.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Hsu</LastName>
						<ForeName>S M</ForeName>
						<Initials>SM</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Pathology, University of Arkansas for Medical Sciences, Little Rock.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Xie</LastName>
						<ForeName>S S</ForeName>
						<Initials>SS</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hsu</LastName>
						<ForeName>P L</ForeName>
						<Initials>PL</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Waldron</LastName>
						<ForeName>J A</ForeName>
						<Initials>JA</Initials>
						<Suffix>Jr</Suffix>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>47462</GrantID>
						<Agency>PHS HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Am J Pathol</MedlineTA>
				<NlmUniqueID>0370502</NlmUniqueID>
				<ISSNLinking>0002-9440</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>207137-56-2</RegistryNumber>
					<NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005871" MajorTopicYN="N">Castleman Disease</DescriptorName>
					<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName>
					<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006689" MajorTopicYN="N">Hodgkin Disease</DescriptorName>
					<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
					<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008221" MajorTopicYN="N">Lymphoid Tissue</DescriptorName>
					<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008228" MajorTopicYN="N">Lymphoma, Non-Hodgkin</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019947" MajorTopicYN="N">Receptors, Interleukin-6</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016539" MajorTopicYN="N">Reed-Sternberg Cells</DescriptorName>
					<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
					<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
					<QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>11</Day>
					<Hour>19</Hour>
					<Minute>15</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>2001</Year>
					<Month>3</Month>
					<Day>28</Day>
					<Hour>10</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>11</Day>
					<Hour>19</Hour>
					<Minute>15</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1632458</ArticleId>
				<ArticleId IdType="pmc">PMC1886582</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Biochim Biophys Acta. 1986 Dec 12;874(3):266-73</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3539201</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1983 Jun;130(6):2666-70</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6222113</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1985 Feb;118(2):209-17</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3970138</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1986 Jul;68(1):285-92</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3013343</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Aug 1;141(3):849-55</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2969394</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1988 Apr;18(4):653-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3130269</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunol Lett. 1990 Mar-Apr;24(1):1-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2197219</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1990 Jun;87(11):4068-72</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1693429</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer Res. 1990 Apr 1;50(7):2049-55</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2156611</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1990 Jan;136(1):181-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1688689</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1988 Dec;85(24):9743-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3144002</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lab Invest. 1989 Dec;61(6):588-602</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2481148</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>FEBS Lett. 1989 Jan 2;242(2):237-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2464504</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell Immunol. 1989 Jul;121(2):372-82</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2500254</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer Surv. 1989;8(4):905-19</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2701735</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1989 Sep;135(3):427-33</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2675620</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1989 Dec;19(12):2379-81</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2606144</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1989 Feb;73(2):517-26</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2783861</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1989 Sep 25;264(27):16072-82</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2789217</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1989 Sep;74(4):1360-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2788466</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1988 Oct;72(4):1134-40</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3262381</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Aug 15;141(4):1185-90</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3260922</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1990 Aug;137(2):353-67</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2167011</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Int J Hematol. 1991 Aug;54(4):315-26</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1838015</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1991 Sep 1;78(5):1311-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1908723</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1991 Jun 1;77(11):2413-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1710152</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Histopathology. 1991 Mar;18(3):249-53</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1675190</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>FASEB J. 1991 Aug;5(11):2567-74</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1868981</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1986 Jul;68(1):213-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2424524</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Leuk Res. 1986;10(5):487-500</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3713248</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1989 Jul;135(1):33-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2789003</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1989 Oct;135(4):735-45</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2801887</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1989 Jul;74(1):1-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2473791</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1989 Jan;134(1):203-12</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2492402</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1988 May;71(5):1382-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3359046</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1988 Jun;131(3):569-77</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2898211</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1989 May;83(5):1512-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2785119</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1986 Nov;125(2):221-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3538888</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer Res. 1990 Jan 15;50(2):350-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2153049</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1990 Jan 1;75(1):13-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2403816</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1990 May 15;75(10):2049-52</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1692493</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1990 Apr;87(8):3092-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1691500</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Virol. 1990 Jun;64(6):3033-41</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2159561</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1990 Jul;20(7):1591-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2117537</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell Immunol. 1990 Jan;125(1):197-209</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2104575</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1990 Jan;20(1):1-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2407536</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1990 Aug;86(2):592-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2384605</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Jul 1;145(1):161-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2358670</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer Res. 1990 Jun 1;50(11):3154-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2334911</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell Immunol. 1990 Mar;126(1):47-56</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2302741</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Jan 1;144(1):183-90</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2295790</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Histochem Cytochem. 1981 Apr;29(4):577-80</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6166661</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Histochem Cytochem. 1982 Oct;30(10):1079-82</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6182185</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Int J Cancer. 1983 Mar 15;31(3):269-74</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6600721</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1986 Feb;122(2):223-30</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3511721</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1632769</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>08</Month>
				<Day>14</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>06</Month>
				<Day>12</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-291X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>186</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jul</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>Biochemical and biophysical research communications</Title>
					<ISOAbbreviation>Biochem Biophys Res Commun</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Cytokines stimulate lipolysis and decrease lipoprotein lipase activity in cultured fat cells by a prostaglandin independent mechanism.</ArticleTitle>
				<Pagination>
					<MedlinePgn>237-43</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>We previously showed that indomethacin blocked the effect of tumor necrosis factor (TNF) and other cytokines on lipolysis. We now show that TNF stimulates prostaglandin (PG) production, enhances lipolysis and decreases lipoprotein lipase (LPL) activity in 3T3-F442A adipocytes and indomethacin blocks these activities, suggesting that the actions of TNF are mediated by PG's. However, exogenous PGE2 at the levels induced by TNF is not sufficient to affect lipolysis or LPL activity and low doses of indomethacin and flurbiprofen block PG production without affecting TNF's action. Interleukin-1 and interferon-alpha and gamma induce lipolysis and decrease LPL activity but do not stimulate much PG production. These results demonstrate that cytokines enhance lipolysis and decrease LPL activity in 3T3 adipocytes by a PG independent mechanism.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Hardardóttir</LastName>
						<ForeName>I</ForeName>
						<Initials>I</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, University of California, San Francisco.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Doerrler</LastName>
						<ForeName>W</ForeName>
						<Initials>W</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Feingold</LastName>
						<ForeName>K R</ForeName>
						<Initials>KR</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Grünfeld</LastName>
						<ForeName>C</ForeName>
						<Initials>C</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>DK-40990</GrantID>
						<Acronym>DK</Acronym>
						<Agency>NIDDK NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
				<NlmUniqueID>0372516</NlmUniqueID>
				<ISSNLinking>0006-291X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011453">Prostaglandins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>5GRO578KLP</RegistryNumber>
					<NameOfSubstance UI="D005480">Flurbiprofen</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.1.1.34</RegistryNumber>
					<NameOfSubstance UI="D008071">Lipoprotein Lipase</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>XXE1CET956</RegistryNumber>
					<NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D016475" MajorTopicYN="N">3T3 Cells</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005480" MajorTopicYN="N">Flurbiprofen</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008066" MajorTopicYN="N">Lipolysis</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008071" MajorTopicYN="N">Lipoprotein Lipase</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011453" MajorTopicYN="N">Prostaglandins</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1632769</ArticleId>
				<ArticleId IdType="pii">S0006-291X(05)80798-3</ArticleId>
				<ArticleId IdType="doi">10.1016/s0006-291x(05)80798-3</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1638523</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>08</Month>
				<Day>28</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>03</Month>
				<Day>31</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0008-5472</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>52</Volume>
						<Issue>15</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Aug</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Cancer research</Title>
					<ISOAbbreviation>Cancer Res</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia.</ArticleTitle>
				<Pagination>
					<MedlinePgn>4113-6</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>To investigate whether interleukin 6 (IL-6) might be a potential mediator of the depleted fat reserves observed in malignancy-associated cachexia, we measured lipoprotein lipase (LPL) activity in adipose tissue of mice after administration of IL-6 or tumor necrosis factor and in cultured adipocytes after addition of these cytokines. Injection of IL-6 i.p. reduced adipose tissue LPL activity by 53% within 4.5 to 5.5 h. Injection of tumor necrosis factor elevated serum IL-6 levels and reduced adipose tissue LPL activity by 70%. Both human and murine IL-6 reduced heparin-releasable LPL activity in 3T3-L1 adipocytes in a dose-dependent manner; half-maximal inhibition of LPL activity was achieved with 5000 hybridoma growth factor units/ml. Thus, IL-6 reduces adipose LPL activity and may contribute to the loss of body fat stores associated with some cases of cancer cachexia. Since tumor necrosis factor increases circulating IL-6, some of its effects may be mediated or potentiated by IL-6.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Greenberg</LastName>
						<ForeName>A S</ForeName>
						<Initials>AS</Initials>
						<AffiliationInfo>
							<Affiliation>Laboratory of Cellular and Developmental Biology, National Institute of Diabetes, Digestive and Kidney Disease, NIH, Bethesda, Maryland 20892.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nordan</LastName>
						<ForeName>R P</ForeName>
						<Initials>RP</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>McIntosh</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Calvo</LastName>
						<ForeName>J C</ForeName>
						<Initials>JC</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Scow</LastName>
						<ForeName>R O</ForeName>
						<Initials>RO</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Jablons</LastName>
						<ForeName>D</ForeName>
						<Initials>D</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Cancer Res</MedlineTA>
				<NlmUniqueID>2984705R</NlmUniqueID>
				<ISSNLinking>0008-5472</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.1.1.34</RegistryNumber>
					<NameOfSubstance UI="D008071">Lipoprotein Lipase</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D016475" MajorTopicYN="N">3T3 Cells</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002999" MajorTopicYN="N">Clone Cells</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004261" MajorTopicYN="N">DNA Replication</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008066" MajorTopicYN="N">Lipolysis</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008071" MajorTopicYN="N">Lipoprotein Lipase</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>8</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1638523</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1641074</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>09</Month>
				<Day>02</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>02</Month>
				<Day>14</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0028-3835</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>56</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>1992</Year>
							<Month>Jul</Month>
						</PubDate>
					</JournalIssue>
					<Title>Neuroendocrinology</Title>
					<ISOAbbreviation>Neuroendocrinology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin-1 beta and interleukin-6 specifically increase the release of prostaglandin E2 from rat hypothalamic explants in vitro.</ArticleTitle>
				<Pagination>
					<MedlinePgn>61-8</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>It has previously been shown that the cytokines interleukin-1 beta and interleukin-6 (IL-1 beta and IL-6) stimulate directly the release of corticotrophin-releasing-hormone-41 from the rat hypothalamus in vitro, while IL-1 beta can also stimulate the release of somatostatin. These effects can be antagonized by drugs which block prostaglandin (PG) synthesis. PGs are also involved in the control of hypothalamic neuropeptides by other neurotransmitters. In the present study, we have characterized the production of PGs from the rat hypothalamus in vitro, and investigated the effects of IL-1 beta and IL-6, as well as the neurotransmitters norepinephrine, acetylcholine and 5-hydroxytryptamine, on the acute release of PGs, using a well-validated acute hypothalamic incubation system. The rate of release of PGs [PGE2, PGF2 alpha, 6-keto-PGF1 alpha (6KPGF1 alpha) and thromboxane B2 (TXB2) in the medium was found to stabilize after 60 min of preincubation and thereafter remain constant, with TXB2 being the predominant species. Twenty-minute incubation in the presence of human recombinant IL-1 beta or IL-6, in the dose range 1-100 U/ml, had no effect on the release of PGF2 alpha, 6KPGF1 alpha or TXB2; however, the release of PGE2 was significantly increased by both IL-1 beta and IL-6. The effect of IL-1 beta was antagonized by both indomethacin and dexamethasone. None of the other neurotransmitters tested had any effect on the release of any of the PGs.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Navarra</LastName>
						<ForeName>P</ForeName>
						<Initials>P</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Pharmacology, Catholic University Medical School, Rome, Italy.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Pozzoli</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Brunetti</LastName>
						<ForeName>L</ForeName>
						<Initials>L</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ragazzoni</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Besser</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Grossman</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Switzerland</Country>
				<MedlineTA>Neuroendocrinology</MedlineTA>
				<NlmUniqueID>0035665</NlmUniqueID>
				<ISSNLinking>0028-3835</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011453">Prostaglandins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>37H9VM9WZL</RegistryNumber>
					<NameOfSubstance UI="D000001">Calcimycin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>B7IN85G1HY</RegistryNumber>
					<NameOfSubstance UI="D015237">Dinoprost</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000001" MajorTopicYN="N">Calcimycin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015237" MajorTopicYN="N">Dinoprost</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007031" MajorTopicYN="N">Hypothalamus</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011453" MajorTopicYN="N">Prostaglandins</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011919" MajorTopicYN="N">Rats, Inbred Strains</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1992</Year>
					<Month>7</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1641074</ArticleId>
				<ArticleId IdType="doi">10.1159/000126209</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1648713</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>08</Month>
				<Day>14</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>08</Month>
				<Day>18</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0196-9781</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>12</Volume>
						<Issue>2</Issue>
						<PubDate>
							<MedlineDate>1991 Mar-Apr</MedlineDate>
						</PubDate>
					</JournalIssue>
					<Title>Peptides</Title>
					<ISOAbbreviation>Peptides</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Neuropeptide alpha-MSH antagonizes IL-6- and TNF-induced fever.</ArticleTitle>
				<Pagination>
					<MedlinePgn>297-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The pro-opiomelanocortin-derived peptide melanocyte stimulating hormone (alpha-MSH) antagonizes the fever induced by several stimuli including endotoxin, endogenous pyrogen, and certain cytokines. To determine if alpha-MSH can antagonize the pyrogenic action of recombinant IL-6 and TNF directly within the central nervous system, the cytokines were injected with and without alpha-MSH (200 ng) into a lateral cerebral ventricle of rabbits and rectal temperature was monitored continuously. Central administration of both cytokines caused fever. However, when alpha-MSH was injected after cytokine administration, the fevers were markedly reduced. The results are consistent with previous observations on the antipyretic effect of alpha-MSH and they show that the peptide can act within the brain to antagonize pyrogenic actions of specific cytokines believed to be important in CNS mediation of fever.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Martin</LastName>
						<ForeName>L W</ForeName>
						<Initials>LW</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Physiology, University of Texas Southwestern Medical Center, Dallas 75235.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Catania</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hiltz</LastName>
						<ForeName>M E</ForeName>
						<Initials>ME</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lipton</LastName>
						<ForeName>J M</ForeName>
						<Initials>JM</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>NS10046</GrantID>
						<Acronym>NS</Acronym>
						<Agency>NINDS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Peptides</MedlineTA>
				<NlmUniqueID>8008690</NlmUniqueID>
				<ISSNLinking>0196-9781</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011749">Pyrogens</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>581-05-5</RegistryNumber>
					<NameOfSubstance UI="D000521">alpha-MSH</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName>
					<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
					<QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011749" MajorTopicYN="N">Pyrogens</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000521" MajorTopicYN="N">alpha-MSH</DescriptorName>
					<QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>3</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1648713</ArticleId>
				<ArticleId IdType="pii">0196-9781(91)90015-H</ArticleId>
				<ArticleId IdType="doi">10.1016/0196-9781(91)90015-h</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1652755</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>10</Month>
				<Day>03</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>05</Month>
				<Day>01</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0027-8424</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>88</Volume>
						<Issue>17</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Sep</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
					<ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product.</ArticleTitle>
				<Pagination>
					<MedlinePgn>7605-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The aberrant overexpression of interleukin 6 (IL-6) is implicated as an autocrine mechanism in the enhanced proliferation of the neoplastic cell elements in various B- and T-cell malignancies and in some carcinomas and sarcomas; many of these neoplasms have been shown to be associated with a mutated p53 gene. The possibility that wild-type (wt) p53, a nuclear tumor-suppressor protein, but not its transforming mutants might serve to repress IL-6 gene expression was investigated in HeLa cells. We transiently cotransfected these cells with constitutive cytomegalovirus (CMV) enhancer/promoter expression plasmids overproducing wt or mutant human or murine p53 and with appropriate chloramphenicol acetyltransferase (CAT) reporter plasmids containing the promoter elements of human IL-6, c-fos, or beta-actin genes or of porcine major histocompatibility complex (MHC) class I gene in pN-38 to evaluate the effect of the various p53 species on these promoters. Murine and human wt p53 derived from pCMVNc9 and pC53-SN3, respectively, strongly repressed the IL-6 (promoter position -225 to +13), c-fos (-711 to +42), beta-actin (-3400 to +912), and MHC (-528 to -38) promoters in serum-induced HeLa cells; additionally, IL-6 promoter/CAT transcription unit constructs induced by IL-1, phorbol ester, or pseudorabies virus were also repressed by wt human and murine p53. The murine transforming mutant p53 (pCMVc5) was less active in repressing the IL-6, c-fos, beta-actin, and MHC promoter constructs. The human p53 mutant derived from pC53-SCX3 was also less active than the wt protein in repressing the IL-6, c-fos, beta-actin, and MHC promoters, except that serum-induced IL-6/CAT expression was equally repressed by both human wt and mutant p53. In similar transient transfection experiments in HeLa cells, overexpression of the wt human retinoblastoma susceptibility gene product, RB, was found to repress the serum-induced IL-6 (-225 to +13), c-fos (-711 to +42), and beta-actin (-3400 to +912) promoters but not the PRV-induced IL-6 (-110 to +13) or the serum-induced MHC (-528 to -38) promoters. These observations identify transcriptional repression as a property of p53 and suggest that p53 and RB may be involved as transcriptional repressors in modulating IL-6 gene expression during cellular differentiation and oncogenesis.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Santhanam</LastName>
						<ForeName>U</ForeName>
						<Initials>U</Initials>
						<AffiliationInfo>
							<Affiliation>Rockefeller University, New York, NY 10021.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ray</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sehgal</LastName>
						<ForeName>P B</ForeName>
						<Initials>PB</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AI-16262</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
				<NlmUniqueID>7505876</NlmUniqueID>
				<ISSNLinking>0027-8424</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016760">Proto-Oncogene Proteins c-fos</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016160">Retinoblastoma Protein</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.3.1.28</RegistryNumber>
					<NameOfSubstance UI="D015500">Chloramphenicol O-Acetyltransferase</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.7.10.1</RegistryNumber>
					<NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>NI40JAQ945</RegistryNumber>
					<NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015500" MajorTopicYN="N">Chloramphenicol O-Acetyltransferase</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004742" MajorTopicYN="N">Enhancer Elements, Genetic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016161" MajorTopicYN="Y">Genes, Retinoblastoma</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011401" MajorTopicYN="Y">Promoter Regions, Genetic</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016760" MajorTopicYN="N">Proto-Oncogene Proteins c-fos</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011519" MajorTopicYN="N">Proto-Oncogenes</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016160" MajorTopicYN="N">Retinoblastoma Protein</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013755" MajorTopicYN="N">Tetradecanoylphorbol Acetate</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1652755</ArticleId>
				<ArticleId IdType="pmc">PMC52350</ArticleId>
				<ArticleId IdType="doi">10.1073/pnas.88.17.7605</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Am J Pathol. 1989 Sep;135(3):427-33</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2675620</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1989 Dec;9(12):5537-47</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2511437</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1984 Oct;4(10):1961-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6095033</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1985 Oct;5(10):2851-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3915536</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1990 Jun;9(6):1897-906</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2112087</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1990 Aug 16;346(6285):668-71</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2117257</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1990 Sep 14;249(4974):1288-90</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1697983</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1990 May;9(5):1595-602</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1691710</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1990 Aug 31;249(4972):1049-51</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2144364</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1990 Aug 31;249(4972):1046-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2144363</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1990 Aug 24;249(4971):912-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2144057</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Genes Dev. 1990 Jan;4(1):1-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2137806</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1979 Mar 15;278(5701):261-3</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">218111</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunol Today. 1990 Dec;11(12):443-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2127356</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Soc Exp Biol Med. 1990 Nov;195(2):183-91</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2236101</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1991 Mar;11(3):1598-606</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1705009</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Oncogene. 1991 Jan;6(1):131-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1846954</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Cell Biochem. 1991 Apr;45(4):327-34</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2045425</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Cell Biochem. 1991 Jan;45(1):22-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2005181</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1990 Nov;10(11):5736-46</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2233715</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1990 Oct 5;250(4977):113-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2218501</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1988 Feb;8(2):695-703</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2832733</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1989 Dec 7;342(6250):705-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2531845</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1989 Jul;74(1):1-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2473791</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1988 Jan 29;239(4839):502-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2829354</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Oncogene. 1988 Sep;3(3):313-21</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3060794</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1988 Sep;85(18):6701-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3045822</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1989 Aug;86(16):6367-71</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2474833</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Biochem. 1986 Sep 15;159(3):529-34</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2428616</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1989 Nov;86(22):8763-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2530586</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ann N Y Acad Sci. 1989;557:353-61; discussion 361-2</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2786700</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1655384</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>10</Month>
				<Day>30</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>11</Month>
				<Day>30</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0013-7227</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>129</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Oct</Month>
						</PubDate>
					</JournalIssue>
					<Title>Endocrinology</Title>
					<ISOAbbreviation>Endocrinology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Neuropeptide regulation of interleukin-6 production from the pituitary: stimulation by pituitary adenylate cyclase activating polypeptide and calcitonin gene-related peptide.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1797-804</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Interleukin 6 (IL-6) production was shown to be stimulated by vasoactive intestinal peptide via cAMP dependent signal transduction pathway in the pituitary. We were interested in whether other hypothalamic neuropeptides, which activate adenylate cyclase in the pituitary, also stimulate pituitary IL-6 production. Whereas vasoactive intestinal peptide was effective in stimulating pituitary IL-6 production only at concentrations of 10(-6) M or higher, pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38) and calcitonin gene-related peptide (CGRP) at concentrations from 10(-10) to 10(-9) M significantly stimulated IL-6 production. Similar effective concentrations of each peptide were required for activating adenylate cyclase, as measured by extracellular cAMP accumulation. H89, a specific inhibitor of cAMP dependent protein kinase (protein kinase A), inhibited IL-6 production stimulated by PACAP38, CGRP, and (Bu)2cAMP. However, H89 failed to inhibit the IL-6 production stimulated by lipopolysaccharide, a ligand which enhanced IL-6 production in the absence of cAMP accumulation. Two other peptides which are known to activate pituitary adenylate cyclase, corticotropin-releasing factor and GRF failed to stimulate IL-6 production in pituitary cells. Using discontinuous Percoll gradients to fractionate the pituitary cells, the greatest PACAP38-stimulated IL-6 secretion was observed in the low density fraction 1 (F1). This fraction also contained the highest percentage of folliculo-stellate (FS) cells, one of the nonhormone secreting pituitary cells. However, the largest PACAP38-induced accumulation of cAMP was observed in F4. These results suggest that the production of IL-6 stimulated by PACAP and CGRP is mediated by the adenylate cyclase/protein kinase A signal transduction system. FS cells appear to be the most likely target cell type for PACAP-induced IL-6 production. However, IL-6 producing FS cells may not be an exclusive target for PACAP in the pituitary.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Tatsuno</LastName>
						<ForeName>I</ForeName>
						<Initials>I</Initials>
						<AffiliationInfo>
							<Affiliation>US-Japan Biomedical REsearch Laboratories, Tulane University Hebert Center, Belle Chasse, Louisiana 70037.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Somogyvari-Vigh</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mizuno</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gottschall</LastName>
						<ForeName>P E</ForeName>
						<Initials>PE</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hidaka</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Arimura</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>DK 09094</GrantID>
						<Acronym>DK</Acronym>
						<Agency>NIDDK NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Endocrinology</MedlineTA>
				<NlmUniqueID>0375040</NlmUniqueID>
				<ISSNLinking>0013-7227</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D051219">Pituitary Adenylate Cyclase-Activating Polypeptide</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D009418">S100 Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>37221-79-7</RegistryNumber>
					<NameOfSubstance UI="D014660">Vasoactive Intestinal Peptide</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>E0399OZS9N</RegistryNumber>
					<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>JHB2QIZ69Z</RegistryNumber>
					<NameOfSubstance UI="D015740">Calcitonin Gene-Related Peptide</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015740" MajorTopicYN="N">Calcitonin Gene-Related Peptide</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051219" MajorTopicYN="N">Pituitary Adenylate Cyclase-Activating Polypeptide</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010902" MajorTopicYN="N">Pituitary Gland</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009418" MajorTopicYN="N">S100 Proteins</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014660" MajorTopicYN="N">Vasoactive Intestinal Peptide</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1655384</ArticleId>
				<ArticleId IdType="doi">10.1210/endo-129-4-1797</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1655776</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>11</Month>
				<Day>14</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>10</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0021-9258</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>266</Volume>
						<Issue>29</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Oct</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of biological chemistry</Title>
					<ISOAbbreviation>J Biol Chem</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endothelial cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>19162-5</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Tumor necrosis factor-alpha (TNF-alpha) has been shown to enhance the synthesis of interleukin-6 (IL-6) and collagenase in human omental microvascular endothelial (HOME) cell (Mawatari, M., Kohno, K., Mizoguchi, H., Matsuda, T., Asoh, K., Van Damme, J. V., Welgus, H. G., and Kuwano, M. (1989) J. Immunol. 143, 1619-1627). In the present study, we have examined whether the TNF-alpha-induced synthesis of IL-6 or collagenase in HOME cells is mediated by an inducible growth factor. Among several growth factors examined, we found that the expression of basic fibroblast growth factor (bFGF) mRNA was the one most prominently enhanced when HOME cells were treated with TNF-alpha. The increase of bFGF mRNA by TNF-alpha in HOME cells was observed in both a dose- and time-dependent manner when assayed by Northern blot analysis. The induction of bFGF mRNA was observed by 3 h after incubation with TNF-alpha, and the maximal increase of 5-fold was obtained after 12 h of incubation with 100 units/ml TNF-alpha. Western blot analysis confirmed the enhanced synthesis of bFGF by TNF-alpha. Metabolic labeling and immunoprecipitation assays of bFGF showed that exposure to TNF-alpha enhanced secretion of bFGF into culture medium and also that TNF-alpha stimulated the production of bFGF molecules with molecular masses of 18, 21, and 22.5 kDa in HOME cells. TNF-alpha induced the expression of collagenase mRNA and IL-6 mRNA in HOME cells as well, and the coadministration of neutralizing anti-bFGF antibody almost completely blocked the effects of TNF-alpha. The treatment of HOME cells with exogenous bFGF significantly stimulated the expression of collagenase mRNA and IL-6 mRNA in HOME cells. Therefore, the biological effects of TNF-alpha on HOME cells may be mediated, at least in part, by TNF-alpha-induced bFGF.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Okamura</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Biochemistry, Oita Medical School, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sato</LastName>
						<ForeName>Y</ForeName>
						<Initials>Y</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Matsuda</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hamanaka</LastName>
						<ForeName>R</ForeName>
						<Initials>R</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ono</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kohno</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kuwano</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Biol Chem</MedlineTA>
				<NlmUniqueID>2985121R</NlmUniqueID>
				<ISSNLinking>0021-9258</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>103107-01-3</RegistryNumber>
					<NameOfSubstance UI="D016222">Fibroblast Growth Factor 2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.3</RegistryNumber>
					<NameOfSubstance UI="D003012">Microbial Collagenase</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004790" MajorTopicYN="N">Enzyme Induction</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016222" MajorTopicYN="N">Fibroblast Growth Factor 2</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003012" MajorTopicYN="N">Microbial Collagenase</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011233" MajorTopicYN="N">Precipitin Tests</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1655776</ArticleId>
				<ArticleId IdType="pii">S0021-9258(18)54976-0</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1658188</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>12</Month>
				<Day>13</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>03</Month>
				<Day>09</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1007</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>174</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Nov</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of experimental medicine</Title>
					<ISOAbbreviation>J Exp Med</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Tumor necrosis factor induces rapid production of 1'2'diacylglycerol by a phosphatidylcholine-specific phospholipase C.</ArticleTitle>
				<Pagination>
					<MedlinePgn>975-88</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Tumor necrosis factor (TNF) is a proinflammatory polypeptide that is able to induce a great diversity of cellular responses via modulating the expression of a number of different genes. One major pathway by which TNF receptors communicate signals from the membrane to the cell nucleus involves protein kinase C (PKC). In the present study, we have addressed the molecular mechanism of TNF-induced PKC activation. To this, membrane lipids of the human histiocytic cell line U937 were labeled by incubation with various radioactive precursors, and TNF-induced changes in phospholipid, neutral lipid, and water-soluble metabolites were analyzed by thin layer chromatography. TNF treatment of U937 cells resulted in a rapid and transient increase of 1'2'diacylglycerol (DAG), a well-known activator of PKC. The increase in DAG was detectable as early as 15 s after TNF treatment and peaked at 60 s. DAG increments were most pronounced (approximately 360% of basal levels) when cells were preincubated with [14C]lysophosphatidylcholine, which was predominantly incorporated into the phosphatidylcholine (PC) pool of the plasma-membranes. Further extensive examination of changes in metabolically labeled phospholipids indicated that TNF-stimulated hydrolysis of PC is accompanied by the generation of phosphorylcholine and DAG. These results suggest the operation of a PC-specific phospholipase C. Since no changes in phosphatidic acid (PA) and choline were observed and the production of DAG by TNF could not be blocked by either propranolol or ethanol, a combined activation of phospholipase D and PA-phosphohydrolase in DAG production appears unlikely. TNF-stimulated DAG production as well as PKC activation could be blocked by the phospholipase inhibitor p-bromophenacylbromide (BPB). Since BPB did not inactivate PKC directly, these findings underscore that TNF activates PKC via formation of DAG. TNF stimulation of DAG production could be inhibited by preincubation of cells with a monoclonal anti-TNF receptor (p55-60) antibody, indicating that activation of a PC-specific phospholipase C is a TNF receptor-mediated event.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Schütze</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
						<AffiliationInfo>
							<Affiliation>Institut für Medizinische Mikrobiologie und Hygiene, Technische Universität München, Germany.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Berkovic</LastName>
						<ForeName>D</ForeName>
						<Initials>D</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tomsing</LastName>
						<ForeName>O</ForeName>
						<Initials>O</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Unger</LastName>
						<ForeName>C</ForeName>
						<Initials>C</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Krönke</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Exp Med</MedlineTA>
				<NlmUniqueID>2985109R</NlmUniqueID>
				<ISSNLinking>0022-1007</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D004075">Diglycerides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010713">Phosphatidylcholines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.7.11.13</RegistryNumber>
					<NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.1.1.32</RegistryNumber>
					<NameOfSubstance UI="D010741">Phospholipases A</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.1.4.-</RegistryNumber>
					<NameOfSubstance UI="D010738">Type C Phospholipases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.1.4.4</RegistryNumber>
					<NameOfSubstance UI="D010739">Phospholipase D</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>SY7Q814VUP</RegistryNumber>
					<NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004075" MajorTopicYN="N">Diglycerides</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010713" MajorTopicYN="N">Phosphatidylcholines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010739" MajorTopicYN="N">Phospholipase D</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010741" MajorTopicYN="N">Phospholipases A</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010738" MajorTopicYN="N">Type C Phospholipases</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>11</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1658188</ArticleId>
				<ArticleId IdType="pmc">PMC2118987</ArticleId>
				<ArticleId IdType="doi">10.1084/jem.174.5.975</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Biol Chem. 1990 Apr 25;265(12):6642-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2324095</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1990 May 25;248(4958):1019-23</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2160731</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1990 Aug 25;265(24):14497-504</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1696947</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunology. 1990 May;70(1):82-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2162326</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1990 Apr 20;61(2):361-70</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2158863</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1990 Apr 20;61(2):351-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2158862</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Apr 1;144(7):2604-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2156927</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem Biophys Res Commun. 1990 Jun 29;169(3):933-40</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2114110</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1990 Jun 15;61(6):1113-20</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2112426</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1990 Jul 1;172(1):151-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2193094</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunol Today. 1990 May;11(5):176-80</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2186752</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Chromatogr. 1990 Jan 26;525(1):85-91</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2338450</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Carcinogenesis. 1987 Jan;8(1):173-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3802389</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1988 May 15;263(14):6865-71</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3360811</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>FEBS Lett. 1985 Nov 18;192(2):189-93</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3934001</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1985 Jul 5;260(13):7861-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3924909</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1988 Dec 15;263(35):19098-104</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2848815</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1988 Sep;85(18):6802-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2842790</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1986 Apr 17-23;320(6063):584-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3010124</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem Biophys Res Commun. 1987 Jan 15;142(1):235-41</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3028403</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biochem. 1986 Sep;100(3):531-41</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3023310</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem J. 1987 Mar 15;242(3):749-54</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3036100</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1987 May;84(10):3293-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3033642</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Arch Biochem Biophys. 1987 Mar;253(2):453-61</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3032105</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem J. 1988 Feb 15;250(1):125-32</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3128274</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunology. 1988 May;64(1):81-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3133309</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Int J Cancer. 1986 Jul 15;38(1):127-33</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3087891</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lymphokine Res. 1987 Spring;6(2):119-25</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3108589</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell Signal. 1989;1(4):367-75</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2484435</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1985 Nov 8;230(4726):630-2</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2413547</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1990 Mar;10(3):1276-80</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2304467</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1984 Aug 10;259(15):9369-73</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6746652</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1983 Jul 25;258(14):8769-73</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6134732</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Methods Enzymol. 1983;99:288-98</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6316094</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Cell Biol. 1982 Aug;94(2):325-34</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6980885</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1981 Feb;78(2):1189-93</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6972041</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Adv Lipid Res. 1978;16:267-326</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">362867</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1967 Feb 10;242(3):477-84</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6022844</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochemistry. 1974 Mar 26;13(7):1446-54</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4856505</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1976 Mar 10;251(5):1392-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1254572</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Can J Biochem Physiol. 1959 Aug;37(8):911-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">13671378</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1990 Oct 5;265(28):16846-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2120207</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>DNA Cell Biol. 1990 Dec;9(10):705-15</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1702293</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1990 Oct;9(10):3269-78</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1698610</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1990 Nov 1;172(5):1517-20</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2172437</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1990 Oct;87(19):7380-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2170974</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1990 Oct 1;172(4):1019-23</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2170559</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1990 Nov 2;63(3):459-65</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2225061</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1989 Oct 25;264(30):18128-36</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2808369</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1987 Nov 5;262(31):15309-15</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3117799</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>FASEB J. 1988 Aug;2(11):2670-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2456243</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem J. 1989 Sep 15;262(3):947-52</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2556114</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1989 Sep 5;264(25):14927-34</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2549042</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1989 Sep 5;264(25):14646-52</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2549028</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1989 Feb 25;264(6):3562-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2536751</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1989 May 25;264(15):9069-76</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2498324</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>FEBS Lett. 1989 Dec 4;258(2):269-73</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2599093</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem Biophys Res Commun. 1989 Oct 31;164(2):804-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2818589</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1989 Nov;86(21):8417-21</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2813400</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1989 Oct 15;264(29):17069-77</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2793844</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem Biophys Res Commun. 1989 Aug 30;163(1):301-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2775267</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem J. 1989 Jun 15;260(3):909-13</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2764912</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1988 Jul 1;54(1):73-81</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2898301</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Mar 1;167(3):1211-27</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3351436</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Anal Biochem. 1984 Nov 1;142(2):406-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6084960</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Annu Rev Cell Biol. 1986;2:149-78</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3548765</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1986 Sep;83(18):6785-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3462727</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochim Biophys Acta. 1987 Nov 12;931(2):242-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3663718</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Cell Physiol. 1987 Mar;130(3):382-91</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3558493</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochim Biophys Acta. 1987 Feb 14;917(2):296-307</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3801504</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1990 Sep;87(17):6537-41</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2168551</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem J. 1990 Apr 15;267(2):501-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2159287</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem J. 1990 Apr 1;267(1):91-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1691638</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1990 Jan 5;265(1):235-40</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1688428</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1990 Sep 5;265(25):14858-63</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2394701</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1990 Aug;9(8):2423-8, 2389</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2196173</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1659519</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>12</Month>
				<Day>27</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>11</Month>
				<Day>30</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0013-7227</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>129</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>Endocrinology</Title>
					<ISOAbbreviation>Endocrinology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Tumor necrosis factor alpha inhibits gonadotropin action in cultured porcine Leydig cells: site(s) of action.</ArticleTitle>
				<Pagination>
					<MedlinePgn>2933-40</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>In the present study, we have tested the direct effects of tumor necrosis factor-alpha (TNF-alpha) on basal and human (h)CG-stimulated testosterone secretion by cultured purified Leydig cells isolated from immature porcine testes. TNF-alpha reduced (as much as 90% decrease) hCG-stimulated, but not basal testosterone secretion in a dose- and time-dependent manner. The maximal and half-maximal effects were, respectively, 3.75 ng/ml (2.2 x 10(-10) M) and 0.66 ng/ml (3.9 x 10(-11) M) of TNF-alpha after 48 h treatment. TNF-alpha antagonizes the gonadotropin hormonal action by affecting at least two types of biochemical steps. First, TNF-alpha reduced LH/hCG binding to a maximal decrease of 45% obtained with 2 ng/ml of TNF-alpha after 48 h of treatment. TNF-alpha also inhibited (44% decrease) hCG-stimulated cAMP production in optimal conditions (20 ng/ml, 72 h). Second, TNF-alpha significantly (P less than 0.001) reduced testosterone secretion stimulated with 8-bromo-cAMP (3 x 10(-3) M) in a similar range (86% decrease) to that observed with the gonadotropin. Such an observation indicates that the antigonadotropic action of the cytokine is exerted in a predominant manner at a step(s) located beyond cAMP formation. Furthermore, incubation of Leydig cells with 22R-hydroxycholesterol (5 micrograms/ml, 2 h) reversed most of the inhibitory effect of TNF-alpha on androgen production. Indeed, the TNF-alpha (20 ng/ml, 72 h) inhibitory effect on testosterone production was limited to about 20% (P less than 0.03) in Leydig cells supplied with 22R-hydroxycholesterol. Such a moderate effect of the cytokine in the presence of 22R-hydroxycholesterol compared with that observed when androgen secretion was stimulated with the gonadotropin (up to 90% inhibition) indicate that TNF-alpha acts by dramatically reducing cholesterol substrate availability in the mitochondria. Such an effect of TNF-alpha is directly exerted on Leydig cells since TNF-alpha receptors (dissociation constant approximately 5.4 x 10(-10) M) are present in primary cultures of purified porcine Leydig cells. Together, the present findings show that in Leydig cells TNF-alpha antagonizes the gonadotropin action on testosterone formation predominantly through a decrease in the availability of cholesterol substrate in the mitochondria.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Mauduit</LastName>
						<ForeName>C</ForeName>
						<Initials>C</Initials>
						<AffiliationInfo>
							<Affiliation>INSERM CJF No. 90-08, Groupe de Recherches sur les Communications Cellulaires, Hôpital Sainte Eugénie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hartmann</LastName>
						<ForeName>D J</ForeName>
						<Initials>DJ</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Chauvin</LastName>
						<ForeName>M A</ForeName>
						<Initials>MA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Revol</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Morera</LastName>
						<ForeName>A M</ForeName>
						<Initials>AM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Benahmed</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Endocrinology</MedlineTA>
				<NlmUniqueID>0375040</NlmUniqueID>
				<ISSNLinking>0013-7227</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006063">Chorionic Gonadotropin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006888">Hydroxycholesterols</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>17711-16-9</RegistryNumber>
					<NameOfSubstance UI="C003585">22-hydroxycholesterol</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>23583-48-4</RegistryNumber>
					<NameOfSubstance UI="D015124">8-Bromo Cyclic Adenosine Monophosphate</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>3XMK78S47O</RegistryNumber>
					<NameOfSubstance UI="D013739">Testosterone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9002-67-9</RegistryNumber>
					<NameOfSubstance UI="D007986">Luteinizing Hormone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>E0399OZS9N</RegistryNumber>
					<NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015124" MajorTopicYN="N">8-Bromo Cyclic Adenosine Monophosphate</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006063" MajorTopicYN="N">Chorionic Gonadotropin</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006888" MajorTopicYN="N">Hydroxycholesterols</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007985" MajorTopicYN="N">Leydig Cells</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007986" MajorTopicYN="N">Luteinizing Hormone</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1659519</ArticleId>
				<ArticleId IdType="doi">10.1210/endo-129-6-2933</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1663147</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>02</Month>
				<Day>26</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>11</Month>
				<Day>11</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0740-7769</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>8</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of in vitro fertilization and embryo transfer : IVF</Title>
					<ISOAbbreviation>J In Vitro Fert Embryo Transf</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Effects of sex steroids on immunoglobulin M production by Epstein-Barr virus-transformed B-cell line SKW6-CL4.</ArticleTitle>
				<Pagination>
					<MedlinePgn>329-35</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The effects of estradiol (E2), progesterone (P), and testosterone (T) on the production of immunoglobulin (Ig) M by Epstein-Barr virus-transformed B-cell line, SKW6-CL4, were investigated. Interleukin 6 (IL-6) induced IgM production by SKW6-CL4 cells in a dose-dependent manner without any significant increase in thymidine incorporation. E2 at concentrations ranging from 10(-10) to 10(-9) M enhanced IL-6-induced IgM production by SKW6-CL4 cells, whereas E2 at a high concentration of 10(-7) M inhibited both the IgM production and the growth of SKW6-CL4 cells. Time-course studies revealed that E2 acts in the early phase of differentiation of SKW6-CL4 cells in response to IL-6. On the other hand, P and T at physiological and superphysiological levels did not influence either the IgM production or the proliferation of SKW6-CL4 cells. These findings suggest a direct immunoregulatory effect of E2 on human B lineage cells and support the concept that E2 may have a role in the pathogenesis of some autoimmune diseases.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Mori</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Obstetrics and Gynecology, Gifu University School of Medicine, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sawairi</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Itoh</LastName>
						<ForeName>N</ForeName>
						<Initials>N</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hanabayashi</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tamaya</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J In Vitro Fert Embryo Transf</MedlineTA>
				<NlmUniqueID>8412594</NlmUniqueID>
				<ISSNLinking>0740-7769</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>10028-17-8</RegistryNumber>
					<NameOfSubstance UI="D014316">Tritium</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>3XMK78S47O</RegistryNumber>
					<NameOfSubstance UI="D013739">Testosterone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>4G7DS2Q64Y</RegistryNumber>
					<NameOfSubstance UI="D011374">Progesterone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>4TI98Z838E</RegistryNumber>
					<NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>VC2W18DGKR</RegistryNumber>
					<NameOfSubstance UI="D013936">Thymidine</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName>
					<QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011374" MajorTopicYN="N">Progesterone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013936" MajorTopicYN="N">Thymidine</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1663147</ArticleId>
				<ArticleId IdType="doi">10.1007/BF01133023</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Immunol. 1988 Jul 1;141(1):91-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3288699</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1981 Dec 1;154(6):1935-45</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6459399</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1983 Nov;62(5):996-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6626749</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Int J Cancer. 1981 Jun 15;27(6):733-41</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6945298</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1983 Dec;131(6):2767-71</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6605988</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1985 Aug;82(16):5490-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2410927</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Feb 1;167(2):332-44</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3258006</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1985 Jan 18;227(4684):257-61</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3871252</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Pediatrics. 1971 Jan;47(1):120-3</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4925678</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1983 Jan;13(1):31-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6339249</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Arthritis Rheum. 1985 Feb;28(2):121-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3871614</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1967 Jun 17;214(5094):1224-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4169229</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Acta Endocrinol (Copenh). 1986 Jul;112(3):409-14</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3489342</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ann Neurol. 1981 Nov;10(5):420-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6975596</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Neurology. 1976 Jul;26(7):651-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">945513</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Arthritis Rheum. 1978 Sep-Oct;21(7):849-52</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">697955</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1977 Jun;74(6):2561-3</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">267950</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Klin Wochenschr. 1989 Jul 17;67(14):697-706</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2504990</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1987 Oct 1;166(4):967-81</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2821154</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Annu Rev Immunol. 1988;6:485-512</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3289574</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Int J Immunopharmacol. 1985;7(2):207-13</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3874174</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1665302</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>03</Month>
				<Day>31</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>08</Month>
				<Day>24</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0065-4299</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>34</Volume>
						<Issue>1-2</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Sep</Month>
						</PubDate>
					</JournalIssue>
					<Title>Agents and actions</Title>
					<ISOAbbreviation>Agents Actions</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Leukotriene B4 up-regulates IL-6 rather than IL-1 synthesis in human monocytes.</ArticleTitle>
				<Pagination>
					<MedlinePgn>42-5</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Leukotriene B4 (LTB4) preferentially induced IL-6 mRNA accumulation and IL-6 protein release as assessed by ELISA and the B9 cell bioassay. In contrast, minimal IL-1 mRNA or protein was induced by LTB4 either in the absence or presence of muramyl dipeptide. Supernatants of LTB4-treated monocytes consistently showed enhanced thymocyte costimulatory activity and this was abrogated by 75-80% by anti-IL-1 antibody. Baseline production of IL-1 appeared however to be sufficient for a synergistic stimulation of thymocytes in the presence of IL-6. Our results now help clarify that LTB4 stimulated preferentially IL-6 production and that the observed LTB4-induced augmentation in thymocyte responses to monocyte supernatants is due to augmented IL-6 contents in the presence of baseline minimal IL-1 production.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Poubelle</LastName>
						<ForeName>P E</ForeName>
						<Initials>PE</Initials>
						<AffiliationInfo>
							<Affiliation>Unité de Recherche Inflammation et Immunologie-Rhumatologie, Centre de Recherche du CHUL, Boul Laurier, Québec, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Stankova</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Grassi</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rola-Pleszczynski</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Switzerland</Country>
				<MedlineTA>Agents Actions</MedlineTA>
				<NlmUniqueID>0213341</NlmUniqueID>
				<ISSNLinking>0065-4299</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1HGW4DR56D</RegistryNumber>
					<NameOfSubstance UI="D007975">Leukotriene B4</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>53678-77-6</RegistryNumber>
					<NameOfSubstance UI="D000119">Acetylmuramyl-Alanyl-Isoglutamine</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000119" MajorTopicYN="N">Acetylmuramyl-Alanyl-Isoglutamine</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006825" MajorTopicYN="N">Hybridomas</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007975" MajorTopicYN="N">Leukotriene B4</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1665302</ArticleId>
				<ArticleId IdType="doi">10.1007/BF01993233</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Immunol Methods. 1989 Oct 24;123(2):193-210</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2681422</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Aug 1;143(3):964-70</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2545780</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1978 May;120(5):1497-503</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">149171</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunol Today. 1985 Oct;6(10):302-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">25290781</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Scand J Clin Lab Invest Suppl. 1968;97:77-89</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4179068</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1990 Jan 1;75(1):40-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2294996</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Biochem. 1985 Oct 15;152(2):253-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3876934</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Mar 1;167(3):1253-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3127525</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1985 Dec;135(6):3958-61</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2999234</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nucleic Acids Res. 1984 Jul 25;12(14):5627-38</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6087294</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1987 Oct;17(10):1411-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3500054</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 Aug 15;139(4):1273-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3039000</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Aug 1;143(3):896-901</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2526177</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Anal Biochem. 1987 Apr;162(1):156-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2440339</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1688428</PMID>
			<DateCompleted>
				<Year>1990</Year>
				<Month>02</Month>
				<Day>02</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>10</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0021-9258</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>265</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>1990</Year>
							<Month>Jan</Month>
							<Day>05</Day>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of biological chemistry</Title>
					<ISOAbbreviation>J Biol Chem</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Down-modulation of epidermal growth factor receptor affinity in fibroblasts treated with interleukin 1 or tumor necrosis factor is associated with phosphorylation at a site other than threonine 654.</ArticleTitle>
				<Pagination>
					<MedlinePgn>235-40</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Interleukin 1 or tumor necrosis factor alpha can cause a transient down-modulation of epidermal growth factor (EGF) binding to quiescent fibroblast monolayers; the effect results from a reduction in EGF receptor (EGF-R) affinity and appears to be mediated by a protein kinase C (PKC)-independent mechanism. Here we show transient increases in EGF-R serine/threonine phosphorylation which are temporally coordinated with the effects on EGF binding; we also demonstrate that the cytokine-mediated phosphorylations, unlike those caused by PKC activators, have little discernible effect upon intrinsic EGF-R-associated tyrosine kinase activity. Cytokine-mediated EGF-R phosphorylation is resistant to staurosporine, an extremely potent inhibitor of PKC. Analysis of tryptic 32P-phosphopeptides reveals that Thr654, the unique site of PKC-mediated phosphorylation, is not phosphorylated in cytokine-treated cells, but a different, relatively acidic, peptide containing phosphoserine can be detected instead.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Bird</LastName>
						<ForeName>T A</ForeName>
						<Initials>TA</Initials>
						<AffiliationInfo>
							<Affiliation>Cytokine Biochemistry Group, Strangeways Research Laboratory, Wort's Causeway, Cambridge, United Kingdom.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Saklatvala</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Biol Chem</MedlineTA>
				<NlmUniqueID>2985121R</NlmUniqueID>
				<ISSNLinking>0021-9258</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1114-81-4</RegistryNumber>
					<NameOfSubstance UI="D010769">Phosphothreonine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>17885-08-4</RegistryNumber>
					<NameOfSubstance UI="D010768">Phosphoserine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>21820-51-9</RegistryNumber>
					<NameOfSubstance UI="D019000">Phosphotyrosine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>2ZD004190S</RegistryNumber>
					<NameOfSubstance UI="D013912">Threonine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>42HK56048U</RegistryNumber>
					<NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>62229-50-9</RegistryNumber>
					<NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.7.10.1</RegistryNumber>
					<NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>NI40JAQ945</RegistryNumber>
					<NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004815" MajorTopicYN="N">Epidermal Growth Factor</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005881" MajorTopicYN="N">Gingiva</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010768" MajorTopicYN="N">Phosphoserine</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010769" MajorTopicYN="N">Phosphothreonine</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019000" MajorTopicYN="N">Phosphotyrosine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013755" MajorTopicYN="N">Tetradecanoylphorbol Acetate</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013912" MajorTopicYN="N">Threonine</DescriptorName>
					<QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName>
					<QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1990</Year>
					<Month>1</Month>
					<Day>5</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1990</Year>
					<Month>1</Month>
					<Day>5</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1990</Year>
					<Month>1</Month>
					<Day>5</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1688428</ArticleId>
				<ArticleId IdType="pii">S0021-9258(19)40221-4</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1689350</PMID>
			<DateCompleted>
				<Year>1990</Year>
				<Month>03</Month>
				<Day>23</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2017</Year>
				<Month>11</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1767</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>144</Volume>
						<Issue>4</Issue>
						<PubDate>
							<Year>1990</Year>
							<Month>Feb</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
					<ISOAbbreviation>J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Detection by in situ hybridization and phenotypic characterization of cells expressing IL-6 mRNA in human stimulated blood.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1317-22</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>IL-6 has manifold biologic functions in immune and inflammatory responses and is produced by a variety type of cells. In this work, we used the whole blood culture to identify the cells expressing IL-6 gene/protein after various stimulation. When the whole blood was incubated with LPS or Con A, much IL-6 activity, measured by the growth promoting assay using a murine IL-6-dependent hybridoma clone, was detected in the plasma as early as 4 h of culture and continued to increase with time, reaching a plateau around 12 h. Immunocytochemical analysis with anti-rIL-6 antiserum revealed that a proportion of mononuclear cells (MNC) contained intracytoplasmic IL-6 in LPS- or Con A-stimulated blood. Northern blot analysis for MNC from the blood stimulated with these stimuli showed that their transcripts for IL-6 peaked at 4 h, then rapidly declined and was undetectable after 24 h of stimulation. In situ hybridization technique with radiolabeled antisense RNA probe for IL-6 demonstrated that a fraction of MNC from LPS- as well as Con A-stimulated blood expressed IL-6 mRNA. With the combined use of in situ hybridization and immunofluorescence by corresponding mAb, it was confirmed that IL-6 mRNA expressing cells in stimulated blood were exclusively monocytes. In the whole blood culture, it was shown that expression of IL-6 mRNA by monocytes was inhibited by dexamethasone, but not by cyclosporin A. These results suggest that monocytes are the major cells expressing IL-6 gene/protein in the circulation after exposure to external stimuli.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Kato</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Pediatrics, School of Medicine, Kanazawa University, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Yokoi</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Takano</LastName>
						<ForeName>N</ForeName>
						<Initials>N</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kanegane</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Yachie</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Miyawaki</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Taniguchi</LastName>
						<ForeName>N</ForeName>
						<Initials>N</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Immunol</MedlineTA>
				<NlmUniqueID>2985117R</NlmUniqueID>
				<ISSNLinking>0022-1767</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015214">Antigens, Differentiation, Myelomonocytic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000954">Antigens, Surface</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D003524">Cyclosporins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>11028-71-0</RegistryNumber>
					<NameOfSubstance UI="D003208">Concanavalin A</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>7S5I7G3JQL</RegistryNumber>
					<NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015214" MajorTopicYN="N">Antigens, Differentiation, Myelomonocytic</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000954" MajorTopicYN="N">Antigens, Surface</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003208" MajorTopicYN="N">Concanavalin A</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003524" MajorTopicYN="N">Cyclosporins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009693" MajorTopicYN="N">Nucleic Acid Hybridization</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1990</Year>
					<Month>2</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1990</Year>
					<Month>2</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1990</Year>
					<Month>2</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1689350</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1692493</PMID>
			<DateCompleted>
				<Year>1990</Year>
				<Month>06</Month>
				<Day>19</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2022</Year>
				<Month>04</Month>
				<Day>08</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-4971</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>75</Volume>
						<Issue>10</Issue>
						<PubDate>
							<Year>1990</Year>
							<Month>May</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>Blood</Title>
					<ISOAbbreviation>Blood</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Inducible production of interleukin-6 by human polymorphonuclear neutrophils: role of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha.</ArticleTitle>
				<Pagination>
					<MedlinePgn>2049-52</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The recent demonstration of the ability of human polymorphonuclear neutrophils (PMN) to secrete various cytokines in response to the granulocyte activator granulocyte-macrophage colony-stimulating factor (GM-CSF) but not to other cytokines, has led to the identification of PMN as biosynthetically active cells. In this study we have investigated the ability of PMN to secrete interleukin-6 (IL-6), a molecule known to be involved in inflammatory reactions. Using RNA blotting analysis and bioassays, we show that PMN could be induced to synthesize transcripts specific for IL-6, indistinguishable in size from IL-6 mRNA produced by activated human macrophages. Consequently, PMN released IL-6-like activity into their culture supernatants that could be neutralized by monospecific anti-IL-6 antibody. Interleukin-6 secretion by PMN, however, required previous stimulation with GM-CSF or tumor necrosis factor-alpha (TNF-alpha), whereas other cytokines, including interleukin-3 (IL-3), granulocyte-CSF (G-CSF), macrophage-CSF (M-CSF), interferon gamma (IFN-gamma), and lymphotoxin (LT), failed to induce IL-6 mRNA accumulation and protein secretion by PMN. Similar to GM-CSF and TNF-alpha, other compounds, including the inhibitor of protein synthesis cyclohexemide (CHX), endotoxin (Escherichia coli-derived lipopolysaccharide), and phorbol myristate acetate (PMA) (but not the chemoattractant N-formyl-methionyl-leucyl-phenylalanine [FMLP]), induced detectable levels of IL-6 transcripts in PMN.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Cicco</LastName>
						<ForeName>N A</ForeName>
						<Initials>NA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Hematology and Oncology, University of Freiburg, FRG.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lindemann</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Content</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Vandenbussche</LastName>
						<ForeName>P</ForeName>
						<Initials>P</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lübbert</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gauss</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mertelsmann</LastName>
						<ForeName>R</ForeName>
						<Initials>R</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Herrmann</LastName>
						<ForeName>F</ForeName>
						<Initials>F</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Blood</MedlineTA>
				<NlmUniqueID>7603509</NlmUniqueID>
				<ISSNLinking>0006-4971</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D003115">Colony-Stimulating Factors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006133">Growth Substances</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008233">Lymphotoxin-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>143011-72-7</RegistryNumber>
					<NameOfSubstance UI="D016179">Granulocyte Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>81627-83-0</RegistryNumber>
					<NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>83869-56-1</RegistryNumber>
					<NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003115" MajorTopicYN="N">Colony-Stimulating Factors</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016179" MajorTopicYN="N">Granulocyte Colony-Stimulating Factor</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006133" MajorTopicYN="N">Growth Substances</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008233" MajorTopicYN="N">Lymphotoxin-alpha</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016173" MajorTopicYN="N">Macrophage Colony-Stimulating Factor</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1990</Year>
					<Month>5</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1990</Year>
					<Month>5</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1990</Year>
					<Month>5</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1692493</ArticleId>
				<ArticleId IdType="pii">S0006-4971(20)84337-7</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1696166</PMID>
			<DateCompleted>
				<Year>1990</Year>
				<Month>09</Month>
				<Day>12</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2006</Year>
				<Month>11</Month>
				<Day>15</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0008-5472</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>50</Volume>
						<Issue>16</Issue>
						<PubDate>
							<Year>1990</Year>
							<Month>Aug</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>Cancer research</Title>
					<ISOAbbreviation>Cancer Res</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>5072-6</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The immune response at the molecular level is characterized by a carefully coordinated interplay of both cytokine production and receptor induction. The regulation of these molecules including the closely related tumor necrosis factors alpha (TNF) and beta (lymphotoxin, LT) is still incompletely understood. We have examined the effects of various cytokines on the expression of TNF and LT mRNA in human peripheral blood mononuclear cells (PBMC). Northern blot analysis with total cellular RNA from mixed populations of PBMC revealed that genes coding for TNF and LT were not spontaneously expressed. Treatment of PBMC with recombinant interleukin (IL)-2 resulted in a high level expression of TNF and LT mRNA. Whereas IL-1 beta was equally effective as IL-2 in inducing both TNF and LT mRNA, granulocyte-macrophage colony-stimulating factor selectively induced only TNF mRNA. Both TNF and LT mRNA were minimally induced by IL-1 alpha, IL-3, interferon (IFN)-alpha, or IFN-gamma. Similarly TNF alone had little effect on induction of TNF and LT mRNA. In conjunction with IL-2, cytokines such as IFN-alpha, IFN-gamma, or TNF did not interfere with IL-2 induction of TNF and LT mRNA. Interestingly, IL-4 in combination with IL-2 inhibited the IL-2-driven induction of TNF and LT mRNA. This inhibitory effect of IL-4 was also observed at the level of TNF and LT protein secretion. Furthermore, IL-4 was also inhibitory of IL-2-mediated induction of Tac mRNA in PBMC. These results extend the interrelationship of cytokine regulation of TNF and LT expression. In particular, they reveal the previously unrecognized function of IL-4 in antagonizing the IL-2 induction of TNF, LT, and Tac mRNA in PBMC.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Kasid</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Director</LastName>
						<ForeName>E P</ForeName>
						<Initials>EP</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Stovroff</LastName>
						<ForeName>M C</ForeName>
						<Initials>MC</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lotze</LastName>
						<ForeName>M T</ForeName>
						<Initials>MT</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rosenberg</LastName>
						<ForeName>S A</ForeName>
						<Initials>SA</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Cancer Res</MedlineTA>
				<NlmUniqueID>2984705R</NlmUniqueID>
				<ISSNLinking>0008-5472</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000199">Actins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D001685">Biological Factors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D003115">Colony-Stimulating Factors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006133">Growth Substances</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008233">Lymphotoxin-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>63231-63-0</RegistryNumber>
					<NameOfSubstance UI="D012313">RNA</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>83869-56-1</RegistryNumber>
					<NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<CommentsCorrectionsList>
				<CommentsCorrections RefType="ErratumIn">
					<RefSource>Cancer Res 1991 May 15;51(10):2749</RefSource>
				</CommentsCorrections>
			</CommentsCorrectionsList>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001685" MajorTopicYN="N">Biological Factors</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003115" MajorTopicYN="N">Colony-Stimulating Factors</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006133" MajorTopicYN="N">Growth Substances</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008233" MajorTopicYN="N">Lymphotoxin-alpha</DescriptorName>
					<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName>
					<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1990</Year>
					<Month>8</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1990</Year>
					<Month>8</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1990</Year>
					<Month>8</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1696166</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1698773</PMID>
			<DateCompleted>
				<Year>1990</Year>
				<Month>11</Month>
				<Day>16</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>10</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0021-9258</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>265</Volume>
						<Issue>28</Issue>
						<PubDate>
							<Year>1990</Year>
							<Month>Oct</Month>
							<Day>05</Day>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of biological chemistry</Title>
					<ISOAbbreviation>J Biol Chem</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression.</ArticleTitle>
				<Pagination>
					<MedlinePgn>17238-45</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Primary and passaged human synovial fibroblasts isolated from rheumatoid pannus were treated with recombinant interleukin-1 (IL-1) alpha or beta, tumor necrosis factor-alpha (TNF), or phorbol myristate acetate (PMA) to determine the effects of these stimuli on the relative expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases (TIMP). The steady-state mRNA levels for these genes and glyceraldehyde-3-phosphate dehydrogenase were determined on Northern blots. Immunoblot analyses of the conditioned media using monoclonal antibodies generated against recombinant human stromelysin, collagenase, or TIMP showed that protein levels reflected the corresponding steady-state mRNA levels. The results revealed that 1) stromelysin and collagenase were not always coordinately expressed; 2) IL-1 was more potent than TNF or PMA in the induction of stromelysin expression; 3) neither IL-1 nor TNF significantly affected TIMP expression; 4) PMA induced both metalloproteinase and TIMP expression; and 5) the combination of IL-1 plus TNF had a synergistic effect on stromelysin expression. Dose response and time course experiments demonstrated that the synergistic effect of IL-1 plus TNF occurred at saturating concentrations of each cytokine and lasted for 7 days. In summary, the ability of IL-1 and TNF to preferentially induce stromelysin and collagenase expression, versus TIMP, may define a pivotal role for these cytokines in the pathogenesis of rheumatoid arthritis.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>MacNaul</LastName>
						<ForeName>K L</ForeName>
						<Initials>KL</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Molecular Immunology, Merck Sharp and Dohme Research Laboratories, Rahway, New Jersey 07065.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Chartrain</LastName>
						<ForeName>N</ForeName>
						<Initials>N</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lark</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tocci</LastName>
						<ForeName>M J</ForeName>
						<Initials>MJ</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hutchinson</LastName>
						<ForeName>N I</ForeName>
						<Initials>NI</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Biol Chem</MedlineTA>
				<NlmUniqueID>2985121R</NlmUniqueID>
				<ISSNLinking>0021-9258</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019714">Tissue Inhibitor of Metalloproteinases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>63231-63-0</RegistryNumber>
					<NameOfSubstance UI="D012313">RNA</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9007-49-2</RegistryNumber>
					<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.-</RegistryNumber>
					<NameOfSubstance UI="D008666">Metalloendopeptidases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.17</RegistryNumber>
					<NameOfSubstance UI="D019278">Matrix Metalloproteinase 3</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.4.24.3</RegistryNumber>
					<NameOfSubstance UI="D003012">Microbial Collagenase</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>NI40JAQ945</RegistryNumber>
					<NameOfSubstance UI="D013755">Tetradecanoylphorbol Acetate</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName>
					<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003001" MajorTopicYN="N">Cloning, Molecular</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019278" MajorTopicYN="N">Matrix Metalloproteinase 3</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008666" MajorTopicYN="N">Metalloendopeptidases</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003012" MajorTopicYN="N">Microbial Collagenase</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013583" MajorTopicYN="N">Synovial Membrane</DescriptorName>
					<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013755" MajorTopicYN="N">Tetradecanoylphorbol Acetate</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019714" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinases</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1990</Year>
					<Month>10</Month>
					<Day>5</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1990</Year>
					<Month>10</Month>
					<Day>5</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1990</Year>
					<Month>10</Month>
					<Day>5</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1698773</ArticleId>
				<ArticleId IdType="pii">S0021-9258(17)44894-0</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1701815</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>01</Month>
				<Day>29</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>07</Month>
				<Day>23</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-202X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>95</Volume>
						<Issue>6 Suppl</Issue>
						<PubDate>
							<Year>1990</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of investigative dermatology</Title>
					<ISOAbbreviation>J Invest Dermatol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interaction of interferons with skin reactive cytokines: from interleukin-1 to interleukin-8.</ArticleTitle>
				<Pagination>
					<MedlinePgn>90S-93S</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The skin as an organ contains a large pool of cells, important for the production of various cytokines. This study focuses on interferon-beta (IFN-beta), interleukin-6 (IL-6), and interleukin-8 (IL-8) production by fibroblasts and epithelial cells in response to interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha). Both these primary cytokines show multiple biologic activities in the skin. Their antiviral activity on fibroblasts is mediated by IFN-beta and not by IL-6. In addition, TNF-alpha and IL-1 have a growth stimulatory effect on dermal fibroblasts, which is not mediated by IFN-beta or IL-6. IL-1, double-stranded RNA, or virus are potent inducers of IL-6 and IL-8 on dermal fibroblasts, but they are less efficient on epidermal cells. IL-8 has been discovered as an early acting skin reactive factor responsible for the chemotaxis of neutrophilic granulocytes. Furthermore, IL-1 possesses delayed skin reactivity upon intradermal injection which presumably is mediated by local release of IL-8. These findings demonstrate that cytokines also interact in the skin and that dermal fibroblasts play an important role in the regulation of aspecific host defense.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Van Damme</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
						<AffiliationInfo>
							<Affiliation>Rega Institute for Medical Research, University of Leuven, Belgium.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Opdenakker</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Invest Dermatol</MedlineTA>
				<NlmUniqueID>0426720</NlmUniqueID>
				<ISSNLinking>0022-202X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016209">Interleukin-8</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9008-11-1</RegistryNumber>
					<NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000078404" MajorTopicYN="N">Epidermal Cells</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004817" MajorTopicYN="N">Epidermis</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016209" MajorTopicYN="N">Interleukin-8</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1990</Year>
					<Month>12</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1990</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1990</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1701815</ArticleId>
				<ArticleId IdType="pii">0022-202X(90)91197-J</ArticleId>
				<ArticleId IdType="doi">10.1111/1523-1747.ep12874825</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1702139</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>02</Month>
				<Day>01</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>05</Month>
				<Day>08</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1007</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>173</Volume>
						<Issue>1</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Jan</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of experimental medicine</Title>
					<ISOAbbreviation>J Exp Med</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19.</ArticleTitle>
				<Pagination>
					<MedlinePgn>55-64</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The complement system augments the humoral immune response, possibly by a mechanism that involves the B lymphocyte membrane receptor, CR2, which binds the C3dg fragment of C3 and triggers several B cell responses in vitro. The present study demonstrates that CR2 associates with a complex of membrane proteins that may mediate signal transduction by ligated CR2. Monoclonal antibodies to CR2 immunoprecipitated from digitonin lysates of Raji B lymphoblastoid cells a membrane complex containing CR2, approximately equimolar amounts of CD19, which is a member of the immunoglobulin superfamily, and three unidentified components: p130, p50, and p20. The complex, which was immunoprecipitated also with anti-CD19, could be dissociated by Nonidet P-40, accounting for its absence in previous studies of CR2. Expression of recombinant CR2 and CD19 in K562 erythroleukemia cells led to formation of a complex that contained not only these two proteins but also p130, p50, and p20, and another component, p14. These unidentified components of the CR2/CD19 complex coimmunoprecipitated with CD19 and not with CR2 from singly transfected cells, indicating primary association with the former. CD19 replicated the capacity of CR2 to interact synergistically with mIgM for increasing free intracellular Ca2+, suggesting that the complex mediates this function of CR2. Therefore, CR2 associates directly with CD19 to become a ligand-binding subunit of a pre-existing signal transduction complex of the B cell that may be representative of a family of membrane protein complexes. This interaction between the complement and immune systems differs from that between immunoglobulin and Clq by involving membrane rather than plasma proteins, and by having complement involved in the afferent phase of the immune response.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Matsumoto</LastName>
						<ForeName>A K</ForeName>
						<Initials>AK</Initials>
						<AffiliationInfo>
							<Affiliation>Division of Molecular and Clinical Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kopicky-Burd</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Carter</LastName>
						<ForeName>R H</ForeName>
						<Initials>RH</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tuveson</LastName>
						<ForeName>D A</ForeName>
						<Initials>DA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tedder</LastName>
						<ForeName>T F</ForeName>
						<Initials>TF</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fearon</LastName>
						<ForeName>D T</ForeName>
						<Initials>DT</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AI-22833</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>AI-28191</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>T32 GM-07309</GrantID>
						<Acronym>GM</Acronym>
						<Agency>NIGMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Exp Med</MedlineTA>
				<NlmUniqueID>2985109R</NlmUniqueID>
				<ISSNLinking>0022-1007</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018941">Antigens, CD19</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000944">Antigens, Differentiation, B-Lymphocyte</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011951">Receptors, Complement</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017464">Receptors, Complement 3d</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>KOO5CM684H</RegistryNumber>
					<NameOfSubstance UI="D004072">Digitonin</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018941" MajorTopicYN="N">Antigens, CD19</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000944" MajorTopicYN="N">Antigens, Differentiation, B-Lymphocyte</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004072" MajorTopicYN="N">Digitonin</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004915" MajorTopicYN="N">Leukemia, Erythroblastic, Acute</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011951" MajorTopicYN="N">Receptors, Complement</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017464" MajorTopicYN="N">Receptors, Complement 3d</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1702139</ArticleId>
				<ArticleId IdType="pmc">PMC2118751</ArticleId>
				<ArticleId IdType="doi">10.1084/jem.173.1.55</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Exp Med. 1989 Dec 1;170(6):2159-64</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2479707</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1983 Oct 1;158(4):1021-33</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6225820</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Oct 15;141(8):2569-76</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2459218</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Apr 1;167(4):1271-80</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2451706</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 May 1;138(9):2793-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2437199</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1986 Aug 1;137(3):952-61</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2424993</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1985 Jul;41(3):999-1006</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2408764</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1989 Dec 5;264(34):20576-82</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2555366</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Sep 15;143(6):1755-60</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2528579</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1989 Oct 26;341(6244):752-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2529442</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1989 Jan 12;337(6203):187-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2521376</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1989 Sep 1;170(3):877-86</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2788709</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochemistry. 1987 Feb 10;26(3):743-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3552030</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1986 Jan 1;163(1):101-15</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3484510</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 Jan 1;138(1):312-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3782802</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1985 Sep 19-25;317(6034):264-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3876511</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1984 Feb;81(3):881-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6230668</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1984 Aug;133(2):678-83</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6234356</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1983 Apr;130(4):1668-73</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6220062</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1983 Jul;131(1):244-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6408173</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1978 Nov;121(5):2043-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">81862</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunology. 1977 Jul;33(1):31-40</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">301502</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>N Engl J Med. 1979 May 17;300(20):1124-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">431636</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1978 Nov;121(5):2048-51</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">712077</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1975 May 25;250(10):4007-21</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">236308</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1988 Aug;18(8):1217-22</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3416908</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 Dec 1;139(11):3604-13</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2824610</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1989 Dec 1;170(6):1931-46</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2479703</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1989 Dec 22;246(4937):1608-11</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2531918</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1985 Nov 5;260(25):13824-30</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4055758</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunology. 1988 Oct;65(2):237-41</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2461345</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Feb 1;167(2):664-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2450163</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Jul 15;143(2):712-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2472450</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1987 Dec;84(24):9194-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2827171</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Mar 1;167(3):1047-66</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2832506</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Jan 1;140(1):170-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2826586</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1987 Jun 18-24;327(6123):629-32</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3037375</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Nov 1;168(5):1699-717</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2972794</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Jul 15;141(2):457-63</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2968402</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1985 Dec;135(6):4100-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2933459</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1986 Mar 20-26;320(6059):272-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2938011</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>N Engl J Med. 1986 Aug 21;315(8):488-95</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2942776</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1985 Jan;15(1):73-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3155687</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1990 Jun 28;345(6278):810-3</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1694265</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1990 Feb;9(2):441-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2154371</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1990 Mar;87(6):2274-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2138330</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Mar 1;144(5):1640-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2137840</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1990 Jul 13;249(4965):146-51</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2371562</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1990 Feb 22;343(6260):760-2</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2304550</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1990 Feb;9(2):449-55</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2303036</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Sep 1;168(3):1205-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2459292</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1705005</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>03</Month>
				<Day>27</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>05</Month>
				<Day>26</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0270-7306</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>11</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Mar</Month>
						</PubDate>
					</JournalIssue>
					<Title>Molecular and cellular biology</Title>
					<ISOAbbreviation>Mol Cell Biol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin-6 signals activating junB and TIS11 gene transcription in a B-cell hybridoma.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1409-18</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The events in interleukin-6 (IL-6) signal transduction leading to primary response gene activation were analyzed in murine B-cell hybridoma and plasmacytoma cells which require IL-6 for growth. IL-6 stimulation of IL-6-deprived cells resulted in the rapid and transient tyrosine phosphorylation of a 160-kDa cellular protein (p160). This was followed by the highly selective induction of two primary response genes, junB/AP-1 transcription factor and TIS11. junB and TIS11 inductions were unaffected by cycloheximide, suggesting that posttranslational modifications accounted for their activation. Activation of junB and TIS11 transcription required rapid tyrosine kinase activity as well as a different protein kinase activity sensitive to the potent kinase inhibitor, H7, and activated following p160 tyrosine phosphorylation. This H7-sensitive kinase appears to be distinct from any well-characterized protein kinase-second messenger system. On the basis of these findings, we propose that IL-6-induced signal transduction proceeds through a novel protein kinase cascade which activates junB and TIS11 gene transcription.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Nakajima</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Microbiology and Immunology, School of Medicine, University of California, Los Angeles 90024.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Wall</LastName>
						<ForeName>R</ForeName>
						<Initials>R</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>CA12800</GrantID>
						<Acronym>CA</Acronym>
						<Agency>NCI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>GM40185</GrantID>
						<Acronym>GM</Acronym>
						<Agency>NIGMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Mol Cell Biol</MedlineTA>
				<NlmUniqueID>8109087</NlmUniqueID>
				<ISSNLinking>0270-7306</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017874">Immediate-Early Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007529">Isoflavones</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007546">Isoquinolines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011506">Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016755">Proto-Oncogene Proteins c-jun</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D051816">Tristetraprolin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C497553">Zfp36 protein, mouse</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>21820-51-9</RegistryNumber>
					<NameOfSubstance UI="D019000">Phosphotyrosine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>42HK56048U</RegistryNumber>
					<NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>84477-87-2</RegistryNumber>
					<NameOfSubstance UI="D019307">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>98600C0908</RegistryNumber>
					<NameOfSubstance UI="D003513">Cycloheximide</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>DH2M523P0H</RegistryNumber>
					<NameOfSubstance UI="D019833">Genistein</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.7.10.1</RegistryNumber>
					<NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D019307" MajorTopicYN="N">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003513" MajorTopicYN="N">Cycloheximide</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005786" MajorTopicYN="Y">Gene Expression Regulation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019833" MajorTopicYN="N">Genistein</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006825" MajorTopicYN="N">Hybridomas</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017874" MajorTopicYN="Y">Immediate-Early Proteins</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007529" MajorTopicYN="N">Isoflavones</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007546" MajorTopicYN="N">Isoquinolines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019000" MajorTopicYN="N">Phosphotyrosine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016755" MajorTopicYN="N">Proto-Oncogene Proteins c-jun</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015533" MajorTopicYN="N">Transcriptional Activation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051816" MajorTopicYN="N">Tristetraprolin</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName>
					<QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>3</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>3</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1705005</ArticleId>
				<ArticleId IdType="pmc">PMC369414</ArticleId>
				<ArticleId IdType="doi">10.1128/mcb.11.3.1409-1418.1991</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Biol Chem. 1989 Aug 25;264(24):14503-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2788167</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1979 Aug;17(4):1025-35</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">487428</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1988 Nov;85(21):8062-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2460861</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1987 Apr 25;262(12):5592-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3106339</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1987 Jun 19;49(6):729-39</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3034432</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1987 Dec;84(24):8834-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3321056</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Annu Rev Biochem. 1988;57:443-78</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3052279</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1989 Aug 11;58(3):573-81</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2788034</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1988 Aug 12;241(4867):825-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3136546</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1988 Jul;85(13):4691-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3133658</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1988 May;8(5):2063-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3133553</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1987 Oct 1;166(4):967-81</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2821154</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1988 Mar 3;332(6159):83-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3258060</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1988 Jan 29;239(4839):502-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2829354</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1987 Dec 4;238(4832):1386-92</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2825349</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1986 Oct;5(10):2529-37</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3023045</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1987 Jun 19;49(6):741-52</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3034433</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1988 Jan;7(1):29-35</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3129290</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1988 Apr 8;53(1):37-43</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3127059</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Mar 1;167(3):1253-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3127525</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1988 Aug 12;54(4):553-60</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3135941</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1988 Aug 12;54(4):541-52</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3135940</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1988 Nov;85(21):7857-61</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3141919</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1988 Dec 2;55(5):907-15</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3142691</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1986 Jan;83(2):295-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3079910</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Annu Rev Immunol. 1988;6:485-512</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3289574</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>FEBS Lett. 1988 Jul 4;234(1):17-21</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3292283</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1989 Mar;86(6):2088-92</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2467301</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Oncogene. 1988 Apr;2(4):305-15</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2452398</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1987 Oct;84(20):7251-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2444978</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1987 Jul;84(13):4408-12</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2440021</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1985 Aug;82(16):5490-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2410927</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1989 May;9(5):2247-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2501665</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1989 Mar;8(3):805-13</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2498083</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1989 Apr;8(4):1111-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2663470</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Oncogene. 1989 Oct;4(10):1263-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2797820</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Oncogene. 1989 Jan;4(1):119-20</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2915901</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1988 Aug;8(8):3546-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3264880</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Sep 1;141(5):1543-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3261754</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1988 Jun;18(6):951-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3260187</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Jan 15;140(2):508-12</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3257241</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Feb 1;167(2):332-44</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3258006</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1988 Nov;85(22):8444-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3186734</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1988 Mar 10;332(6160):166-71</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3347253</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Oncogene. 1987;1(3):263-70</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3330774</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1987 Dec;84(24):9035-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3501121</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1987 Oct;17(10):1435-40</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3500055</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1987 Nov;84(21):7629-33</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3499611</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1986 Sep 25;261(27):12604-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3462188</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1987 Nov 6;238(4828):797-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3672127</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Biochem. 1986 Sep 15;159(3):625-32</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3758081</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1986 Aug 1;233(4763):566-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3726549</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Annu Rev Immunol. 1990;8:253-78</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2188664</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1990 Mar 29;344(6265):463-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2157161</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1990 Feb 15;343(6259):651-3</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2154696</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1984 Jun 25;259(12):7909-15</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6203898</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1983 Apr;32(4):1241-55</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6301687</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1987 Mar 1;165(3):914-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3493322</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1986 Nov 6-12;324(6092):73-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3491322</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1990 Dec 21;63(6):1149-57</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2261637</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1988 Mar;85(5):1487-91</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3422745</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Virol. 1982 Nov;44(2):674-82</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6292525</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1981 Jul;78(7):4354-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6945588</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1988 Nov 11;242(4880):933-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3263702</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1707879</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>05</Month>
				<Day>17</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>10</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0021-9258</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>266</Volume>
						<Issue>11</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Apr</Month>
							<Day>15</Day>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of biological chemistry</Title>
					<ISOAbbreviation>J Biol Chem</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Differential regulation of lymphotoxin and tumor necrosis factor genes in human T lymphocytes.</ArticleTitle>
				<Pagination>
					<MedlinePgn>7108-13</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Lymphotoxin (LT) and tumor necrosis factor (TNF) are related cytokines that share many biological effects. The genes for LT and TNF are adjacent to each other on chromosome 6 in man, but previous data indicate that the kinetics of their production differ markedly. To explain the mechanisms for this difference, we compared the regulation of these two genes in human T lymphocytes, isolated from peripheral blood, after stimulation with the mitogens concanavalin A and phorbol myristate acetate. Differences in the kinetics of protein secretion were paralleled by differences in cognate mRNA accumulation. TNF mRNA accumulated rapidly after stimulation, peaked by 6 h, and returned to unstimulated (base-line) levels by 24 h. In contrast, LT mRNA accumulated slowly after stimulation, usually peaked at approximately 18 h, and remained increased above base-line levels at 48-72 h. By nuclear transcription run-on assays, increased transcription of TNF mRNA and LT mRNA was demonstrated after stimulation. However, TNF transcription peaked earlier and appeared to be 4-10 times greater than that of the LT gene. In contrast, the half-life of LT mRNA was 8-10-fold longer than that of TNF mRNA as demonstrated by actinomycin D pulse-chase experiments. Cycloheximide did not block LT or TNF mRNA accumulation, indicating that new protein synthesis was not required for induction of either gene. These results suggest strongly that the LT and TNF genes are regulated differently in human T lymphocytes after mitogen stimulation. TNF mRNA accumulates rapidly primarily because of increased transcription and decreases rapidly related to its brief half-life. In contrast, LT mRNA accumulates more slowly but persists much longer; the accumulation of this mRNA appears to be controlled largely by post-transcriptional mechanisms.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>English</LastName>
						<ForeName>B K</ForeName>
						<Initials>BK</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Pediatrics, University of Washington, Seatle.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Weaver</LastName>
						<ForeName>W M</ForeName>
						<Initials>WM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Wilson</LastName>
						<ForeName>C B</ForeName>
						<Initials>CB</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="N">
					<Grant>
						<GrantID>AI16760</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>HD18184</GrantID>
						<Acronym>HD</Acronym>
						<Agency>NICHD NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>HL39157</GrantID>
						<Acronym>HL</Acronym>
						<Agency>NHLBI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D003160">Comparative Study</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Biol Chem</MedlineTA>
				<NlmUniqueID>2985121R</NlmUniqueID>
				<ISSNLinking>0021-9258</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008233">Lymphotoxin-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1CC1JFE158</RegistryNumber>
					<NameOfSubstance UI="D003609">Dactinomycin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>63231-63-0</RegistryNumber>
					<NameOfSubstance UI="D012313">RNA</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>98600C0908</RegistryNumber>
					<NameOfSubstance UI="D003513">Cycloheximide</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003513" MajorTopicYN="N">Cycloheximide</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003609" MajorTopicYN="N">Dactinomycin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008233" MajorTopicYN="N">Lymphotoxin-alpha</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>4</Month>
					<Day>15</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>4</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>4</Month>
					<Day>15</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1707879</ArticleId>
				<ArticleId IdType="pii">S0021-9258(20)89617-3</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1707930</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>05</Month>
				<Day>23</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2014</Year>
				<Month>11</Month>
				<Day>20</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1767</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>146</Volume>
						<Issue>9</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>May</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
					<ISOAbbreviation>J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines.</ArticleTitle>
				<Pagination>
					<MedlinePgn>3032-7</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>We evaluated the effects of binary combinations of four cytokines on production of the positive acute phase proteins alpha-1 antichymotrypsin, haptoglobin and fibrinogen, and the negative acute phase proteins albumin and alpha-fetoprotein (AFP) in two human hepatoma cell lines. The effects of the cytokine combinations on the five proteins varied; each protein exhibited a unique and specific pattern of response to the cytokine combinations. In Hep G2 cells, antichymotrypsin was induced by all four cytokines, IL-6, IL-1, TNF-alpha, and transforming growth factor beta 1 alone, and their effects in binary combinations could be attributed to additive or minimally synergistic interactions. Fibrinogen was induced only by IL-6 and this induction was inhibited by IL-1 alpha, TNF-alpha or transforming growth factor beta 1. Haptoglobin was also induced only by IL-6, but TNF-alpha was the only cytokine that inhibited this induction at all concentrations of IL-6. Each of the four cytokines alone down regulated production of AFP and albumin. However, binary combinations of the four cytokines were simply additive, for the most part, in inhibiting AFP production, whereas the inhibitory effects of combinations of cytokines on albumin production differed significantly from simple additive effects. These observations, taken together with studies of effects of cytokine combinations on other acute phase proteins, indicate that the various acute phase proteins respond differently to different combinations of cytokines and that the potential exists for highly specific regulation of synthesis of individual plasma proteins by cytokine interactions. These findings imply that the acute phase response in vivo represents the integrated sum of multiple, separately regulated changes in gene expression.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Mackiewicz</LastName>
						<ForeName>A</ForeName>
						<Initials>A</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH 44109.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Speroff</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ganapathi</LastName>
						<ForeName>M K</ForeName>
						<Initials>MK</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kushner</LastName>
						<ForeName>I</ForeName>
						<Initials>I</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AG02467</GrantID>
						<Acronym>AG</Acronym>
						<Agency>NIA NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Immunol</MedlineTA>
				<NlmUniqueID>2985117R</NlmUniqueID>
				<ISSNLinking>0022-1767</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000209">Acute-Phase Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006242">Haptoglobins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016211">Transforming Growth Factor alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000514">alpha 1-Antichymotrypsin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000509">alpha-Fetoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9001-32-5</RegistryNumber>
					<NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000209" MajorTopicYN="N">Acute-Phase Proteins</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006242" MajorTopicYN="N">Haptoglobins</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016211" MajorTopicYN="N">Transforming Growth Factor alpha</DescriptorName>
					<QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000514" MajorTopicYN="N">alpha 1-Antichymotrypsin</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000509" MajorTopicYN="N">alpha-Fetoproteins</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>5</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1707930</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1708808</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>06</Month>
				<Day>04</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>05</Month>
				<Day>08</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1007</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>173</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>May</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of experimental medicine</Title>
					<ISOAbbreviation>J Exp Med</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1083-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The complement system augments the humoral immune response to low concentrations of antigen. This effect may be partly mediated by complement receptors on the surface of B lymphocytes that bind immunogenic complexes bearing fragments of C3 and C4. We have shown by immunoprecipitation analysis that the two complement receptors expressed by B lymphocytes, complement receptor 1 (CR1) and CR2, form a detergent-sensitive complex on the surface of tonsillar B lymphocytes and on K562 erythroleukemia cells that were co-transfected with cDNAs encoding CR1 and CR2. The CR1/CR2 complex is distinct from the CR2/CD19 complex and may assist B cell activation by efficiently capturing C3b-containing immunogens and maintaining such immunogens on the B cell after CR1 and factor I-mediated cleavage to iC3b and C3dg. The complement activating immunogen may then trigger signal transduction by the CR1/CR2 complex, the CR2/CD19 complex, or membrane immunoglobulin.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Tuveson</LastName>
						<ForeName>D A</ForeName>
						<Initials>DA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ahearn</LastName>
						<ForeName>J M</ForeName>
						<Initials>JM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Matsumoto</LastName>
						<ForeName>A K</ForeName>
						<Initials>AK</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fearon</LastName>
						<ForeName>D T</ForeName>
						<Initials>DT</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>5T32GM07309</GrantID>
						<Acronym>GM</Acronym>
						<Agency>NIGMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>AI-22833</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>AI-28191</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Exp Med</MedlineTA>
				<NlmUniqueID>2985109R</NlmUniqueID>
				<ISSNLinking>0022-1007</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018941">Antigens, CD19</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000944">Antigens, Differentiation, B-Lymphocyte</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011951">Receptors, Complement</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017463">Receptors, Complement 3b</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017464">Receptors, Complement 3d</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9007-49-2</RegistryNumber>
					<NameOfSubstance UI="D004247">DNA</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D018941" MajorTopicYN="N">Antigens, CD19</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000944" MajorTopicYN="N">Antigens, Differentiation, B-Lymphocyte</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
					<QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004915" MajorTopicYN="N">Leukemia, Erythroblastic, Acute</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
					<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014066" MajorTopicYN="N">Palatine Tonsil</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011233" MajorTopicYN="N">Precipitin Tests</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011951" MajorTopicYN="N">Receptors, Complement</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017463" MajorTopicYN="N">Receptors, Complement 3b</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017464" MajorTopicYN="N">Receptors, Complement 3d</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>5</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>5</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1708808</ArticleId>
				<ArticleId IdType="pmc">PMC2118840</ArticleId>
				<ArticleId IdType="doi">10.1084/jem.173.5.1083</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1984 Feb;81(3):881-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6230668</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1984 Mar;132(3):1197-1201</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6229578</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">293688</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1978 Nov;121(5):2043-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">81862</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">266208</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>N Engl J Med. 1979 May 17;300(20):1124-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">431636</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1978 Nov;121(5):2048-51</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">712077</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Nov 1;145(9):2974-83</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2145366</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Immunol. 1988 Aug;18(8):1217-22</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3416908</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1985 Oct;135(4):2687-94</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2411809</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1989 Dec 1;170(6):1931-46</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2479703</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Sep 15;143(6):2058-67</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2528587</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Jul 15;143(2):712-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2472450</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Nov 1;168(5):1699-717</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2972794</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Mol Cell Biol. 1985 Feb;5(2):410-3</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2983194</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Jul 15;141(2):457-63</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2968402</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1985 Dec;135(6):4100-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2933459</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1985 Mar;134(3):1851-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3155775</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1985 Apr;134(4):2580-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3156186</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1987 May 1;138(9):2988-93</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2952731</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Sep 1;168(3):1205-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2459292</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Oct 15;141(8):2569-76</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2459218</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Sep 15;143(6):1755-60</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2528579</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biotechniques. 1989 Oct;7(9):980-2, 984-6, 989-90</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2631796</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochemistry. 1987 Feb 10;26(3):743-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3552030</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 May 1;144(9):3458-67</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2139457</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1990 Aug 1;172(2):665-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1695671</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1984 Aug;133(2):678-83</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6234356</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1710149</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>07</Month>
				<Day>10</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-4971</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>77</Volume>
						<Issue>11</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Jun</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Blood</Title>
					<ISOAbbreviation>Blood</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Further examination of the effects of recombinant cytokines on the proliferation of human megakaryocyte progenitor cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>2339-46</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The effect of several recombinant cytokines, including interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-6, and IL-1 alpha, on megakaryocyte (MK) colony formation by a normal human bone marrow subpopulation (CD34+ DR+), enriched for the MK colony-forming unit (CFU-MK), was studied using a serum-depleted, fibrin clot culture system. IL-3 and GM-CSF, but not IL-6 or IL-1 alpha, stimulated MK colony formation by CD34+ DR+ cells. However, the addition of IL-1 alpha to CD34+ DR+ cultures containing IL-6 resulted in the appearance of CFU-MK-derived colonies, suggesting that IL-6 requires the presence of IL-1 alpha to exhibit its MK colony-stimulating activity (MK-CSA). Addition of neutralizing antibodies to IL-3 and GM-CSF, but not to IL-6 and IL-1 alpha, specifically inhibited the MK-CSA of IL-3 and GM-CSF, respectively. The addition of either anti-IL-6, anti-IL-1 alpha, or anti-IL-3 antisera to cultures containing both IL-6 and IL-1 alpha totally abolished the MK-CSA of the IL-6/IL-1 alpha combination. However, neither anti-IL-3 nor anti-GM-CSF antisera could totally neutralize the additive effect of the combination of IL-3 and GM-CSF on MK colony formation, indicating that these two cytokines act by affecting distinct effector pathways. These results suggest that while IL-3 and GM-CSF can directly affect CFU-MK-derived colony formation, IL-1 alpha and IL-6 act in concert to promote de novo elaboration of IL-3 and thereby promote CFU-MK proliferative capacity.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Bruno</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, Indiana University School of Medicine, Indianapolis.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Cooper</LastName>
						<ForeName>R J</ForeName>
						<Initials>RJ</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Briddell</LastName>
						<ForeName>R A</ForeName>
						<Initials>RA</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hoffman</LastName>
						<ForeName>R</ForeName>
						<Initials>R</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>CA 34841</GrantID>
						<Acronym>CA</Acronym>
						<Agency>NCI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Blood</MedlineTA>
				<NlmUniqueID>7603509</NlmUniqueID>
				<ISSNLinking>0006-4971</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018952">Antigens, CD34</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D006684">HLA-DR Antigens</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007377">Interleukin-3</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>83869-56-1</RegistryNumber>
					<NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018952" MajorTopicYN="N">Antigens, CD34</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016178" MajorTopicYN="N">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006684" MajorTopicYN="N">HLA-DR Antigens</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006412" MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007377" MajorTopicYN="N">Interleukin-3</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008533" MajorTopicYN="N">Megakaryocytes</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>6</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1710149</ArticleId>
				<ArticleId IdType="pii">S0006-4971(20)77819-5</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1714833</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>09</Month>
				<Day>20</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2013</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0013-7227</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>129</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Sep</Month>
						</PubDate>
					</JournalIssue>
					<Title>Endocrinology</Title>
					<ISOAbbreviation>Endocrinology</ISOAbbreviation>
				</Journal>
				<ArticleTitle>The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1513-20</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Interleukin 6 (IL-6) probably plays a central role in the acute phase response and in haemopoiesis and may be involved in the control of bone turnover. We have studied the release of IL-6 from human trabecular bone cells treated with a variety of stimuli using a specific bioassay. In serum free medium, unstimulated human osteoblast-like cells produced IL-6 in the range of 1000-2050 pg/ml/24 h. Recombinant human interleukin 1 (IL-1 alpha) (10(-13)-10(-11) M), tumor necrosis factor alpha (TNF alpha) (10(-9)-10(-7) M) and lipopolysaccharide (5-500 ng/ml) all stimulated release of IL-6 from human bone cells. Maximal levels of 17,000 pg/ml were observed using the highest concentration of IL-1. 1,25(OH)2D3 and PTH did not stimulate IL-6 release. Using a specific sheep antihuman IL-6 antibody, all IL-6 activity could be neutralized. In parallel studies, ROS 17/2.8 rat osteosarcoma cells released around 50 pg/ml of IL-6 under basal conditions which were increased to a maximum of 900 pg/ml by treatment with PTH (10(-9) M). The cytokines were less effective and 1,25(OH)2D3 again had no effect. Modulation of expression of IL-6 mRNA in human osteoblast cells was examined using a human complementary deoxyribonucleic acid probe. The mRNA was constitutively expressed, and IL-1 (10(-11) M) and TNF (10(-7) M) induced further mRNA expression within 2 h, which was sustained over 24 h. 1,25(OH)2D3 (10(-7) M), IL-6 (2000 pg/ml), and PTH (10(-9) M) exerted no effects at any time point. Dexamethasone (10(-6) M) suppressed both basal and IL-1- and TNF-induced IL-6 mRNA expression. IL-6 receptor mRNA was constitutively expressed but was not regulated by any of the above agents. It is clear that rodent and human osteoblasts differ in their production of IL-6 and its modulation. These data support the hypothesis that IL-6 is produced locally in human bone by osteoblasts under the direction of other cytokines. This could have implications in bone remodeling, haemopoiesis, and systemic responses to local injury.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Littlewood</LastName>
						<ForeName>A J</ForeName>
						<Initials>AJ</Initials>
						<AffiliationInfo>
							<Affiliation>Bath Institute for Rheumatic Diseases, University of Bath, United Kingdom.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Russell</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Harvey</LastName>
						<ForeName>G R</ForeName>
						<Initials>GR</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hughes</LastName>
						<ForeName>D E</ForeName>
						<Initials>DE</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Russell</LastName>
						<ForeName>R G</ForeName>
						<Initials>RG</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Gowen</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Endocrinology</MedlineTA>
				<NlmUniqueID>0375040</NlmUniqueID>
				<ISSNLinking>0013-7227</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015342">DNA Probes</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010281">Parathyroid Hormone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>10T9CSU89I</RegistryNumber>
					<NameOfSubstance UI="D019379">Teriparatide</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>63231-63-0</RegistryNumber>
					<NameOfSubstance UI="D012313">RNA</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>FXC9231JVH</RegistryNumber>
					<NameOfSubstance UI="D002117">Calcitriol</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D015152" MajorTopicYN="N">Blotting, Northern</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002117" MajorTopicYN="N">Calcitriol</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015342" MajorTopicYN="N">DNA Probes</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010006" MajorTopicYN="N">Osteoblasts</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010281" MajorTopicYN="N">Parathyroid Hormone</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019947" MajorTopicYN="N">Receptors, Interleukin-6</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019379" MajorTopicYN="N">Teriparatide</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1714833</ArticleId>
				<ArticleId IdType="doi">10.1210/endo-129-3-1513</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1744226</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>01</Month>
				<Day>10</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>18</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0048-0444</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>58</Volume>
						<Issue>5</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Oct</Month>
						</PubDate>
					</JournalIssue>
					<Title>Nihon Ika Daigaku zasshi</Title>
					<ISOAbbreviation>Nihon Ika Daigaku Zasshi</ISOAbbreviation>
				</Journal>
				<ArticleTitle>[Enhancement of epidermal growth factor receptor (EGF-R) expression on glioma cells by cytokines].</ArticleTitle>
				<Pagination>
					<MedlinePgn>537-46</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Recombinant tumor necrosis factor alpha (TNF-alpha) significantly enhanced epidermal growth factor receptor (EGF-R) expression in U373-MG glioma cell line as determined by binding of anti-EGF-R monoclonal antibody (MAb) 425. The optimal dose of TNF-alpha was 1000 U/ml of media. When TNF-alpha was combined with recombinant interferon gamma (IFN-gamma), further upregulation of EGF-R was observed. However, IFN-gamma itself did not show any EGF-R enhancement in this cell line. Scatchard analysis of receptor binding revealed that this enhancement of EGF-R expression was due to an increase in the EGF-R density. TNF-alpha did not affect expression of other brain tumor-associated antigens defined by MAb ASHE2, ASHG4 and ASAY1. Cultured fibroblasts showed no upregulation of EGF-R by TNF-alpha, suggesting a differential effect of TNF-alpha on EGF-R expression on glioma cells and normal cells. We investigated whether TNF-alpha treatment of glioma cells increased the tumoricidal effects of radiolabeled MAb 425 which correlate with MAb density on tumor cell surfaces. Growth inhibition of glioma cells in culture by 125I-labeled MAb 425 was significantly enhanced after treatment of the cells with TNF-alpha. In previous clinical trials, 125I-labeled MAb 425 has shown immunotherapeutic effects in glioma patients. The present study provides the basis for considerations of combined immunotherapy of glioma patients with 125I-labeled MAb 425 and cytokines.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Adachi</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Neurosurgery, Nippon Medical School, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Herlyn</LastName>
						<ForeName>D</ForeName>
						<Initials>D</Initials>
					</Author>
				</AuthorList>
				<Language>jpn</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Japan</Country>
				<MedlineTA>Nihon Ika Daigaku Zasshi</MedlineTA>
				<NlmUniqueID>7505726</NlmUniqueID>
				<ISSNLinking>0048-0444</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>82115-62-6</RegistryNumber>
					<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 2.7.10.1</RegistryNumber>
					<NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
					<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005910" MajorTopicYN="N">Glioma</DescriptorName>
					<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
					<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
					<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
					<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1744226</ArticleId>
				<ArticleId IdType="doi">10.1272/jnms1923.58.537</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1752960</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>01</Month>
				<Day>29</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2018</Year>
				<Month>11</Month>
				<Day>13</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0021-9738</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>88</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Dec</Month>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of clinical investigation</Title>
					<ISOAbbreviation>J Clin Invest</ISOAbbreviation>
				</Journal>
				<ArticleTitle>On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin.</ArticleTitle>
				<Pagination>
					<MedlinePgn>2026-31</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Tumor necrosis factor (TNF), a protein released by activated macrophages, is a central mediator of the host response to infection and inflammation. The TNF-binding protein I (TNF-BP-I) is a soluble fragment of the p60 transmembrane TNF receptor and an antagonist to TNF. The level of serum TNF-BP-I was found to be increased in patients with renal insufficiency as a result of a decrease in the glomerular filtration rate. During hemodialysis of patients with renal failure there was a rapid but transient increase in serum TNF-BP-I. This increase was found to be caused by heparin given before dialysis and a similar dose-dependent response to heparin was observed also in healthy individuals. The finding of a repeated release of TNF-BP-I into the circulation with intermittent injections of heparin indicates that TNF-BP-I is present both in a storage pool and in a circulating pool. The mechanism for the heparin-mediated release of TNF-BP-I was not explained; TNF-BP did not show affinity for heparin. On the other hand, TNF was found to have affinity for heparin and it could also be dissociated from heparin by TNF-BP-I. It is suggested that heparin-like molecules of the extracellular matrix can retain TNF in physical proximity with target cells and restrict the actions of TNF and protect against systemic harmful manifestations.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Lantz</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, University Hospital, Lund, Sweden.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Thysell</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nilsson</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Olsson</LastName>
						<ForeName>I</ForeName>
						<Initials>I</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D016441">Retracted Publication</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Clin Invest</MedlineTA>
				<NlmUniqueID>7802877</NlmUniqueID>
				<ISSNLinking>0021-9738</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D047888">Receptors, Tumor Necrosis Factor, Type I</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D053319">Tumor Necrosis Factor Decoy Receptors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>1IEO802L3J</RegistryNumber>
					<NameOfSubstance UI="C069521">recombinant human tumor necrosis factor-binding protein-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>9005-49-6</RegistryNumber>
					<NameOfSubstance UI="D006493">Heparin</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<CommentsCorrectionsList>
				<CommentsCorrections RefType="RetractionIn">
					<RefSource>J Clin Invest. 1993 Feb;91(2):737</RefSource>
					<PMID Version="1">16695966</PMID>
				</CommentsCorrections>
			</CommentsCorrectionsList>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018124" MajorTopicYN="Y">Receptors, Tumor Necrosis Factor</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D047888" MajorTopicYN="N">Receptors, Tumor Necrosis Factor, Type I</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006435" MajorTopicYN="N">Renal Dialysis</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D053319" MajorTopicYN="N">Tumor Necrosis Factor Decoy Receptors</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1752960</ArticleId>
				<ArticleId IdType="doi">10.1172/JCI115530</ArticleId>
				<ArticleId IdType="pmc">PMC295793</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>DNA Cell Biol. 1990 Dec;9(10):705-15</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1702293</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1103152</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>EMBO J. 1990 Oct;9(10):3269-78</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1698610</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1990 Nov;86(5):1396-1402</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2173717</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Haematol. 1988 Nov;41(5):414-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2850215</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Apr 1;167(4):1511-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2833558</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1985 Jul;76(1):93-100</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3926823</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1988 Mar 24;332(6162):376-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2965305</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Cell Biol. 1988 Oct;107(4):1269-77</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3049617</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1987 Jan 23;235(4787):442-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2432664</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1989 Jul 15;264(20):11974-80</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2545693</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1989 Jul 15;264(20):11966-73</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2545692</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Eur J Haematol. 1989 Mar;42(3):270-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2924890</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1987 Dec 17-23;330(6149):662-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3317066</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1987 Mar 26-Apr 1;326(6111):330-1</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3494200</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1985 Aug 30;229(4716):869-71</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3895437</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1990 Apr 20;61(2):361-70</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2158863</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1990 Apr 20;61(2):351-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2158862</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1990 Jan 25;265(3):1531-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2153136</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1981 Oct;68(4):995-1002</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6457061</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Scand J Clin Lab Invest. 1979 Nov;39(7):619-26</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">119302</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Scand J Clin Lab Invest. 1972 Nov;30(3):271-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4629674</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Clin Chim Acta. 1973 Feb 12;43(3):305-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4690902</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1759331</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>02</Month>
				<Day>06</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>12</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0300-5623</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>19</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1991</Year>
						</PubDate>
					</JournalIssue>
					<Title>Urological research</Title>
					<ISOAbbreviation>Urol Res</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Tumor necrosis factor in benign and malign tissue of the kidney.</ArticleTitle>
				<Pagination>
					<MedlinePgn>367-73</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The use of tumor necrosis factor (TNF) in immunotherapy of tumor diseases has attracted increasing interest. Since the direct antitumor effect of the TNF is mediated by receptor-bound TNF, we immunohistologically stained both benign and malignant tissue from 35 tumor-bearing human kidneys for TNF. Using a polyclonal anti-TNF-antiserum, paraffin sections were tested in the presence and absence of in vitro preincubation with TNF. Furthermore, all specimens were stained immunohistologically for Tamm-Horsfall protein (THP) because this renospecific glycoprotein can bind TNF in a lectin-like manner. In the absence of TNF preincubation, malignant tissue was TNF-positive in 34 specimens, as was benign tissue from the same tumor-bearing kidneys in 35 cases. In several specimens the staining was so intense that preincubation with TNF did not enhance the reaction. Whereas TNF staining in tumor tissue was relatively homogenous, that in benign tissue was intensive in distal tubuli, moderate in proximal tubuli, and negative in glomeruli. THP staining was negative in malignant kidney tissue but positive in the distal tubuli of benign tissue, i.e., in the regions in which TNF staining was most intense. These results indicate that TNF binds not only to membrane, most likely in a receptor-mediated manner, but also to THP both in vivo and in vitro. In vivo binding of TNF to THP was confirmed in animal experiments in which pigs were given injections of TNF. Immunohistological staining of the animals' kidneys revealed positive reactions for both TNF and THP at the distal tubuli, indicating TNF binding to THP after in vivo TNF administration.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Bichler</LastName>
						<ForeName>K H</ForeName>
						<Initials>KH</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Urology, University of Tübingen, FRG.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kleinknecht</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Nelde</LastName>
						<ForeName>H J</ForeName>
						<Initials>HJ</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Strohmaier</LastName>
						<ForeName>W L</ForeName>
						<Initials>WL</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Germany</Country>
				<MedlineTA>Urol Res</MedlineTA>
				<NlmUniqueID>0364311</NlmUniqueID>
				<ISSNLinking>0300-5623</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D009088">Mucoproteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011257">Pregnancy Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="C548612">UMOD protein, human</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D058949">Uromodulin</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002292" MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName>
					<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
					<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007680" MajorTopicYN="N">Kidney Neoplasms</DescriptorName>
					<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009088" MajorTopicYN="N">Mucoproteins</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011257" MajorTopicYN="N">Pregnancy Proteins</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
					<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D058949" MajorTopicYN="N">Uromodulin</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1759331</ArticleId>
				<ArticleId IdType="doi">10.1007/BF00310152</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>Schweiz Med Wochenschr. 1989 Dec 9;119(49):1756-61</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2482541</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer. 1989 Nov 15;64(10):2076-80</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2804896</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Pathol. 1969 May;22(3):334-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4891482</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer Res. 1987 Jun 1;47(11):2986-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3567916</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Urologe A. 1975 Sep;14(5):246-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1209805</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lancet. 1988 Apr 30;1(8592):969-71</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2896830</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1987 Sep 18;237(4821):1479-84</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3498215</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell. 1988 Apr 8;53(1):45-53</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3349526</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1986 Dec;83(23):9119-23</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3538018</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer Res. 1990 Apr 15;50(8):2371-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2317822</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunol Lett. 1988 Nov;19(3):183-91</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3069706</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Dtsch Med Wochenschr. 1989 Feb 24;114(8):312-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2646094</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1986 Oct 15;261(29):13404-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3489714</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Urol Int. 1990;45(5):269-83</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2219564</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer. 1988 Nov 1;62(9):1946-51</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2458824</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1985 Aug 8-14;316(6028):552-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2993897</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lab Invest. 1983 Sep;49(3):317-26</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6193332</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Int J Cancer. 1984 Aug 15;34(2):263-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6469400</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Hinyokika Kiyo. 1987 Mar;33(3):329-35</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3113191</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer Res. 1989 May 15;49(10):2606-14</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2496917</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1985 Dec 19-1986 Jan 1;318(6047):665-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3001529</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunobiology. 1986 Sep;172(3-5):283-90</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3100430</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Br J Haematol. 1988 Jun;69(2):149-52</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3291927</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lab Invest. 1987 Mar;56(3):234-48</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3029503</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Pathol. 1988 Dec;133(3):564-72</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3202118</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1961 Aug;40(8 Pt 1-2):1453-65</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">16695876</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1988 Apr 15;263(11):5418-24</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3356692</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Soc Exp Biol Med. 1950 May;74(1):106-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">15430405</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Oncol. 1989 Mar;7(3):291-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2645383</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Onkologie. 1989 Jun;12(3):136-41</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2668836</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer. 1972 Apr;29(4):977-81</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4335980</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1987 Apr 3;236(4797):83-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3453112</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1103152</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Urol Res. 1973 May;1(2):50-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4204525</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lancet. 1985 Nov 23;2(8465):1190</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2865645</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Gan To Kagaku Ryoho. 1987 Jul;14(7):2378-80</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3606157</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Br J Urol. 1975;47(7):733-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1222338</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Prog Exp Tumor Res. 1969;12:1-54</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4189889</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Onkologie. 1989 Jun;12(3):131-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2668835</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1985 Apr 12;228(4696):149-54</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3856324</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1986 Sep 4-10;323(6083):86-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3092113</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1985 Nov 22;230(4728):943-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3933111</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell Immunol. 1989 Aug;122(1):1-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2502315</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>S Afr Med J. 1988 Oct 15;74(8):411-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3055358</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cell Immunol. 1989 Sep;122(2):405-15</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2548738</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Exp Cell Res. 1987 Jun;170(2):428-38</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3109929</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Urol Int. 1973;28(3):184-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4753572</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Cancer Res Clin Oncol. 1989;115(2):189-92</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2654135</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Urol Res. 1976 Nov 10;4(3):119-23</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1014172</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer Chemother Pharmacol. 1989;24(6):391-2</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2791193</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Cancer Res. 1987 Aug 1;47(15):3948-53</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3496953</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1761639</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>02</Month>
				<Day>07</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>18</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0271-9142</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>11</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Nov</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of clinical immunology</Title>
					<ISOAbbreviation>J Clin Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Elevated monocyte interleukin-6 (IL-6) production in immunosppressed trauma patients. II. Downregulation by IL-4.</ArticleTitle>
				<Pagination>
					<MedlinePgn>336-44</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Aberrant monocyte mediator production is pivotal in the development of posttrauma immunosuppression. We have previously shown that immunodepressed trauma patients' monocytes produce elevated interleukin-6, suggesting their in vivo preactivation. This study confirms that preactivated patients' Mø produce greater levels of IL-6 than normals' Mø to the same in the in vitro Fc gamma RI stimulation. We also demonstrate the capacity of interleukin-4 to downregulate the elevated interleukin-6 production of trauma patients' in vivo preactivated monocytes. Monocyte interleukin-6 downregulation by interleukin-4 is dose dependent and occurs whether Fc gamma RI cross-linking, muramyl dipeptide, indomethacin plus muramyl dipeptide, or interferon-gamma plus muramyl dipeptide is the interleukin-6 inducing stimulus. Furthermore, interleukin-4-dependent downregulation of monocyte interleukin-6 expression is confirmed at both the supernatant and the mRNA levels. Simultaneous downregulation of posttrauma elevated monokines implies a possible therapeutic benefit of interleukin-4 for trauma patients.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Szabo</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Surgery, University of Massachusetts Medical Center, Worcester 01655.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Kodys</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Miller-Graziano</LastName>
						<ForeName>C L</ForeName>
						<Initials>CL</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>GM36214-05</GrantID>
						<Acronym>GM</Acronym>
						<Agency>NIGMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Netherlands</Country>
				<MedlineTA>J Clin Immunol</MedlineTA>
				<NlmUniqueID>8102137</NlmUniqueID>
				<ISSNLinking>0271-9142</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>207137-56-2</RegistryNumber>
					<NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007108" MajorTopicYN="N">Immune Tolerance</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>11</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>11</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1761639</ArticleId>
				<ArticleId IdType="doi">10.1007/BF00918799</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Immunol. 1986 Mar 1;136(5):1641-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2936805</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Jun 1;142(11):3857-61</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2785566</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Immunol. 1991 Nov;11(6):326-35</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1837029</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Burn Care Rehabil. 1987 Nov-Dec;8(6):503-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2963826</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lancet. 1987 Oct 17;2(8564):921</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2889120</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Ann N Y Acad Sci. 1989;557:130-41, discussion 141-3</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2500051</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1986 Oct;78(4):1120-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3020090</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Apr 1;142(7):2321-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2784459</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Arch Surg. 1989 Dec;124(12):1437-41; discussion 1441-2</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2511821</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunology. 1990 Sep;71(1):70-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2120129</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Jul 15;145(2):569-75</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2114443</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Lymphokine Res. 1990 Summer;9(2):231-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1692598</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Arch Surg. 1988 Mar;123(3):287-92</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3124800</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Scand J Immunol. 1989 Jun;29(6):689-98</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2544986</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunol Today. 1988 Sep;9(9):253-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3255346</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Arch Surg. 1988 Mar;123(3):293-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2963603</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1990 Feb;87(3):1233-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2105500</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Anal Biochem. 1983 Jul 1;132(1):6-13</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6312838</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Leukoc Biol. 1990 May;47(5):475-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2335755</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Trauma. 1987 Aug;27(8):837-48</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2956432</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Leukoc Biol. 1990 Mar;47(3):206-16</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2137848</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Apr 15;144(8):3046-51</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2139076</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Arch Surg. 1990 Jan;125(1):29-35</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2104744</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1991 May 15;146(10):3431-6</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2026872</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1988 Sep 2;241(4870):1218-21</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2457950</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunol Rev. 1991 Feb;119:163-79</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2045119</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Jan 15;144(2):625-30</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2153171</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Sep 1;145(5):1435-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2200823</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1990 Sep 1;145(5):1337-42</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2143517</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Crit Care Clin. 1989 Apr;5(2):353-67</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2650822</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Anal Biochem. 1987 Apr;162(1):156-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2440339</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Transplantation. 1990 Aug;50(2):301-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2143326</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1989 Sep;74(4):1222-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2504304</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Blood. 1989 Oct;74(5):1704-10</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2790194</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1990 May;85(5):1694-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2139669</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Clin Immunol Immunopathol. 1990 Mar;54(3):361-71</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2406054</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1989 May;86(10):3803-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2786204</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Scand J Immunol. 1990 Apr;31(4):529-33</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1692157</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1989 Jun 15;142(12):4339-45</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2786029</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Clin Immunol Immunopathol. 1989 Mar;50(3):399-401</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2465111</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1773338</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>03</Month>
				<Day>03</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>06</Month>
				<Day>13</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-8993</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>562</Volume>
						<Issue>2</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Oct</Month>
							<Day>25</Day>
						</PubDate>
					</JournalIssue>
					<Title>Brain research</Title>
					<ISOAbbreviation>Brain Res</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>199-206</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Fever induced by endogenous as well as exogenous pyrogens is often prevented by cyclooxygenase inhibitors; endogenous pyrogens stimulate prostaglandin E2 (PGE2) in or near the thermoregulatory centers of the brain. The cytokines, interleukin-1 (IL-1) and tumor necrosis factor (TNF), are two pyrogens which stimulate brain PGE2 formation during fever and also increase PGE2 synthesis in human mononuclear cells in vitro. In the present study, we examined whether interleukin-6 (IL-6) stimulates PGE2 formation in a manner similar to IL-1 and TNF. Both glycosylated and non-glycosylated forms of recombinant human IL-6 were tested. Following intravenous injection into rabbits, the glycosylated IL-6 was more pyrogenic than the non-glycosylated form and there was no evidence of synergy in the production of fever when IL-6 and IL-1 were given simultaneously. IL-6 fever was blocked by prior administration of the cyclooxygenase inhibitor ibuprofen. IL-6 was also pyrogenic in the cat by either the systemic or the intraventricular route. However, in both species, IL-6 was less effective than IL-1 beta. When given intraventricularly to cats, IL-6 produced an increase in PGE2 levels of the cerebrospinal fluid in parallel with the rise in body temperature. In the latter respect, IL-6 imitated IL-1 beta; however, IL-6 from 0.15-15 micrograms/ml did not increase mononuclear cell PGE2 production in vitro whereas IL-1 beta induced 20-30-fold increases in PGE2 at 100 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Dinarello</LastName>
						<ForeName>C A</ForeName>
						<Initials>CA</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, Tufts University School of Medicine, Boston, MA.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Cannon</LastName>
						<ForeName>J G</ForeName>
						<Initials>JG</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Mancilla</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bishai</LastName>
						<ForeName>I</ForeName>
						<Initials>I</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lees</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Coceani</LastName>
						<ForeName>F</ForeName>
						<Initials>F</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AI 15614</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>AR-39595</GrantID>
						<Acronym>AR</Acronym>
						<Agency>NIAMS NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D003160">Comparative Study</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Netherlands</Country>
				<MedlineTA>Brain Res</MedlineTA>
				<NlmUniqueID>0045503</NlmUniqueID>
				<ISSNLinking>0006-8993</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007375">Interleukin-1</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011749">Pyrogens</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002415" MajorTopicYN="N">Cats</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
					<QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007375" MajorTopicYN="N">Interleukin-1</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011749" MajorTopicYN="Y">Pyrogens</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>25</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>25</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>25</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1773338</ArticleId>
				<ArticleId IdType="pii">0006-8993(91)90622-3</ArticleId>
				<ArticleId IdType="doi">10.1016/0006-8993(91)90622-3</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1774306</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>03</Month>
				<Day>03</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>05</Month>
				<Day>26</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0095-1137</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>29</Volume>
						<Issue>9</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Sep</Month>
						</PubDate>
					</JournalIssue>
					<Title>Journal of clinical microbiology</Title>
					<ISOAbbreviation>J Clin Microbiol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Effect of beta-estradiol on production of the cell-detaching factor of Trichomonas vaginalis.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1847-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Despite over 40 years of study, the pathogenetic mechanisms of Trichomonas vaginalis are just starting to be elucidated. We have recently reported that T. vaginalis produces a virulence factor, cell-detaching factor (CDF), that likely causes the cell sloughing seen in clinical disease. This 200-kDa glycoprotein is acid and heat labile and correlates with clinical symptoms. We applied a McCoy cell culture system to study the effects of various concentrations of beta-estradiol (10(-6) to 10(-10) M) on T. vaginalis growth and CDF production. T. vaginalis growth was unaffected by the different concentrations of beta-estradiol studied, in comparison with the growth of control cultures without beta-estradiol. However, beta-estradiol significantly diminished the activity of CDF at all concentrations and did so most profoundly at 10(-7) and 10(-8) M (P less than 0.0001). This suggests that the symptoms of T. vaginalis infection may be influenced by the vaginal concentration of estrogens, and further studies of the interactions between T. vaginalis and estrogens are warranted.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Garber</LastName>
						<ForeName>G E</ForeName>
						<Initials>GE</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, University of Ottawa, Ottawa General Hospital, Ontario, Canada.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Lemchuk-Favel</LastName>
						<ForeName>L T</ForeName>
						<Initials>LT</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Rousseau</LastName>
						<ForeName>G</ForeName>
						<Initials>G</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Clin Microbiol</MedlineTA>
				<NlmUniqueID>7505564</NlmUniqueID>
				<ISSNLinking>0095-1137</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>4TI98Z838E</RegistryNumber>
					<NameOfSubstance UI="D004958">Estradiol</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001422" MajorTopicYN="N">Bacterial Adhesion</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014247" MajorTopicYN="N">Trichomonas Vaginitis</DescriptorName>
					<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014246" MajorTopicYN="N">Trichomonas vaginalis</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName>
					<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>9</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1774306</ArticleId>
				<ArticleId IdType="pmc">PMC270222</ArticleId>
				<ArticleId IdType="doi">10.1128/jcm.29.9.1847-1849.1991</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Parasitol. 1957 Aug;43(4):488-90</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">13463700</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Jpn Obstet Gynecol Soc. 1968 Jul;15(3):168-72</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">5705314</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Microbiol. 1989 Jul;27(7):1548-53</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2788661</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Gen Microbiol. 1988 Jun;134(6):1623-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3265429</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Microbiol. 1987 Jul;25(7):1275-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3497171</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Am J Obstet Gynecol. 1987 May;156(5):1119-21</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3495180</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>G Batteriol Virol Immunol. 1985 Jan-Jun;78(1-6):52-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3879810</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Int J Fertil. 1981;26(3):196-202</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6118339</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Br J Vener Dis. 1984 Apr;60(2):99-105</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6608395</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Sex Transm Dis. 1979 Oct-Dec;6(4):261-3</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">316933</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Med Clin North Am. 1972 Sep;56(5):1203-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4538260</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>G Batteriol Virol Immunol. 1974 Jan-Jun;67(1-6):31-40</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4475655</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Minerva Ginecol. 1972 Jan 15;24(1):23-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4671752</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Practitioner. 1972 Nov;209(253):639-44</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4635620</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Chemotherapy. 1967;12(3):137-45</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">4861602</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Microbiol. 1990 Nov;28(11):2415-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2254417</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1814850</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>06</Month>
				<Day>22</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>09</Month>
				<Day>07</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0192-0561</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>13</Volume>
						<Issue>8</Issue>
						<PubDate>
							<Year>1991</Year>
						</PubDate>
					</JournalIssue>
					<Title>International journal of immunopharmacology</Title>
					<ISOAbbreviation>Int J Immunopharmacol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Inhibition by cyclo-oxygenase inhibitors of interleukin-6 production by human peripheral blood mononuclear cells.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1137-46</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The effects of cyclo-oxygenase inhibitors on interleukin-6 (IL-6) production by human peripheral blood mononuclear cells were examined. Indomethacin and Y-9223, a novel cyclo-oxygenase inhibitor, inhibited the increases in the IL-6 level in the culture medium of both mitogen-stimulated adherent cells and non-adherent cells fractionated from mononuclear cells. Northern blotting showed that the mitogen-induced increase in the expression of IL-6 mRNA was inhibited by indomethacin and Y-9223, indicating that these agents inhibit IL-6 biosynthesis. Aspirin, ibuprofen, and phenylbutazone also inhibited IL-6 production by adherent cells stimulated with lipopolysaccharide (LPS). There was, however, no direct relationship between inhibition of IL-6 and prostaglandin E2 (PGE2) production by these agents. The addition of PGE2 corresponding to the amount produced by adherent cells stimulated with LPS slightly increased IL-6 production by unstimulated adherent cells, but to a lower level than that reached with LPS. An anti-PGE2 antibody partially blocked IL-6 production by adherent cells stimulated with LPS. These results suggest that, in addition to the inhibition of PGE2 production, other mediators including cyclooxygenase products or other action mechanisms are involved in the inhibition of IL-6 production by these drugs.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Komatsu</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
						<AffiliationInfo>
							<Affiliation>Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd, Saitama, Japan.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Yaju</LastName>
						<ForeName>H</ForeName>
						<Initials>H</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Chiba</LastName>
						<ForeName>K</ForeName>
						<Initials>K</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Okumoto</LastName>
						<ForeName>T</ForeName>
						<Initials>T</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>England</Country>
				<MedlineTA>Int J Immunopharmacol</MedlineTA>
				<NlmUniqueID>7904799</NlmUniqueID>
				<ISSNLinking>0192-0561</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D001578">Benzopyrans</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D016861">Cyclooxygenase Inhibitors</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>6ON0780D7G</RegistryNumber>
					<NameOfSubstance UI="C062726">tilnoprofenic acid</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>K7Q1JQR04M</RegistryNumber>
					<NameOfSubstance UI="D015232">Dinoprostone</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>XXE1CET956</RegistryNumber>
					<NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D001578" MajorTopicYN="N">Benzopyrans</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002448" MajorTopicYN="N">Cell Adhesion</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D016861" MajorTopicYN="N">Cyclooxygenase Inhibitors</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015232" MajorTopicYN="N">Dinoprostone</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1814850</ArticleId>
				<ArticleId IdType="pii">0192-0561(91)90165-4</ArticleId>
				<ArticleId IdType="doi">10.1016/0192-0561(91)90165-4</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1818300</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>07</Month>
				<Day>15</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2006</Year>
				<Month>11</Month>
				<Day>15</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<JournalIssue CitedMedium="Print">
						<Volume>33</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1991</Year>
						</PubDate>
					</JournalIssue>
					<Title>Nouvelle revue francaise d'hematologie</Title>
					<ISOAbbreviation>Nouv Rev Fr Hematol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Tumor necrosis factor alpha: a costimulator for cytotoxic cell differentiation.</ArticleTitle>
				<Pagination>
					<MedlinePgn>471-5</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Large granular lymphocytes (LGL) can be activated by interleukin-2 (IL-2) into lymphokine-activated killers (LAK). Tumor Necrosis factor alpha was found to act synergistically with very low concentrations of IL-2 which were ineffective by themselves in inducing LAK activity. We demonstrate that the failure of low doses of IL-2 to induce LAK generation was related to their incapacity to induce TNF production by LGL. When specific antibodies against TNF were added to the culture, the differentiation of LGL into LAK effectors by optimal concentrations of IL-2 in our system was partially inhibited suggesting that TNF may be a physiologic mediator in the sequential activation stages of LGL into LAK effectors. We have also investigated the functional interaction between IL-2 and TNF on the generation of alloreactive CTL. Using primary mixed cultures of lymphocytes from a MHC-recombinant sibling identical for MHC class II antigens and displaying MHC class I disparity, our data indicate that addition of exogenous TNF at the sensitizing phase of the primary mixed lymphocyte reaction did not result in CTL activation. However, when simultaneously added with IL-2, TNF could promote an optimal induction of cytotoxic T cell generation. The TNF property to potentiate the cytotoxic function appears to involve an enhancement of IL-2 induced serine esterase activity suggesting that TNF may affect some components of the cellular lytic machinery. In conclusion the data presented here are most consistent with the suggestion that TNF could increase the IL-2 signaling efficiency or potentiate activation signaling involved in the acquisition of lytic competence by cytotoxic T cells.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Chouaib</LastName>
						<ForeName>S</ForeName>
						<Initials>S</Initials>
						<AffiliationInfo>
							<Affiliation>Cytokines et immunité antitumorale URA 1156, CNRS, Institut Gustave Roussy, Villejuif, France.</Affiliation>
						</AffiliationInfo>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Germany</Country>
				<MedlineTA>Nouv Rev Fr Hematol</MedlineTA>
				<NlmUniqueID>7909092</NlmUniqueID>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015375">Receptors, Interleukin-2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.1.-</RegistryNumber>
					<NameOfSubstance UI="D004950">Esterases</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>EC 3.1.-</RegistryNumber>
					<NameOfSubstance UI="C022635">serine esterase</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004950" MajorTopicYN="N">Esterases</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015979" MajorTopicYN="N">Killer Cells, Lymphokine-Activated</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015375" MajorTopicYN="N">Receptors, Interleukin-2</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>1</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1818300</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1828424</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>07</Month>
				<Day>15</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2004</Year>
				<Month>11</Month>
				<Day>17</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0014-2980</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>21</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Jun</Month>
						</PubDate>
					</JournalIssue>
					<Title>European journal of immunology</Title>
					<ISOAbbreviation>Eur J Immunol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>A recombinant extracellular domain of the human interleukin 4 receptor inhibits the biological effects of interleukin 4 on T and B lymphocytes.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1365-9</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Human interleukin 4 (IL4) acts on various hematopoietic cell types through interaction with a specific cell surface receptor (IL4R), whose cDNA has been cloned. We have produced a cDNA encoding a soluble form of the extracellular domain of the human IL 4R (sIL4R) and describe here the capacity of sIL4R to antagonize the in vitro activities of IL4 on normal B and T lymphocytes. sIL4R inhibited IL4-induced proliferation of both phytohemagglutinin-preactivated peripheral blood mononuclear cells (PBMC) and anti-IgM co-stimulated tonsil B cells with similar efficiency. This inhibitory activity was specific since sIL4R did not affect IL2-dependent proliferation of these cells. sIL4R also blocked IL4-dependent induction of the low-affinity receptor for IgE on B cells and inhibited IgE production by IL4-activated PBMC. Thus, in contrast to the IL6R extracellular domain which stimulates IL6 biological activity, the IL4R extracellular domain is a powerful antagonist of its specific ligand.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Garrone</LastName>
						<ForeName>P</ForeName>
						<Initials>P</Initials>
						<AffiliationInfo>
							<Affiliation>Schering-Plough, Laboratory for Immunological Reseach, Dardilly, France.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Djossou</LastName>
						<ForeName>O</ForeName>
						<Initials>O</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Galizzi</LastName>
						<ForeName>J P</ForeName>
						<Initials>JP</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Banchereau</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Germany</Country>
				<MedlineTA>Eur J Immunol</MedlineTA>
				<NlmUniqueID>1273201</NlmUniqueID>
				<ISSNLinking>0014-2980</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000888">Antibodies, Anti-Idiotypic</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000944">Antigens, Differentiation, B-Lymphocyte</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011961">Receptors, Fc</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017455">Receptors, IgE</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D019948">Receptors, Interleukin-4</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011975">Receptors, Mitogen</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>207137-56-2</RegistryNumber>
					<NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>37341-29-0</RegistryNumber>
					<NameOfSubstance UI="D007073">Immunoglobulin E</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000888" MajorTopicYN="N">Antibodies, Anti-Idiotypic</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000944" MajorTopicYN="N">Antigens, Differentiation, B-Lymphocyte</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007073" MajorTopicYN="N">Immunoglobulin E</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName>
					<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
					<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011961" MajorTopicYN="N">Receptors, Fc</DescriptorName>
					<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017455" MajorTopicYN="N">Receptors, IgE</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D019948" MajorTopicYN="N">Receptors, Interleukin-4</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011975" MajorTopicYN="N">Receptors, Mitogen</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>6</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>6</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1828424</ArticleId>
				<ArticleId IdType="doi">10.1002/eji.1830210606</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1832645</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>10</Month>
				<Day>24</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2013</Year>
				<Month>11</Month>
				<Day>21</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0301-472X</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>19</Volume>
						<Issue>9</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Oct</Month>
						</PubDate>
					</JournalIssue>
					<Title>Experimental hematology</Title>
					<ISOAbbreviation>Exp Hematol</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Concomitant histamine, interleukin 4, and interleukin 6 production by hematopoietic progenitor subsets in response to interleukin 3.</ArticleTitle>
				<Pagination>
					<MedlinePgn>934-40</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>Murine interleukin 3 (IL-3) induces a strong, concomitant increase in histamine, interleukin 6 (IL-6), and interleukin 4 (IL-4) synthesis by progenitor-enriched bone marrow cell populations, whereas interleukin 2 (IL-2) or interferon-gamma (IFN-gamma) are undetectable. This phenomenon is observed between 4 and 12 h after exposure to the growth factor and attains maximal cytokine and histamine levels within 24 and 48 h, respectively. None of these mediators is produced by lymphoid populations such as lymph node cells or by granulocytes. Splenocytes secrete only low histamine and IL-6 levels, in accordance with the lower incidence of progenitors in the spleen, whereas total bone marrow cells generate substantial amounts of the three mediators even before enrichment. Histamine, IL-4-, and IL-6-producing cells copurify with immature cells and cannot be separated from each other throughout the sorting procedures used herein. They are concentrated in the low-density layers (buoyant density 1.069-1.086 g/cm3) of a discontinuous Ficoll gradient (less than 4% of the total bone marrow) together with the majority of hematopoietic progenitors (marrow-repopulating ability [MRA] cells, spleen colony-forming units [CFU-S] day-8 and day-12, granulocyte-macrophage colony-forming units [CFU-GM], and mast cell precursors). Their lightscatter characteristics are those of relatively large, granular cells. They do not belong to the most primitive stem cell subset (MRA and part of CFU-S day-12), but to a population with high mitochondrial activity identified by their important rhodamine retention (colony-forming unit cells [CFU-C], blast cells). In addition, we provide evidence that histamine, IL-4, and IL-6 do not depend on each other for their respective expression. Taken together, our data are consistent with the notion that in certain conditions, immature hematopoietic cells are a potent source of histamine and cytokines.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Dy</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
						<AffiliationInfo>
							<Affiliation>CNRS URA 1461, Hôpital Necker, The Netherlands.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Jankovic</LastName>
						<ForeName>D</ForeName>
						<Initials>D</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ploemacher</LastName>
						<ForeName>R</ForeName>
						<Initials>R</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Theze</LastName>
						<ForeName>J</ForeName>
						<Initials>J</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Schneider</LastName>
						<ForeName>E</ForeName>
						<Initials>E</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>Netherlands</Country>
				<MedlineTA>Exp Hematol</MedlineTA>
				<NlmUniqueID>0402313</NlmUniqueID>
				<ISSNLinking>0301-472X</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007377">Interleukin-3</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>207137-56-2</RegistryNumber>
					<NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>820484N8I3</RegistryNumber>
					<NameOfSubstance UI="D006632">Histamine</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002469" MajorTopicYN="N">Cell Separation</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006412" MajorTopicYN="N">Hematopoietic Stem Cells</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006632" MajorTopicYN="N">Histamine</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007377" MajorTopicYN="N">Interleukin-3</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
					<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D013047" MajorTopicYN="N">Specific Pathogen-Free Organisms</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>10</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1832645</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1836011</PMID>
			<DateCompleted>
				<Year>1992</Year>
				<Month>01</Month>
				<Day>15</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2019</Year>
				<Month>05</Month>
				<Day>08</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0022-1007</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>174</Volume>
						<Issue>6</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Dec</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>The Journal of experimental medicine</Title>
					<ISOAbbreviation>J Exp Med</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.</ArticleTitle>
				<Pagination>
					<MedlinePgn>1451-60</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>CR1/CR2 chimeric receptors in which various short consensus repeats (SCRs) of CR1 were attached to CR2 were transiently expressed on COS cells, and assessed for the binding of polymerized C3b (pC3b) and anti-CR2 by immunofluorescence. Of COS cells expressing chimeras containing SCR 1-4, 1-3, 2-4, 1-2, and 2-3 of the long homologous repeats (LHRs) -B or -C, 96%, 66%, 23%, 0%, and 0%, respectively, bound pC3b. K562 cells were stably transfected with wild-type CR1, deletion mutants of CR1, and the CR1/CR2 chimeras, respectively, and assayed for binding of 125I-pC3b. The dissociation constants (Kd) for pC3b of wild-type CR1 and the LHR-BD and -CD constructs were in the range of 1.0-2.7 nM, and of the CR1/CR2 chimeras containing SCRs 1-4, 1-3, and 2-4 of LHR-B or -C were 1.8-2.4, 6-9, and 22-36 nM, respectively. The factor I-cofactor function of the CR1/CR2 chimeras paralleled the C3b-binding function of the constructs. A CR1/immunoglobulin (Ig) chimeric protein was prepared by fusing SCRs 1-4 of LHR-B to the heavy chains of a murine F(ab')2 anti-nitrophenacetyl (NP) monoclonal antibody. The (CR1)2-F(ab')2 chimera, which retained its specificity for NP, was as effective as soluble, full-length CR1 in binding pC3b, serving as a cofactor for factor I-mediated cleavage of C3b, and inhibiting activation of the alternative pathway, indicating that the bivalent expression of these SCRs reconstitutes the alternative pathway inhibitory function of CR1. The feasibility of creating CR1/Ig chimeras makes possible a new strategy of targeting complement inhibition by the use of Ig fusion partners having particular antigenic specificities.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Kalli</LastName>
						<ForeName>K R</ForeName>
						<Initials>KR</Initials>
						<AffiliationInfo>
							<Affiliation>Graduate Program in Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Hsu</LastName>
						<ForeName>P H</ForeName>
						<Initials>PH</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Bartow</LastName>
						<ForeName>T J</ForeName>
						<Initials>TJ</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Ahearn</LastName>
						<ForeName>J M</ForeName>
						<Initials>JM</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Matsumoto</LastName>
						<ForeName>A K</ForeName>
						<Initials>AK</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Klickstein</LastName>
						<ForeName>L B</ForeName>
						<Initials>LB</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Fearon</LastName>
						<ForeName>D T</ForeName>
						<Initials>DT</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>AI-07247</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>AI-22833</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>AI-28191</GrantID>
						<Acronym>AI</Acronym>
						<Agency>NIAID NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>J Exp Med</MedlineTA>
				<NlmUniqueID>2985109R</NlmUniqueID>
				<ISSNLinking>0022-1007</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D000944">Antigens, Differentiation, B-Lymphocyte</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D003169">Complement Inactivator Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D007140">Immunoglobulin Fab Fragments</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011951">Receptors, Complement</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017463">Receptors, Complement 3b</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D017464">Receptors, Complement 3d</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>80295-43-8</RegistryNumber>
					<NameOfSubstance UI="D003179">Complement C3b</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D000944" MajorTopicYN="N">Antigens, Differentiation, B-Lymphocyte</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003179" MajorTopicYN="N">Complement C3b</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003169" MajorTopicYN="N">Complement Inactivator Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D003170" MajorTopicYN="N">Complement Pathway, Alternative</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D007140" MajorTopicYN="N">Immunoglobulin Fab Fragments</DescriptorName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011951" MajorTopicYN="N">Receptors, Complement</DescriptorName>
					<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017463" MajorTopicYN="N">Receptors, Complement 3b</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D017464" MajorTopicYN="N">Receptors, Complement 3d</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012091" MajorTopicYN="N">Repetitive Sequences, Nucleic Acid</DescriptorName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>12</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1836011</ArticleId>
				<ArticleId IdType="pmc">PMC2119055</ArticleId>
				<ArticleId IdType="doi">10.1084/jem.174.6.1451</ArticleId>
			</ArticleIdList>
			<ReferenceList>
				<Reference>
					<Citation>J Exp Med. 1988 Nov 1;168(5):1699-717</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2972794</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunol Today. 1989 Jun;10(6):177-80</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2751824</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochemistry. 1988 May 31;27(11):4004-12</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2970865</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1985 Mar;134(3):1851-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3155775</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1987 Apr 1;165(4):1095-112</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2951479</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Nature. 1984 Dec 13-19;312(5995):604-8</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6095112</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1987 Nov 1;166(5):1351-61</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">3500259</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1990 Jul 25;265(21):12293-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1695627</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1990 Jul 13;249(4965):146-51</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2371562</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1982 Nov;129(5):2051-60</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6214588</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1984 Feb;81(3):881-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6230668</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1983 Feb;80(3):825-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6402777</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Clin Invest. 1983 Feb;71(2):236-47</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6822663</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Biol Chem. 1981 Apr 25;256(8):3995-4006</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6783652</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1981 May 1;153(5):1138-50</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">6910481</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1982 Dec 1;156(6):1739-54</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">7175439</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">293688</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">266208</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">271968</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Biochem Biophys Res Commun. 1978 Feb 28;80(4):849-57</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">637870</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Science. 1991 Oct 4;254(5028):102-5</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1718035</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1991 May 1;173(5):1083-9</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1708808</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1991 Jan 1;173(1):55-64</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1702139</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Immunology. 1990 Dec;71(4):598-600</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1703989</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1991 Jul 15;147(2):590-4</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1830068</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Proc Natl Acad Sci U S A. 1991 May 15;88(10):4353-7</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1827918</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>Annu Rev Immunol. 1991;9:431-55</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">1910685</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Immunol. 1988 Apr 1;140(7):2249-59</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2832473</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1989 Dec 1;170(6):1931-46</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2479703</ArticleId>
					</ArticleIdList>
				</Reference>
				<Reference>
					<Citation>J Exp Med. 1988 Oct 1;168(4):1255-70</Citation>
					<ArticleIdList>
						<ArticleId IdType="pubmed">2971757</ArticleId>
					</ArticleIdList>
				</Reference>
			</ReferenceList>
		</PubmedData>
	</PubmedArticle>
	<PubmedArticle>
		<MedlineCitation Status="MEDLINE" Owner="NLM">
			<PMID Version="1">1846763</PMID>
			<DateCompleted>
				<Year>1991</Year>
				<Month>03</Month>
				<Day>08</Day>
			</DateCompleted>
			<DateRevised>
				<Year>2021</Year>
				<Month>02</Month>
				<Day>16</Day>
			</DateRevised>
			<Article PubModel="Print">
				<Journal>
					<ISSN IssnType="Print">0006-4971</ISSN>
					<JournalIssue CitedMedium="Print">
						<Volume>77</Volume>
						<Issue>3</Issue>
						<PubDate>
							<Year>1991</Year>
							<Month>Feb</Month>
							<Day>01</Day>
						</PubDate>
					</JournalIssue>
					<Title>Blood</Title>
					<ISOAbbreviation>Blood</ISOAbbreviation>
				</Journal>
				<ArticleTitle>Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms.</ArticleTitle>
				<Pagination>
					<MedlinePgn>542-50</MedlinePgn>
				</Pagination>
				<Abstract>
					<AbstractText>The procoagulant properties of cultured vascular endothelial cells are enhanced in response to inflammatory cytokines such as tumor necrosis factor-alpha (TNF). A major component of this response is a reduction in expression of thrombomodulin, a cell surface cofactor for the activation of protein C. Regulation of thrombomodulin expression by TNF has been reported to occur through multiple mechanisms. To determine the relative roles of transcriptional and posttranscriptional regulation, the effect of TNF on the turnover of thrombomodulin protein and mRNA was examined in human and bovine endothelial cells. Quantitative nuclease S1 protection assays showed a 70% to 90% reduction in thrombomodulin mRNA within 4 hours of the addition of 1.0 nmol/L TNF to the culture medium. The decrease in thrombomodulin mRNA resulted from inhibition of transcription, followed by rapid degradation of thrombomodulin transcripts (t1/2 less than or equal to 3 hours). In pulse-chase incubations, thrombomodulin synthesis decreased parallel with mRNA, but the rate of degradation of radiolabeled thrombomodulin was not significantly altered by TNF. Human thrombomodulin was degraded with a t1/2 of 8.2 +/- 2.4 hours (SD) or 7.5 +/- 1.3 hours (SD) in the absence or presence of TNF, respectively. We conclude that TNF acts primarily to inhibit thrombomodulin transcription. The subsequent decrease in activity results from the inherent instability of thrombomodulin mRNA and protein in these cells, and not from the regulation of thrombomodulin degradation.</AbstractText>
				</Abstract>
				<AuthorList CompleteYN="Y">
					<Author ValidYN="Y">
						<LastName>Lentz</LastName>
						<ForeName>S R</ForeName>
						<Initials>SR</Initials>
						<AffiliationInfo>
							<Affiliation>Department of Medicine, Howard Hughes Medical Institute, Washington University School of Medicine, St Louis, MO 63110.</Affiliation>
						</AffiliationInfo>
					</Author>
					<Author ValidYN="Y">
						<LastName>Tsiang</LastName>
						<ForeName>M</ForeName>
						<Initials>M</Initials>
					</Author>
					<Author ValidYN="Y">
						<LastName>Sadler</LastName>
						<ForeName>J E</ForeName>
						<Initials>JE</Initials>
					</Author>
				</AuthorList>
				<Language>eng</Language>
				<GrantList CompleteYN="Y">
					<Grant>
						<GrantID>HLBI 14147</GrantID>
						<Acronym>HL</Acronym>
						<Agency>NHLBI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
					<Grant>
						<GrantID>T32 HLBI 07088</GrantID>
						<Acronym>HL</Acronym>
						<Agency>NHLBI NIH HHS</Agency>
						<Country>United States</Country>
					</Grant>
				</GrantList>
				<PublicationTypeList>
					<PublicationType UI="D003160">Comparative Study</PublicationType>
					<PublicationType UI="D016428">Journal Article</PublicationType>
					<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
					<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
				</PublicationTypeList>
			</Article>
			<MedlineJournalInfo>
				<Country>United States</Country>
				<MedlineTA>Blood</MedlineTA>
				<NlmUniqueID>7603509</NlmUniqueID>
				<ISSNLinking>0006-4971</ISSNLinking>
			</MedlineJournalInfo>
			<ChemicalList>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D015342">DNA Probes</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D018179">Receptors, Thrombin</NameOfSubstance>
				</Chemical>
				<Chemical>
					<RegistryNumber>0</RegistryNumber>
					<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
				</Chemical>
			</ChemicalList>
			<CitationSubset>IM</CitationSubset>
			<MeshHeadingList>
				<MeshHeading>
					<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015342" MajorTopicYN="N">DNA Probes</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
					<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012323" MajorTopicYN="N">RNA Processing, Post-Transcriptional</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
					<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D018179" MajorTopicYN="N">Receptors, Thrombin</DescriptorName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
					<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
					<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
					<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
				</MeshHeading>
				<MeshHeading>
					<DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
					<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
				</MeshHeading>
			</MeshHeadingList>
		</MedlineCitation>
		<PubmedData>
			<History>
				<PubMedPubDate PubStatus="pubmed">
					<Year>1991</Year>
					<Month>2</Month>
					<Day>1</Day>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="medline">
					<Year>1991</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>1</Minute>
				</PubMedPubDate>
				<PubMedPubDate PubStatus="entrez">
					<Year>1991</Year>
					<Month>2</Month>
					<Day>1</Day>
					<Hour>0</Hour>
					<Minute>0</Minute>
				</PubMedPubDate>
			</History>
			<PublicationStatus>ppublish</PublicationStatus>
			<ArticleIdList>
				<ArticleId IdType="pubmed">1846763</ArticleId>
				<ArticleId IdType="pii">S0006-4971(20)83065-1</ArticleId>
			</ArticleIdList>
		</PubmedData>
	</PubmedArticle>
</PubmedArticleSet>